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 Zusammenfassung 
MicroRNAs (miRNAs) sind nicht-kodierende RNAs mit einer Länge von ~ 21-23 Nukleotiden. Sie 
regulieren die Genexpression auf post-transkriptionaler Ebene durch Bindung an mRNAs. Diese 
Regulation durch miRNAs spielt unter anderem in Entwicklungsprozessen, wie z.B. in der 
Hämatopoese, eine große Rolle. 
Ziel dieser Arbeit war die Charakterisierung der miRNAs in humanen hämatopoetischen Stamm- 
und Vorläuferzellen. Hämatopoetische Stammzellen bilden alle Zelltypen des Blutes und prägen 
eine Reihe von spezifischen Oberflächenmolekülen wie CD34 oder CD133 aus. Verschiedene 
Publikationen weisen daraufhin, dass CD133+ Zellen Vorläuferzellen von CD34+ Zellen sein 
könnten. Das miRNA-Profil dieser Zelltypen kann somit Aufschluss über die Rolle von miRNAs 
bei der Differenzierung von CD133+ Zellen geben.  
Um die Funktion der miRNAs in hämatopoetischen Stammzellen zu untersuchen, wurde eine 
miRNA Microarray Plattform (miRXploreTM) entwickelt, die auch genutzt wurde, um die Daten 
aus Klonierungsexperimenten zu validieren. Standardmäßig erlauben die Profile eine Aussage über 
die relative Expression der miRNAs. Da neben relativen Expressionsstärken aber auch absolute 
Expressionsstärken (Kopienzahlen pro Zelle) von großer Bedeutung sind, wurde eine Methode zur 
absoluten Quantifizierung von miRNAs etabliert. Die absolute Quantifizierung basiert auf einer 
universellen Referenz (UR) – einem Pool mit etwa 1000 synthetischen miRNAs bekannter 
Konzentration. 
Für die Erstellung von miRNA Expressionsprofilen der hämatopoetischen Vorläuferzellen wurden 
CD133+, CD34+CD133– und CD34–CD133– Zellen mittels magnetischer Zellseparation aus 
humanem Knochenmark isoliert. Die Analyse der miRNA Expressionsprofile ergab 18 miRNAs, 
die in CD133+ Zellen im Vergleich zu CD34+CD133– Zellen differentiell exprimiert sind. Diese 
miRNA Kandidaten konnten mittels microRNA qRT-PCR Assays und Solexa Sequenzierung 
validiert werden. Die Funktion der miRNA Kandidaten in CD133+ Zellen wurde unter anderem mit 
Hilfe von bioinformatischen Vorhersagen der möglichen mRNA Targets in Kombination mit 
Arrayanalysen (statistischer Abgleich von miRNA und mRNA Arraydaten) untersucht. Zur 
Validierung der anhand dieser Datenanalysen vorhergesagten Targets ist ein Luciferase-Assay 
etabliert worden. Mittels des Luciferase-Assays konnte unter physiologischen Bedingungen 
bestätigt werden, dass miR-142-3p an CD133 sowie miR-29a an die entsprechende Sequenz von 
FZD5 und TPM1 im 3’-UTR binden kann. TPM1, ein Aktin-bindendes Protein, und FZD5, ein 
Rezeptor des Wnt-Signalweges, spielen beide eine Rolle bei der Modellierung des Cytoskelettes. 
Weitergehende Analysen zeigten, dass die mRNA Targets der differentiell exprimierten miRNAs 
für stammzellrelevante Gene Ontology Kategorien angereichert sind und deuten daraufhin, dass die 
differentiell exprimierten miRNAs die Ausdifferenzierung von CD133+-Zellen inhibieren und eine 
anti-apoptische Wirkung haben. 
Des Weiteren sind erste wegweisende Versuche durchgeführt worden, um einen möglichen 
Einfluss der 18 differentiell exprimierten miRNAs auf die Kultivierung von CD133+ Zellen zu 
untersuchen. Die in vitro Kultivierung der CD133+ Zellen, führt i. A. zu einer Differenzierung der 
Zellen, so dass der Stammzellcharakter verloren geht. Eine Zugabe von bestimmten miRNAs zu 
dem Kulturmedium könnte zu einer Expansion der CD133+ Zellen unter Beibehaltung des 
primitiven Phänotyps führen. Daher wurde in einem ersten Schritt der Einfluss von miRNA 
Transfektionen auf CD133+ Zellen untersucht.  
Die im Rahmen dieser Arbeit erstellte miRNA Signatur von CD133+ Zellen ist die erste 
umfassende Charakterisierung von hämatopoetischen Vorläuferzellen und von großem Nutzen für 
weitere Analysen im Hinblick auf die Verwendung von miRNAs in der regenerativen Medizin. 
 Abstract 
MicroRNAs (miRNAs), short non-coding RNAs of ~ 21 to 23 nucleotides in length, regulate target 
mRNAs post-transcriptionally. They play an important role in many different cellular, 
developmental, and physiological processes including hematopoiesis. 
It was the aim of this study to characterize the miRNA expression in human hematopoietic stem 
and progenitor cells. Hematopoietic stem cells (HSCs) have the ability to generate all different 
kinds of blood cells and express a number of specific surface markers such as CD34 or CD133. As 
CD133+ cells appear to be ancestral to CD34+ cells, the miRNA profile of these cells could broaden 
the knowledge of the miRNA role in the differentiation of CD133+ cells.  
To analyze the function of miRNAs in HSCs, a miRNA microarray platform (miRXploreTM) was 
developed. The platform was used, inter alia, to validate sequencing data of Small RNA libraries. 
Standard array experiments measure relative expression levels. However, absolute expression 
levels in terms of copy numbers per cell are also highly relevant. Therefore, a method for absolute 
quantification of miRNAs that relies on a universal reference – an equimolar pool of about 1000 
synthetic miRNAs of known concentration – was developed.  
To characterize the role of miRNAs in hematopoiesis, different bone marrow subpopulations, 
namely CD133+, CD34+CD133– and CD34–CD133– cells, were isolated by magnetic cell 
separation. The analysis revealed 18 significantly differentially expressed miRNAs between 
CD133+ and CD34+CD133– cells, that could be validated via qRT-PCR and Solexa sequencing. To 
further analyze the role of the differentially expressed miRNAs in CD133+ stem cells, mRNA 
expression profiles were generated and the coexpression of bioinformatically predicted miRNA-
mRNA pairs was examined. Luciferase assays were established to validate the predicted targets 
under physiological conditions. The miRNA-mRNA interactions that could be validated were 
miR-142-3p and CD133, miR-29a and FZD5 as well as miR-29a and TPM1. TPM1, an actin 
binding protein, and FZD5, a receptor of the Wnt-signaling pathway, play a role in the remodelling 
of the cytoskeleton. Further analysis of the predicted miRNA targets revealed that the miRNA 
targets are enriched for Gene Ontoloy categories related to stem cell-relevant processes. The 
differentially expressed miRNAs probably prevent differentiation of CD133+ cells and have an 
anti-apoptotic effect.  
Furthermore, first experiments were performed to analyze the influence of the differentially 
expressed miRNAs on the cultivation of CD133+ cells. In vitro expansion of CD133+ cells has 
turned out to be difficult as most of the tested culture supplements can induce proliferation but are 
unable to prevent differentiation. The addition of miRNAs to the culture medium could lead to an 
expansion of CD133+ cells without losing the primitive phenotype. Therefore, the influence of 
miRNA transfections on CD133+ cells was analyzed in a first step. 
In conclusion, the generated miRNA signature of CD133+ is the first comprehensive 
characterization of hematopoietic progenitor cells on miRNA level and will be highly relevant for 
the application of miRNAs in the field of regenerative medicine.  
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1 Introduction 
1.1 MicroRNAs 
MicroRNAs (miRNAs), short non-coding RNAs of ~ 21 to 23 nucleotides in length, 
regulate target mRNAs post-transcriptionally. Up to now about 900 different miRNAs 
have been identified in the human genome (miRBase 15.0). Each miRNA has the potential 
to target hundreds of mRNAs and one mRNA can be targeted by multiple miRNAs (Lim et 
al. 2005), highlighting the importance of miRNAs in complex networks of gene expression 
regulation. Other main characteristics of miRNAs are their evolutionary conservation and 
unique biogenesis as they are specifically processed form precursors with a hairpin 
structure (Ambros et al. 2003).  
1.1.1 The physiological and biological role of miRNAs 
The processes of miRNA biogenesis (Figure 1) and target mRNA repression have been 
studied intensively during the last years (Winter et al. 2009). miRNA genes are transcribed 
by either RNA polymerase II or RNA polymerase III into primary miRNA transcripts (pri-
miRNA). The pri-miRNA is next endonucleolytically cleaved by the RNase III enzyme 
Drosha to release a 60-70 nt stem-loop intermediate, known as precursor miRNA (pre-
miRNA). The hairpin pre-miRNA is actively exported to the cytoplasm, where it is 
recognized by Dicer and cleaved in a 20-nt miRNA duplex. In the final step of miRNA 
maturation the functional strand of the small RNA duplex is selectively loaded onto the 
RNA-induced silencing complex (RISC), whose core components are the Argonaute 
family proteins. The miRNA then directs the RISC to its target mRNA and represses target 
gene expression by either destabilizing target mRNAs or repressing their translation. A 
major determinant of miRNA target recognition is a perfect match in the so-called seed 
sequence of 6-8 nt at the 5’end of the miRNA (Bartel 2009).  
Inhibition of miRNA biogenesis, e.g. through Dicer knockout, demonstrated that miRNAs 
play an important role in many different cellular, developmental, and physiological 
processes as divergent as cell lineage decisions, cell proliferation, apoptosis, 
morphogenesis, fat metabolism, hormone secretion, neuronal synaptic plasticity, and long-
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term memory (Aravin and Tuschl 2005). In these processes, miRNAs participate in 
signaling networks, both as backups of tissue-specific transcription control and 
feedforward or feeback loops that confer robustness to the output of cell signaling (Inui et 
al. 2010). 
Pri-miRNA
Nucleus Cytoplasm
Drosha/DGCR8
Pre-
miRNA
Exportin 5
Dicer/TRBP
miRNA duplex
Mature 
miRNA
RISC
 
Figure 1.  The biogenesis of miRNAs. MicroRNA genes are transcribed by RNA polymerases II and III into 
primary transcripts called pri-miRNAs that are cleaved into a hairpin-shaped 70-100 nucleotide 
precursor (pre-miRNA) by Drosha. The pre-miRNAs are then transported by exportin 5 into the 
cytoplasm, where they are further processed by the RNAse III enzyme Dicer to give a mature 
double-stranded miRNA. One of the RNA strands is then loaded by Dicer into an RNA-induced 
silencing complex (RISC) that then targets the 3′ untranslated region of the target mRNAs to 
repress translation. Figure adopted from Snove and Rossi (2006). 
1.1.2 Methods for the identification and quantification of miRNAs 
Methods which have been established to identify and quantify miRNAs include Northern 
blotting (Lim et al. 2003), in situ hybridization (Pena et al. 2009), small RNA Library 
Sequencing (Lagos-Quintana et al. 2001), reverse transcription PCR (Chen et al. 2005), 
bead arrays (Chen et al. 2008) and microarray hybridization (Krichevsky et al. 2003; Barad 
et al. 2004; Liu et al. 2004; Landgraf et al. 2007).  
The general methodologies for miRNA analysis are comparable to well established 
conventional mRNA analytics. However, the physicochemical properties of miRNAs 
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which are determined by their short length make it more difficult to analyze them. When 
compared to mRNAs, a much higher dynamic range of melting temperatures is observed 
for miRNAs and a proper selection of hybridization probes or PCR primers is hardly 
possible. With each miRNA having its specific physicochemical properties, each 
probe/miRNA pair displays different hybridization efficiencies. As a consequence, same 
amounts of different miRNAs can give rise to different signal intensities in microarray 
experiments and can lead to different CT values in qRT-PCR experiments, making an 
absolute quantification of miRNAs challenging.  
However, a few approaches including qRT-PCR and primer extension assays (Chen et al. 
2005; Raymond et al. 2005) have been described for the absolute quantification of 
miRNAs. These methods are based on the preparation of standard curves for the estimation 
of the miRNA copy number. As this calibration curves have to be prepared individually for 
every miRNA, the number of analyzable miRNAs is limited. A massive parallel absolute 
quantification of all known miRNAs would be desirable and very helpful to study the 
interaction of miRNAs with other RNA species and proteins.  
Currently, just very little is known about the importance of miRNA expression levels for 
mRNA targeting. One could speculate that the requirements for targeting on miRNA level 
maybe different for class 1 and class 2 targets (Figure 2A) and it is supposable, that the 
expression level of a miRNA has to be higher for effective targeting in the case of class 
2 targets. Another topic with a lot of open questions is the relevance of miRNA copy 
numbers in the context of combinatorial miRNA activity (Figure 2B).  
While miRNA microarrays allow for massive parallel and accurate relative measurement 
of all known miRNAs, they have so far been less useful as an assay for absolute 
quantification. The reason for this is mainly – as described above – the different 
hybridization efficiency of each probe/miRNA pair. To overcome these limitations, one 
part of this thesis was the development of a miRNA microarray platform which enabled a 
quantitative miRNA measurement.  
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Figure 2.  Relevance of absolute miRNA levels for targeting. (A) The two classes of miRNA target sites. 
Class 1 targets (left) have perfect base pairings between the 5′ end of the miRNA (seed) and the 
3′-UTR target sites but insignificant complementarity in the remainder of the miRNA sequence. 
Class 2 targets (right) have an imperfect seed match but a significant higher complementarity of 
the remainder miRNA sequence. (B) Combinatorial activity of miRNAs. One mRNA can be 
targeted by multiple miRNAs. Therefore, miR-1 present with high copy numbers could be more 
effective, although there is just one binding site compared to two binding sites for miR-2 and 
miR-3, respectively (3’UTR_A and 3’UTR_C). Furthermore, low expressed miRNAs maybe 
highly effective in combination with other low expressed miRNAs (miR-2 and miR-3 binding to 
3’UTR_B). Figure part A adopted from Rajewsky (2006). 
1.2 Hematopoietic stem cells 
The hallmark of hematopoietic stem cells (HSCs) is their remarkable ability to self-renew 
as well as to differentiate into all blood cell lineages. The ability of transplanted HSCs to 
reconstitute the hematopoietic system was first demonstrated by experiments in the 1950s 
(Ford et al. 1956). To date, HSCs are the only stem cells in routine clinical use with a main 
focus on HSC-containing grafts for treating a wide variety of blood cell diseases such as 
leukemias and autoimmune disorders. As the life span of mature blood cells is 
predominantly very short, they need to be replenished continuously. The average human 
requires approximately 1.5 x 106 new hematopoietic cells every second, one hundred 
billion each day. This high turnover rate necessitates precise control mechanisms at each 
stage of hematopoiesis.  
Hematopoiesis is a complex process with a rare population of HSCs residing at the top of 
the hierachically organized hematopoietic system (Figure 3). By asymmetrical divisions, 
HSCs give rise to progeny that progressively lose self-renewal potential and become 
restricted in their differentiation capacity. Based on their ability to self-renew, HSCs can 
be classified into long-term HSCs (LT-HSCs), short-term HSCs (ST-HSCs) and 
multipotent progenitors (MPP). LT-HSCs perpetually self-renew and can sustain lifelong 
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hematopoiesis, whereas ST-HSCs are restricted in self-renewal potential, sustaining 
hematopoiesis only for a limited time (~ 6 weeks) in vivo. ST-HSCs generate MPP which 
retain full lineage potential yet have short self-renewal potential and give rise to 
oligopotent progenitors including common myeloid progenitors (CMPs) and common 
lymphoid progenitors (CLPs) (Bryder et al. 2006; Blank et al. 2008; Orkin and Zon 2008).  
ST-HSCLT-HSC MPP
CMP
CLP
 
Figure 3.  The early steps of hematopoiesis. Hematopoietic development is initiated from long-term 
hematopoietic stem cells (LT-HSCs) that differentiate into multipotent progenitor cells (MPPs). 
MPPs differentiate either via the common lymphoid progenitor (CLP) or common myeloid 
progenitor (CMP).  
 
HSCs can be identified by dye efflux (Hoechst 33342), on the basis of their metabolic 
properties (Aldefluor) or by monoclonal antibodies directed to surface markers (Bosio et 
al. 2009). Coupling of these antibodies to supermagnetic particles allows magnetic sorting 
of HSCs (Figure 4). The surface markers frequently used to identify and sort human HSCs 
are CD34 and CD133. 
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Figure 4.  Principle of the positive magnetic cell separation. After labeling of the target cells with a magnetic 
bead conjugated specific antibody, the target cells are magnetically separated and eluted. 
1.2.1 CD133+ and CD34+ hematopoietic stem and progenitor cells 
Human CD34 was the first differentiation marker recognized on hematopoietic stem and 
progenitor cells (HPCs) and is the classical marker used to obtain enriched populations of 
HSCs and HPCs for research and clinical applications. CD34 is expressed on 
approximately 1-4% of the nucleated cells in normal human bone marrow (BM) and on 
<0.1% of the nucleated cells in human peripheral blood (PB) (Wognum et al. 1993). 
Expression of CD34 on the cell surface denotes hematopoietic cells that can reconstitute 
hematopoiesis in vivo (Berenson et al. 1991). The CD34+ subsets also includes HPCs of 
various lineages at different stages of differentiation, but is not expressed on the majority 
of terminally differentiated cells (Bender et al. 1991; Saeland et al. 1992). The usefulness 
of CD34 as a HSC and HPC marker is well established. There is, however, evidence for 
the existence of a very primitive CD34– cell population that has a marked capacity for 
long-term repopulation and may be a more primitive precursor of CD34+ cells (Zanjani et 
al. 1999; Guo et al. 2003). A marker of primitive HSCs and HPCs expressed by CD34– and 
immature CD34+ stem cell subsets is CD133 (Gallacher et al. 2000).  
CD133 – also known as prominin-1 – was first detected on HSCs using a monoclonal 
antibody that was raised against CD34+ blood cells. It was originally found on HSCs and 
HPCs deriving from human fetal liver, bone marrow, peripheral blood and leukapheresis 
products from cytokine-mobilized donors with frequencies below 1.5 %. CD133 is a five 
trans-membrane domain glycoprotein with an extracellular N-terminus, a cytoplasmatic 
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C-terminus and two large extracellular loops with eight consensus sites for N-linked 
glycosylation (Yin et al. 1997).  
Further studies revealed that long-term culture–initiating cells (LTC–ICs), the most 
primitive human hematopoietic cells analyzable in vitro, are highly enriched among 
CD133+ cells (Matsumoto et al. 2000). Moreover, CD133+ cells in the quiescent phase of 
the cell cycle have a phenotype consistent with HSCs and are highly enriched for 
repopulating activity (Boxall et al. 2009). As CD34+ cells can be generated in vitro from 
CD133+CD34–cells (Summers et al. 2004), CD133+ cells appear to be ancestral to 
CD34+cells. Gene expression profiles and repopulation assays provided further evidence 
for a more primitive phenotyp of CD133+ cells compared to CD34+ cells: CD133+ cells 
display a more primitive gene expression profile than CD34+ Cells (Hemmoranta et al. 
2006) and only CD34+CD133+ cells are capable of repopulating NOD/SCID mice 
compared to CD34+CD133– cells (de Wynter et al. 1998). 
Currently, CD133+ cells are used in stem cell-based therapy for treatment of leukaemia 
(Feller et al. 2005; Isidori et al. 2007), neurodegenerative diseases (Martinez et al. 2009), 
myocardial infarction (Stamm et al. 2003; Stamm et al. 2007) and liver regeneration (Furst 
et al. 2007). 
1.2.2 In vitro expansion of hematopoietic stem and progenitor cells 
HSCs have a tremendous potential to reconstitute the hematopoietic system and are 
therefore used in clinical transplantation protocols to treat a variety of malignant and non-
malignant disorders. Existing limitations are the number of HSCs that can be isolated from 
sources such as bone marrow, mobilized peripheral blood and umbilical cord blood. If 
limited numbers of HSCs are used in transplantation settings, engraftment periods of 
50 days or more are standard and lead to a high risk of serious infectious complications for 
the patients. Therefore, the ability to increase the number of HSCs in vitro would improve 
the rate of immune reconstitution and provide new treatment options. But growing HSCs in 
vitro has turned out to be surprisingly difficult.  
For more than 40 years, different culture media with combinations of growth factors have 
been tested. However, the factors tested so far can induce extensive proliferation but are 
unable to prevent differentiation of HSCs (Reya 2003). Hence, a lot of research is 
performed to identify factors that cause significant expansion in the number of immature 
HSCs with transplantable HSC activity resulting in improved engraftment. 
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The current attempts to expand HSCs in vitro can be divided into three main categories 
(Sorrentino 2004): transcription factors (e.g. HoxB4), cell cycle regulators (e.g. p18) and 
signaling molecules (e.g. cytokines, Wnt-proteins). 
One study that identified conditions resulting in an appropriate increase in HSC numbers 
was performed by Zhang et al. (2008). Using a serum-free culture containing the cytokines 
SCF, TPO, FGF-1, Angptl5 and IGFBP2, they could achieve a 20-fold net expansion of 
repopulating human cord blood HSCs.  
A recent study of Delaney et al. (2010) used an ex vivo culture strategy to significantly 
expand cord blood HSCs through activiation of the Notch pathway by synthetic Delta 
ligand. Within a phase I clinical trial, they could show that the time to neutrophil recovery 
was substantially shortened when ex vivo expanded HSCs were transplanted. Thus, it is 
possible to take advantage of the Notch pathway to improve hematopoietic transplantation 
in a clinically compliant manner. However, there were incidences for an impaired long-
term HSC function as the culture probably altered the self-renewal potential of the HSCs.  
It is currently hardly understood how the source and isolation of starting material as well as 
the culture conditions alter the differentiation capacity and self-renewal potential of HSCs. 
The molecular profiling of miRNAs, mRNAs and proteins during cultivation of HSCs have 
the potential to widen the horizon for clinical application of efficacious cell therapy 
products. 
1.3 miRNAs in hematopoietic stem cells 
The biological role of miRNAs in hematopoiesis has been studied by genetic inactivation 
of individual miRNAs and of all miRNAs. The latter approach is based on knockout of 
Dicer, the key enzyme for the processing of pre-miRNAs into mature miRNAs. As Dicer 
knockouts are embryonic lethal (Bernstein et al. 2003), its in vivo role in adult 
hematopoiesis can only be studied by conditional knockouts. Conditional dicer inactivation 
in hematopoietic stem cells and progenitors leads to a dramatic phenotype as 
transplantation of Dicer-deficient bone marrow is unable to radioprotect lethally irradiated 
mice (Martinez and Busslinger 2007). Furthermore, conditional inactivation of Ago2, a 
protein of the RISC complex, led to severe hematopoietic defects (O'Carroll et al. 2007). 
DGCR8 null ES cells accumulate in the G1 phase of the cell cycle and exhibit defective 
differentiation (Wang et al. 2007b; Wang et al. 2008b). 
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Genetic inactivation of individual miRNAs can also produce dramatic phenotypes, e.g. 
knockout of miR-155 affected T-cell differentiation, germinal centre B-Cell responses and 
responses to bacterial and viral infection (Rodriguez et al. 2007; Thai et al. 2007).  
The further analysis of individual miRNAs showed that miRNAs fine tune essentially each 
step in hematopoiesis, as summarized in Figure 5 and in recent reviews (Gangaraju and Lin 
2009; Xiao and Rajewsky 2009). Ectopic expression of miR-181 in lineage negative (Lin-) 
hematopoietic progenitor cells from mouse bone marrow increased the fraction of 
B-lineage cells (CD19+) in vitro and in vivo (Chen et al. 2004). Furthermore, it was 
demonstrated that miR-150 drives megakaryocyte-erythrocyte progenitor (MEP) 
differentiation towards megakaryocytes at the expense of erythroid cells (Lu et al. 2008). 
Erythropoiesis was reported to be promoted by miR-451, miR-16 and miR-144 and 
negatively regulated by miR-150, miR-155, miR-221, miR-222 and miR-223 (Felli et al. 
2005; Bruchova et al. 2007; Zhan et al. 2007; Dore et al. 2008). The miRNA cluster 
miR-17-5p-92 controls monocytopoiesis (Fontana et al. 2007) and miR-424 is upregulated 
during monocyte/macrophage differentiation. Within the lymphoid lineage, the decision 
between T cells and B cells is regulated by miR-150 (Xiao et al. 2007; Zhou et al. 2007). 
The early steps of HSC differentiation, e.g. the role of miRNAs in self-renewal of the 
LT-HSCs and ST-HSC as well as the function of miRNAs in mulipotent progenitors, are 
currently mostly unknown. Up to now, only two studies analyzed the expression of 
miRNAs in primitive CD34+CD38– cells (Liao et al. 2008; Han et al. 2010). Liao and 
coworkers found miR-520h to be overexpressed in CD34+ CD38– stem cells and suggested 
miR-520h to promote differentiation into progenitor cells by inhibiting ABCG2 expression 
(Liao et al. 2008). Han et al. (2010) could show that miR-29a induces aberrant self-renewal 
capacity in CMPs and GMPs.  
More data is available for CD34+ progenitor cells including miRNA expression profiles of 
CD34+ from bone marrow and mobilized peripheral blood cells (Georgantas et al. 2007) as 
well as CD34+ cord blood cells (Merkerova et al. 2009).  
The influence of miRNAs on the differentiation potential of CD34+ cells in vitro was 
investigated by performing HSC-CFU assays. Georgantas and co-workers showed that 
miR-155 transduced CD34+ cells generated fewer myeloid and erythroid colonies. Labbaye 
et al. demonstrated (2008) that miR-146 transduced CD34+ cells generated fewer 
megakaryocytic colonies. 
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Figure 5.  miRNAs in hematopoiesis. The miRNAs that regulate the different steps of hematopoiesis are 
shown in red. The depicted miRNAs were mainly identified in in-vitro assays with human cells. 
The role of the miRNAs labeled with ‡, e.g. miR-181‡ that drives differentiation towards CLPs, 
were identified in mouse experiments. The transcription factors are selected according to Orkin 
and Zon (2008). Abbreviations: LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term 
hematopoietic stem cell; MP, multipotent progenitors; CMP, common myeloid progenitor; CLP, 
common lymphoid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-
macrophage progenitor; ErP, erythroid progenitor; MkP, megakaryocyte progenitor; RBC, red 
blood cells; NK, natural killer. 
In essence, the characterization of hematopoietic cells with respect to miRNAs is well 
advanced for more committed progenitors and mature cells but has almost not been 
addressed for the early steps of HSC differentiation. This is partly due to difficulties in 
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isolating enough stem cells for a proper miRNA analysis. Likely, improved isolation 
methods and a higher sensitivity of miRNA assays will broaden the available data on 
miRNAs in HSCs.  
1.4 Aim of the study 
MicroRNAs repress target gene expression by binding to the 3’UTR of mRNAs. This 
process plays an important role in complex networks of gene expression regulation. 
Rescently, it was shown for the first time that miRNAs are involved in hematopoietic 
lineage differentiation. So far, mainly mature hematopoietic cells haven been characterized 
with respect to their miRNA expression and very little is known about the role of miRNAs 
in early hematopoiesis. Therefore, the aim of this thesis is to analyze the miRNAs in 
hematopoietic stem and progenitor cells in terms of relative and absolute expression.  
Microarrays are the methods of choice to study all known miRNAs simultaneously. 
However, they have so far been unsuitable as an assay for absolute quantification. Thus, 
the first part of this work is the development of a miRNA microarray platform which 
enables a quantitative miRNA measurement.  
The second part aims at describing the miRNA signature of CD133 and CD34 expressing 
hematopoietic stem and progenitor cells. CD133+ cells appear to be ancestral to CD34+ 
cells. A comprehensive miRNA expression comparison of both subpopulations may give 
further insights in the molecular differences that account for the more primitive character 
of CD133+ cells. The role of the significantly differentially expressed miRNAs between 
CD133+ and CD34+ cells should then be further analyzed to determine if they firstly play a 
role for early differentiation steps of CD133+ and CD34+ cells and secondly are useful for 
the in vitro expansion of CD133+ cells.  
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2 Material and Methods 
2.1 Cells and cell separation 
Bone marrow was obtained by sternal aspiration after written consent from the local Ethics 
Committee. Peripheral blood was obtained as buffy coat (Uniklinikum, Dortmund) and 
PBMCs were isolated by density gradient centrifugation. 
Granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood was obtained 
from healthy donors after informed consent (Allcells, Berkley, USA) and CD133+ cells 
were isolated and stored in liquid nitrogen with human AB serum containing 10% DMSO. 
2.1.1 CliniMACS and MiniMACS separation 
CD133+ bone marrow cells were enriched with the CliniMACS CD133 Reagent (clone 
AC133, Miltenyi Biotec Bergisch Gladbach, Germany) using the CliniMACS Cell 
Separation System (Miltenyi Biotec). CD34+/CD133– cells were isolated by enrichment of  
CD34+ cells with the CliniMACS CD34 Reagent (clone QBEND/10, Miltenyi Biotec) 
using the negative fraction of the first separation. 
CD133+ cells from PBMCs were enriched using the CD133 Cell Isolation Kit (Miltenyi 
Biotec). Following labeling with CD133 monoclonal antibody (clone AC133), two cell 
separation cycles were run using Mini-MACS MS or LS columns according to the 
protocol. After magnetic separation, the purity of isolated cell subsets was analyzed by 
flow cytometry. 
2.1.2 Flow cytometric analysis of hematopoietic cells 
For standard flow cytometric analysis, cells were stained according to the manufacturer’s 
protocol (Miltenyi Biotec). Briefly, cells were washed with PBS, blocked with FcR-
blocking reagent and stained using the antibodies CD133/2-PE (clone 293C3), CD34-APC 
(clone AC136) and CD45-FITC (clone 5B1) for analysis of CD133+ cells. CD34+CD133– 
cells were stained with CD34-PE and CD45-FITC. Isotype controls were performed using 
IgG2a-APC (clone S43.10) and IgG2b-PE (CD133+ cell analysis) or IgG2a-PE (clone 
S43.10).  
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Cells were analyzed on FACSCalibur (Becton-Dickinson, Heidelberg, Germany) or 
MACSQuant Analyzer (Miltenyi Biotec). Cell debris and dead cells were excluded from 
the analysis based on scatter signals and PI fluorescence. 
Data analysis was performed with CELLQuest software (Becton-Dickinson) or 
MACSQuantify software (Miltenyi Biotec) according to ISHAG (Sutherland et al. 1996). 
2.2 miRNA and mRNA analysis 
2.2.1 RNA sources and isolation 
Total RNA was isolated from mouse liver and brain using Trizol (Sigma.-Aldrich, St. 
Louis, USA) and from hematopoietic subpopulations using Trizol (Sigma-Aldrich) or 
miRNeasy Mini (Qiagen, Hilden, Germany).  
RNA concentration was photometrically measured using a Nanodrop device (NanoDrop 
Technologies Inc., Rockland, USA) and RNA quality was confirmed using a RNA 6000 
Pico total RNA kit and the 2100 Bioanalyzer (Agilent Technologies, Böblingen, 
Germany). RINs (RNA Integrity Numbers) were between 8.2 and 9.4. 
Synthetic 5' phosphorylated, HPLC-purified oligoribonucleotides were obtained from 
Sigma Proligo. Quality of each single oligonucleotide was controlled by mass spectroscopy 
and in addition by PAGE analysis. The concentration of each oligonucleotide was 
determined by at least two independent photometric measurements. Synthetic 
oligoribonucleotides were used to prepare a Universal Reference (UR), consisting of a pool 
of 816 (Universal Reference, vers. 0.9, (Landgraf et al. 2007), or 954 miRNAs (Universal 
Reference vers. 1.0 covering all human, mouse and rat miRNAs according to miRBase 9.2 
(Griffiths-Jones 2006); miRXploreTM Universal Reference, Miltenyi), with each individual 
oligoribonucleotide having a final concentration of 5 fmol/µl.  
2.2.2 RNA labeling and hybridization for miRNA profiling 
Four different labeling procedures were investigated, one using the miRCury Power 
Labelling Kit (Exiqon, Vedbaek, Denmark), and three generic approaches using either 
Rnl1 (Fermentas International Inc., Burlington, Canada), Rnl2(1-249) (Ho et al. 2004), or 
Rnl2K227Q (Wang et al. 2007a) to ligate a chemically adenylated Cy3 or Cy5 (AppX) to 
the 3’- end of miRNAs. In the latter three cases 2.5 fmol of each individual miRNA 
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(universal reference vers. 0.9) was incubated with the respective ligase in 2 µl 10x RNA 
ligation buffer (Pfeffer et al. 2005), 6 µl 50% DMSO and 2-100 µM AppX (the synthesis 
and structure of the dye has been described previously by Pfeffer et al. (2005)) in a final 
volume of 20 µl as indicated in the results section. The samples were heated at 95°C for 
30 s and immediately placed on ice for 1 min before the ligation reaction that was carried 
out for 4 h to 24 h. 
Hybridization was performed using an automated hybridization instrument following the 
manufacturer’s instructions (a-HybTM Hybridization Station, Miltenyi Biotec). Briefly, the 
volume of labeled sample was adjusted to 100 μl with nuclease-free water and 100 μl 2x 
Hybridization Solution (Miltenyi) pre-warmed to 42°C was added. After mixing, the 
solution was preheated to 70°C for 2 min prior to application to the a-Hyb Station. 
Microarray processing in the a-Hyb was performed as follows: incubation in Pre-Hyb 
Solution (Miltenyi) for 5 min at 42°C, hybridization with the labeled RNAs for 960 min at 
42°C, washes with Wash Buffer I (Miltenyi) for 1 min at 10°C (2 cycles), and with Wash 
Buffer II (Miltenyi) for 1 min at 10°C (2 cycles). The pump speed at all incubations was 
set to 1 ml/min. Microarrays were blow-dried and scanned with the Agilent DNA-
Microarray Scanner (Agilent).  
2.2.3 RNA amplification, labeling and hybridization for mRNA profiling 
For the generation of amplified cDNA, we used the µMACSTM SuperAmpTM Kit 
(Miltenyi). Briefly, 5-20 ng total RNA were added to SuperAmp Lysis Buffer, the mRNA 
was labeled using magnetic beads, and in-column cDNA synthesis was performed using 
tagged random and oligo(dT) primer. First strand cDNA was 3′ tagged using a terminal 
deoxynucleotidyl transferase. Tagged cDNA was globally amplified using primer 
complementary to the tag sequence and incubating at 78 °C for 30 s, 20 cycles of 94 °C for 
15 s, 65 °C for 30 s, and 68 °C for 2 min followed by 21 cycles of 94 °C for 15 s, 65 °C for 
30 s, and 68 °C for 2.5 min with an extension of 10 s/cycle and a final step of 68 °C for 
7 min. PCR product was purified using the High Pure PCR Purification Kit (Roche, 
Mannheim, Germany) and cDNA yield was measured by NanoDrop (NanoDrop 
Technologies Inc.).  
200 ng purified PCR product was labeled Cy3-dCTP (GE Healthcare, Waukesha, USA) in 
a Klenow Fragment (10 units per sample) reaction for 2 h at 37 °C before heat inactivating 
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at 70 °C for 5 min. Labeled cDNA was purified using the CyScribe GFX Purification Kit 
(GE Healthcare) and quantified by OD measurement. 
Agilent whole human genome 4x44k microarrays were hybridized according to the 
manufacturer's instructions. Briefly, 1.5 μg of of Cy3- labeled and purified cDNAs were 
adjusted to a volume of 44 μl and denatured 3 min at 70 °C. After adding 11 µl Blocking 
Agent (Agilent) and 55 μl 2× Hybridization Buffer (Agilent), samples were incubated on 
the microarrays at 65 °C for 17 h at 10rpm. Afterwards microarrays were washed with 
Wash Buffer I (Agilent) for 1 min at 25 °C, with Wash Buffer II (Agilent) for 1 min at 
37 °C, and dried after 30 s incubation in Acetonitrile. Scanning was performed using the 
Agilent DNA-Microarray Scanner. 
2.2.4 Microarrays 
The design of the miRNA microarrays changed slightly during the course of analysis with 
respect to the newest miRBase sequence database (Griffiths-Jones 2006). The exact 
configuration of each microarray is deposited at the National Center for Biotechnology 
Information Gene Expression Omnibus (see section 5.1, Table A1). In the latest version, 
each microarray contained 1376 quadruplicate spots of DNA oligonucleotides reverse 
complementary to miRNAs from human, mouse, rat, and viruses and in addition 97 control 
oligonucleotides. Because some miRNAs are perfectly conserved between species, the 
1376 oligonucleotides covered altogether 2063 miRNAs, including 871 human, 
634 mouse, 426 rat, and 132 viral miRNAs as deposited in the miRBase sequence database 
vers. 12.0. The 97 positive and negative control probes were chosen as follows: 
miRControl 1 (four sequences) and miRControl 2 (single sequence) were used to assess 
efficiency and sensitivity of labeling, while miRControl 3 (18 sequences) was used to 
normalize signal intensities across different samples and arrays. All miRControls were 
artificial sequences which were chosen by bioinformatic means to have no homology with 
any of the human, mouse, rat or viral genomes and validated experimentally for cross 
hybridization with any of the probes represented on the microarray. A fourth set of positive 
controls (36 sequences) was composed of probes for other small non-coding RNAs 
including rRNAs, tRNAs, U2 and U6 snRNAs. A fifth set of oligonucleotides 
(13 sequences) are single and double mismatch probes at different positions, antisense and 
scrambled miRNA sequences, all resembling negative controls for hybridization. The 
microarrays were manufactured by Miltenyi Biotec. Briefly, 1.2 nl of 10 μM HPLC 
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purified, 5' amino-modified DNA oligonucleotides (Metabion, Martinsried, Germany) 
were spotted four times on aminopropyltrimethoxysilane/phenylendiisothiocyanate coated 
glass slides using a customized piezoelectric spotter. 
Signal processing and quantification of the scanned images was done as described before 
(Landgraf et al. 2007). Depending on the experimental setup, different ratio calculation and 
normalization methods were applied using an in house software (miRXplorer) as 
previously described (Bissels et al. 2009).  
For Agilent whole genome arrays, scanned images were analyzed using the Agilent 
Feature Extraction software (Version 9.1) by which the local background was subtracted. 
A two-tailed t-test was used to determine the signal versus background significance. The 
significance values were used for filtering of the data set, considering only those signals 
with p-values of <0.01 on at least three out of eight arrays (CD133 and CD34 samples), or 
two out of four arrays (Neg samples). After that, the signal intensity data was normalized 
to the array median and multiplied by the median calculated from all values.  
For downstream statistical analysis of miRNA and mRNA array data, ratios were log2 
transformed and data imported in TIGR MeV (Saeed et al. 2003). Two dimensional 
hierarchical clustering (Eisen et al. 1998) was done using Euclidean Distance. The 
statistical analysis of microarrays was performed using SAM (Tusher et al. 2001) with at 
least 100 permutations per analysis, t-test (Pan 2002) with p-value of < 0.05 and adjusted 
Bonferroni correction or t-test with p-value of <0.01.  
2.2.5 qRT-PCR and Solexa sequencing 
The miScript PCR System (Qiagen) was used to validate some of the differentially 
expressed miRNAs. The RT-PCR reaction and the real-time PCR were carried out 
according to the manufacturer’s protocol. Data were normalized using RNU6B 
(MS00014000) or RN5S1(MS00007574). PCR reactions were performed in triplicates and 
carried out in an ABI Prism 7000 SDS Real Time PCR machine (Applied Biosystems, 
Foster City, USA) and analyzed using ABI Prism 7000 System SDS software (version 1.1). 
Total RNA samples were processed as previously described (Hafner et al. 2008). Briefly, 
small RNAs were isolated using denaturing polyacrylamid gel electrophoresis, followed by 
adapter ligation using Rnl2(1-249)K227Q (Wang et al. 2007a)and T4 Rnl1 (Fermentas), 
reverse transcription, PCR amplification and sequencing-by-synthesis (Solexa, Illumina, 
San Diego, USA). 
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2.2.6 Luciferase Assays for miRNA target validation 
60mer DNA oligonucleotides (Metabion) consisting of the test sequence (Table 1) flanked 
by PmeI, XhoI (overhangs) and NdeI or NotI (internal) restriction sites were cloned 
downstream of the firefly luciferase gene into the pmirGLO Dual-Luciferase miRNA 
Target Expression Vector (Promega, Madison, USA) using standard procedures.  
HEK293T cells were plated into 96-well plates and cotransfected with the described 
luciferase reporter construct and the appropriate miRNA precursor (Applied Biosystems) 
using Attractene (Qiagen). Lumincescence was quantitated 48 hours after transfection by 
using the Dual Glo Luciferase Assay System (Promega) on a GENios Reader (Tecan 
Männedorf, Switzerland). 
 
Table 1.  DNA sequences cloned into pmirGlo Dual-Luciferase miRNA Target Expression Vector. 
name of DNA oligo sequence (sense orientation) GeneBank 
FZD5_29 AAACTACATATGGCCAAGGTCACTTCCGTTTACCTTCATGGTGCTGTTGCCCCCTCCCC NM_003468 
FZD5_24_99 
AAACTACATATGAGATTTGGTGACTTTTGAT
ACGGGTTTGGTGCAGGTGAATTTATTACTGA
GCCAAATGC 
NM_003468 
TPM1 AAACTACATATGTGTTGGAAACACAATCAGGTGTGGATTGGTGCTACTTTGAACAAAAC NM_001018007 
Trib_125 AAACTACATATGTGTTAGCATTTAACTTCT TGTTAGGATTCAGGGAAGGAACAGTTGGC NM_021643 
Trib_99 AAACTACATATGGTGATGTATTAAGCCAGTACTTCAATTACGGGTTGACTTGGGATGAC NM_021643 
CD34 AAACTAGCGGCCGCGGGACCAGGTCTTGGAGCTGAGCCTCTCACCTGTACTCTTCCGAAAC NM_001025109, NM_001773 
CD133 AAACTAGCGGCCGCACTTTTTTACACTGAGTTTCTATTTAGACACTACAACATATGGGGTGC NM_006017.2 
HoxB4 AAACTACATATGTGATAATATTATTATTACTATTTTTTTGTGTCATGTGAGTCCTCTCTC NM_024015 
Myb AAACTAGCGGCCGCGTAAATGCCAAATGAAAAACGTTTTTTGCTGCTATGGTCTTAGCCTC NM_001130173 
miR-15 AAACTACATATGCACAAACCATTATGTGCTGCTAC MI0000069 
 
2.3 Bioinformatics 
2.3.1 Prediction of miRNA targets 
Prediction of miRNA targets was performed using TargetScan (Lewis et al. 2005), miRDB 
(Wang 2008; Wang and El Naqa 2008), PicTar (Krek et al. 2005), ElMMo (Gaidatzis et al. 
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2007), miRanda (John et al. 2004) and PITA (Kertesz et al. 2007). For further analysis, 
targets predicted by at least three out of six target prediction tools were used or targets 
predicted exclusively by TargetScan. 
2.3.2 Combined analysis of miRNA and mRNA profiles 
Combined analysis of miRNA and mRNA profiles was carried out by investigating the 
coexpression of the bioinformatically predicted miRNA-mRNA pairs. The predicted 
targets were selected based on (1) their expression level and/or (2) based on inversed 
expression, e.g. miRNA up-regulated and the predicted mRNA down-regulated.  
The expressed (detected) probes were filtered as follows: probes with a p-value below 0.01 
on 75% of the arrays were considered if the probe was not present in the lowest quartile of 
the array and if it was detected on more than 75% of the arrays.  
The predicted and coexpressed mRNAs were tested for a significant enrichment of 
annotations using the proprietary TreeRanker software (Miltenyi Biotec GmbH). As 
annotation sources, databases containing information on Gene Ontology (GO) categories, 
protein sequence motifs, interaction data, complex membership and involvement in 
biological pathways were used. As background for the analysis, the probe set of the filtered 
Agilent Whole Human Genome Oligo Microarray was chosen. Enrichment p-values were 
computed by Fisher’s exact test with subsequent correction for multiple testing using 
Benjamini Hochberg FDR. The Enrichment Factor is a parameter that shows the extent to 
which genes in an annotation group are overrepresented, e.g. if A of B analyzed genes are 
annotated as "category X" and overall C of D genes on the whole microarray are annotated 
as "category X", the Enrichment Factor is (A/B)/(C/D). The p-value threshold was 0.05 
and the factor of enrichment was required to be at least 3. 
2.4 Cell culture 
2.4.1 Cultivation of CD133+ cells 
CD133+ cells were cultivated in StemSpan serum-free medium (StemCell Technologies, 
Vancouver, Canada) or in CellGro (CellGenix, Freiburg, Germany) supplemented with 
STF+I+A: 10 µg/mL heparin (Ratiopharm, Ulm, Germany), 10 ng/mL mouse SCF (R&D 
Systems, Minneapolis, USA), 20 ng/mL mouse TPO (R&D Systems), 10 ng/mL human 
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FGF-1 (Invitrogen, Frederick, MD), human IGFBP2 (R&D Systems) and human Angptl5 
(Abnova, Taipei City, Taiwan). STF supplement is the same without IGFBP2 and Angptl5.  
Cells were cultured at 37°C in 5% CO2 in U-bottom 96-well plates with 150-200 µl of the 
indicated medium.  
2.4.2 CFSE and CFU assay 
The number of cell divisions was analyzed using CFSE labeling. In brief, cells were 
washed in PBS with 0.1% FCS and then stained with carboxyfluorescein diacetate N-
succinimidyl ester (CFSE; Sigma-Aldrich, Steinheim, Germany) at a final concentration of 
2.5 µM for 10 min at 37°C. Staining reaction was stopped with ice cold RPMI 1640 
(Miltenyi) with 10% FCS (Gibco, Eggstein, Germany) for 5 min. with three subsequent 
washes.  
Colony forming unit (CFU) assays were performed to study the developmental potential of 
CD133+ and CD34+cells. For cultivation cells were added to methylcellulose media (HSC-
CFU complete with Epo; Miltenyi) and plated in 6-well plates at a final concentration of 
100 CD34+cells/ml. After incubation for 14 days at 37° C and 5 % CO2 colonies were 
classified by their color and morphology using an inverted microscope. 
2.4.3 miRNA transfection of cultivated CD133+ cells 
CD133+ cells from mobilized peripheral blood were thawed, washed and plated at 104 cells 
per 150 µl in StemSpan + STF (see section 2.4.1) in one well of a U bottom 96-well plate. 
After one day of cultivation CD133+ cells were transfected with double-stranded RNAs 
that mimic endogenous precursor miRNAs (Applied Biosystems). A FITC labeled 
transfection control was obtained from Qiagen (AllStars Negative Control siRNA). 
Transfection was performed by using HiPerfect (Qiagen). Briefly, miRNA mimics and 
0.75 µl HiPerfect were added to 25 µl StemSpan. After vortexing and incubation for 
10 min, the transfection mix was added to the cells. The medium was changed after 24h 
transfection.  
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3 Results  
3.1 Setup of microarray platform 
One of the techniques used for miRNA analysis are microarrays. Microarrays allow for 
screening and measurement of all known miRNAs simultaneously. A microarray 
experiment entails extraction and labeling of RNA, followed by a hybridization step, where 
the labeled nucleic acids bind to the complementary sequences of the respective probes.  
For the analysis of miRNAs by using microarrays, the peculiarities of miRNAs such as the 
short length have to be taken into account. The short length of miRNAs results in a high 
dynamic range of melting temperatures and therefore impedes a proper selection of 
detection probes. 
3.1.1 Microarray probe design 
Different probe designs were investigated with respect to sensitivity and selectivity of 
microarray hybridization. An array with 11 different variants of oligonucleotides for miR-
122a and miR-16 was produced (Figure 6). This included an attempt to normalize the 
melting temperatures (Tm) for the probe/miRNA pairs by altering the probe length (Goff et 
al. 2005)). Tm were calculated using the OligoAnalyzer 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx?c=EU) and were 
adjusted to the miRNA probe with the lowest melting temperature (50.2 °C ± 0.43).  
Synthetic miR-16 and miR-122a oligoribonucleotides were labeled enzymatically with 
Cy3 and hybridized to the array to test the hybridization efficiency of the different 
oligonucleotide variants. 
The DNA probes immobilized via a C6-amino linker gave the highest signal intensities 
whereas all other oligonucleotide variants reduced the hybridization efficiency (Figure 6).  
The nine oligo variants with an adjusted Tm showed a decrease in sensitivity of 40-93%. 
Moreover, as also observed for the variation of the other parameters, the effect of adjusted 
probe length was dependent on the miRNA sequence underlining the difficulty of thorough 
theoretic Tm estimation in complex assays. Based on these results, the standard DNA 
oligonucleotide carrying a C6-amino linker was used for microarray production.  
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Figure 6.  Relative signal intensities of different oligodeoxynucleotide probes for miR-16 and miR-122. The 
signal intensity of each different oligo variant is displayed in relation to the corresponding 
standard probe signal intensity which is set to 100%. All oligodeoxynucleotide probes comprise 
the reverse complementary sequence of miR-16 and miR-122 and are covalently linked to the slide 
surface via C6-amino linker except for the no linker controls. a: standard probe: perfect match 
reverse complementary miRNA, C6-amino linker; b-d: probe variants with an additional spacer of 
6, 12, and 18 random nucleotides on the 5´-end; e,f: dimer or trimer probe variants; g,h: truncated 
probe variants; i-l: probe variants without linker. 
3.1.2 Probe-target specificity 
The selectivity and specificity of the microarrays was tested by comparing the absolute and 
relative signal intensities of perfectly matched, single mismatched, double mismatched, 
antisense, and scrambled probes for several miRNAs. Cross hybridization signals of the 
single and double mismatched probes were in the range of <25 % and <2% respectively 
when compared to perfect match probes (Figure 7). No significant signal could be detected 
for antisense or scrambled probes (data not shown).  
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Figure 7.  Probe-target specificity. Signal intensities detected for perfect match, single mismatch and double 
mismatch probes targeting hsa-miR-9, hsa-miR-23a, and hsa-miR-27a. The probe sequences 
(reverse complement to mature miRNA sequence) are given below diagrams with mismatches 
indicated. Signal intensities were normalized to the perfect match probe-target hybrid for each 
microarray (rel. SI: relative signal intensity). 
3.1.3 Sensitivity and linear dynamic range of miRNA detection 
The linear dynamic range and sensitivity of the microarray was measured by hybridizing 
dilution series of a Universal Reference vers. 1.0 (UR), an equimolar mixture of synthetic 
miRNAs. The UR was hybridized in stepwise dilutions starting with 10 fmol down to 
1 amol of each individual miRNA. Signal intensity was plotted against the amount of 
20 selected miRNAs detected in all hybridizations. The slope of the dlog-Plots was 1.004 
(+/- 0.05 SD) with a regression coefficient of >0.98 (Figure 8). These results show that the 
linear dynamic range of the microarray exceeded four orders of magnitudes with an 
absolute detection sensitivity of less than 1 amol target miRNA.  
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Figure 8.  Dynamic range of the miRNA microarrays. An equimolar mixture of miRNAs was labeled and 
hybridized to microarrays in amounts of 1 amol to 10 fmol per miRNA. Net signal intensities 
(background subtracted signals) for 20 miRNAs are shown. The slope within the dlog-Plots was 
1.004 (+/- 0.05 SD) with a regression coefficient of >0.98.  
3.1.4 Comparison between sequencing and microarray 
The standard method to explore new miRNAs is small RNA sequencing. Recently, a large 
scale study was performed to identify miRNAs and to assess their expression patterns in 
over 250 small RNA libraries from over 26 different organ systems enriched in neuronal as 
well as normal and malignant hematopoietic cells and tissues (Landgraf et al. 2007). 
We have used our arrays within this large scale study to validate the results of the miRNA 
profiling achieved by sequence analysis of small RNA clone libraries. Therefore, five 
samples that were cloned within the study were also hybridized using 5 µg total RNA of 
each sample. Each sample was hybridized in a dual color approach versus the UR 
(version 0.9). One sample, namely total RNA of CD4+ T-cells (CD4-A301) was also 
analyzed using 10 μg of total RNA to check for reproducibility and potential bias due to 
varying amounts of input RNA.  
Both cloning and microarray profiling gave highly reproducible results (Figure 41), with 
Spearman correlation coefficients of 0.94 (cloning) and 0.92 (microarray), and Pearson 
correlation coefficients of 0.91 (cloning) and 0.99 (microarray).  
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Figure 9.  Correlation of clone count data (left) and microarray hybridization (right). 5 µg of total T-cell 
RNA were hybridized on array 517067, 10 µg on array 517068. The correlation coefficients were 
calculated by the group of Mihaela Zavolan. rP: Pearson correlation; rS: Spearman correlation; 
pool: UR. 
 
Even the results generated by the two independent methods showed a remarkable high 
correlation with Spearman correlation coefficients in the range of 0.4-0.7 (Figure 10A).  
Furthermore, our miRNA microarray data were compared with published studies (Barad et 
al. 2004; Liu et al. 2004; Nelson et al. 2004; Sempere et al. 2004; Baskerville and Bartel 
2005; Lu et al. 2005; Shingara et al. 2005; Wang et al. 2007a) for liver and brain sample.  
Comparisons of the miRNA expression profiles from these studies with our array resulted 
in Spearman correlation coefficient rS > 0.5 with many other studies, in particular those of 
Landgraf, Baskerville, Wang, Sempere and Barad (Figure 10B). Thus, our array data 
correlated well not only with other array studies (Baskerville, Wang and Barad) but also 
with the cloning study (Landgraf) and the Northern blotting study (Sempere).  
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Figure 10. Comparison between small RNA cloning and microarray hybridization. (A) Spearman’s rank 
correlation of clone count data and microarray data. 5 µg of RNA samples were hybridized, except 
for CD4-A301 (517068) where 10 µg were used. The RNA samples were obtained from the 
following organs and cell lines (details in Supp Tab 1 of Landgraf et al. (2007)): 
Hippocampus: hsa_Hippocamp-adult; SNB19: hsa_Gliobl-SNB19 (Glioblastoma); PLC: 
hsa_Hepatoma-PLC, Huh7-mock: hsa_Hepatocell-carcinoma-Huh7-mock, CD4-A301: hsa_T-
cell-CD4-A301. (B) Heatmap of Spearman’s rank correlation for different studies (computed and 
illustrated in Mihaela Zavolan’s group). Our microarray (Miltenyi) was hierarchically clustered 
together with the cloned hippocampus samples (Landgraf). 
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3.2 Quantification of miRNAs by using a universal reference 
To allow for quantitative miRNA measurement, a universal reference (UR) was used, 
consisting of 954 synthetic human, mouse, rat and viral miRNAs, with each individual 
oligoribonucleotide present in equimolar concentrations. Hybridization of the UR resulted 
in a broad range of signal intensities although equal amounts were hybridized (Figure 11). 
Furthermore, there was no correlation between signal intensity and GC content of the 
miRNAs. Therefore, the signal intensities of different miRNA are not easily predictable 
and do not directly correspond with their absolute amount in terms of copy numbers per 
cell. 
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Figure 11. Hybridization of the UR. An equimolar amount of 954 synthetic miRNAs was hybridized. The net 
signal intensities of the 954 hybridized miRNAs that were sorted according to their GC content 
are shown. The miRNA with the lowest GC content is shown on the left (number 1).  
 
Now, in theory, using the UR any single miRNA detected on a microarray can be 
quantified by directly comparing its signal intensity with the one obtained by the same 
miRNA sequence present in the UR, adjusting for biases related to sequence, labeling, 
hybridization or signal detection.  
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3.2.1 The influence of different miRNA ligases on miRNA labeling and 
quantification 
Besides the nature of the oligonucleotide such as the GC content, it was also tested whether 
different ligases and ligation parameters used for the labeling of miRNAs influence the 
outcome of miRNA quantification upon microarray hybridization. Therefore, universal 
reference (v0.9) was labeled with three ligases, Rnl1, Rnl2(1-249), and Rnl2K227Q. 
Additionally, the labeling incubation time was varied as well as the amount of labeling dye 
for the labeling reaction. The influence of labeling time (4 to 24 h) and amount of labeling 
dye (2 – 100 µM) was miniscule (data not shown) and therefore the data of these arrays 
were combined. For an overall analysis significance analyses of microarrays (SAM) were 
performed separately for the combined time course experiment (3 arrays per ligase) and the 
dye concentration experiment (4 arrays per ligase). The intersection of both analyses led to 
51 miRNA candidates (False Discovery Rate (Median): 0.00000 %) that are significantly 
differently labeled by the different ligases. A hierarchical cluster analysis (Figure 12) of 
these 51 miRNAs illustrates the potential bias when comparing miRNA data generated 
using different ligases. The influence of the ligases on the labeling efficiency underscores 
the difficulty of absolute quantification.  
Taken together, the data showed that it is necessary to use the same labelig procedure in 
one experiment series. From now on only the Rnl1 labeling was used.  
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Figure 12. Average linkage cluster of miRNAs that are differently labeled by the three tested RNA-ligases. 
The universal reference (vers. 0.9) was labeled with Cy5 by three RNA ligases, Rnl1, Rnl2(1-
249), and Rnl2K227Q (n=7 for each ligase). Discriminatory gene analysis of the microarray signal 
intensities by the SAM (Significance Analysis of Microarrays) algorithm resulted in 51 miRNAs 
that are differentially labeled by the different ligases. These miRNAs were grouped according to 
similarities using two-dimensional hierarchical clustering (Euclidian distance, average linkage). 
Log2-transformed expression ratios are indicated from −3 (green) to 3 (red). 1-7: sample 1-7 
labeled by Rnl2K227Q; 8-14: sample 8-14 labeled by Rnl2(1-249); 15-21: sample 15-21 labeled 
by Rnl1. 
3.2.2 Relative quantification of miRNAs across multiple experiments 
Next, it was analyzed to which extent the universal reference can be used as a tool for the 
relative quantification of miRNAs across multiple experiments. Therefore, direct 
hybridizations (i.e. two samples labeled with two different colors on the same array) were 
compared to indirect hybridizations (i.e. one array per sample, labeled with Cy5 with the 
UR (v1.0) labeled with Cy3 and hybridized in parallel). For the direct hybridizations, 5µg 
liver total RNA vs 5 µg brain total RNA (n = 3) were labeled and hybridized to the arrays. 
The experiments were carried out in triplicates. For the indirect hybridization 5 µg liver or 
brain total RNA and 5 fmol/miRNA of the UR were labeled and the experiments carried 
out in triplicates. The so-called re-ratios for the indirect hybridizations were calculated by 
dividing the ratios of sample signal and UR signal of the liver arrays and the brain arrays. 
These re-ratios were compared with the ratio of the liver and brain sample signals from the 
direct hybridizations. Pearson correlation coefficients were about 0.98 for the array 
replicates and about 0.95 comparing the direct hybridizations with the indirect 
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hybridizations (Table 2). Taken together, these results demonstrate that the universal 
reference can be used as a common reference sample for a relative quantification of 
miRNA expression measured in independent experiments.  
 
Table 2. Correlation matrix showing the relationship between direct hybridization (B_Cy5_L_Cy3, n=3) 
and indirect hybridization (B_Cy5_L_Cy5, n=3). For the direct hybridizations (Table 1, 4-6), 5µg 
liver total RNA labeled with Cy5 and 5 µg brain total RNA labeled with Cy3 were hybridized on 
the same microarray and for the indirect hybridization (Table 1, 1-3) 5 µg liver or brain total RNA 
labeled with Cy5 together with the UR (5 fmol/miRNA) labeled with Cy3 (highlighted in gray). 
The ratio of the signal intensities from brain total RNA and the liver total RNAs was the basis for 
the Pearson correlation. B: brain; L: liver. 
   B_Cy5_L_Cy5 B_Cy5_L_Cy3 
 Hybridization   1 2 3 4 5 6 
1  - 0.975 0.978 0.943 0.947 0.948 
2 0.975 -  0.976 0.937 0.946 0.945 B_Cy5_L_Cy5 
3 0.978 0.976 -  0.943 0.949 0.949 
4 0.943 0.937 0.943  - 0.984 0.995 
5 0.947 0.946 0.949 0.984  - 0.993 B_Cy5_L_Cy3 
6 0.948 0.945 0.949 0.995 0.993  - 
3.2.3 Absolute quantification of miRNAs – proof of principle 
A direct absolute quantification of miRNAs by measurement of the array signal intensity is 
impossible due to the sequence dependent labeling and hybridization efficiencies of 
miRNAs. In order to test whether the equimolar universal reference (UR) could 
compensate for sequence dependent differences and thus allow for an absolute 
quantification of miRNAs the amount of spiked-in miRNAs was measured in complex 
hybridization experiments. First, the miRNA expression profiles of mouse liver was 
measured by microarray hybridization (n=20) and 75 miRNAs were selected which were 
not detected in this tissue. Then, mouse liver total RNA was supplemented with 75 
synthetic oligoribonucleotides corresponding to these miRNAs. The spike-in miRNAs 
were added to 500 ng or 1 µg liver total RNA in varying amounts ranging from 0.3125 
fmol to 20 fmol – with 7 miRNAs present in amounts of 0.3125 fmol, five sets of 12 
miRNAs containing 0.625, 1.25, 2.5, 5, 10 fmol per miRNA, respectively, and 8 miRNAs 
with 20 fmol. The liver-RNA including the 75 spike-ins was enzymatically labeled with 
Cy5 and hybridized together with the UR (vers. 0.9) and the 75 spike-ins with 2.5 
fmol/miRNA labeled with a Cy3 dye. After normalizing the array by calculating the 
median of the miRControl 3 present in the liver and UR sample, the miRNA amount of the 
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liver spike-ins was calculated with respect to the corresponding miRNA in the UR. The 
experiments were carried out in quadruplicates. 
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Figure 13. Absolute quantification of spike-in miRNAs. (A) Liver total RNA was spiked with 75 synthetic 
miRNAs not detectable in liver in amounts ranging from 0.3125 to 20 fmol and hybridized vs. the 
universal reference. The measured and expected amounts for the 75 spike-ins are shown (empty 
black diamonds). The measured mean value and its standard deviation are shown as black square. 
The diagram displays one of four array experiments (complete data are shown in the appendix, see 
section 5.2, Figure A1). (B) Two dimensional hierarchical cluster analysis (Euclidian distance, 
single linkage) of signal ratios (log2 transformed) obtained from the 75 spike-ins versus UR. The 
75 spike-ins are shown for four array experiments (that are also described in A) with the added 
fmolar amount in front of their name.  
 
The expected values, and the actually measured values are shown in Figure 13A and in the 
appendix (Figure A1). 59% (n=4) of the 75 spike ins lay within the symmetric 50% 
interval of the expected value, i.e. 44±5 of the 75 spike ins showed a deviation of less than 
25%. Furthermore, the absolute amount of miRNA abundance could be quantified with a 
mean accuracy of 22-31% (median 17-25%) for the four arrays. For example, miR-302b* 
was spiked in with 0.625 fmol (representing the expected value) while the measurement of 
miR-302b* yielded 0.469 fmol showing a negative deviation of 25%. The absolute 
measurement of miRNAs across the multiple replicates was highly reproducible with a 
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mean variation coefficient of 11.5%. The data of the measured amount of the spiked in 
miRNAs is available in the appendix (see section 5.2, Table A2).  
However, 17 outliers were also observed which reproducibly deviated from the expected 
value by more than 25% on all four arrays. The measured amount of the worst outlier 
differed from the expected value by the factor of two (Figure 13B).  
The fact that these deviations were highly reproducible pointed to a systematic error and 
prompted to further investigate potential sources of bias. These could be crosshybridization 
in the Cy3 or Cy5 channel, labeling artifacts, a non linear dynamic response of the 
spike-ins, and pipetting errors. Pipetting errors were excluded as multiple independent 
repetitions pipetted showed the same deviations (data not shown). Probe-target 
crosshybridization of liver targets with spike-in probes would lead to an overestimation of 
the spike-in amount (Cy5 channel). An underestimation would occur in case of UR target 
crosshybridization to a spike in probe (Cy3 channel). These potential sources of bias could 
be excluded as no crosshybridization were observed on spike-in probes when hybridizing 
the UR or the liver RNA without the spike-ins. A non linear dynamic relation between the 
concentration of a miRNA and the resulting hybridization signal could also lead to a 
distortion of miRNA measurement. However, a linear dynamic range at least from 0.3125 
to 10 fmol was measured (see section 3.1.3) and in addition, no trend of increasing 
deviation towards lower concentrations of spike-ins was observed.  
Labeling artifacts such as differing labeling efficiency for the highly purified pool of 
synthetic RNAs compared to total RNA extracted from tissue could also be the reason for 
the outliers. Therefore, self-self hybridizations of the UR were performed and the labeling 
of synthetic RNAs was compared with the labeling of synthetic RNAs in the context of 
total RNA. This was a possibility to rule out that the complex mixture of different RNA 
species present in total RNA interferes with the labeling efficiency. No significantly 
differing signal intensities of individual miRNAs were observed for the two different dyes 
in self-self hybridizations of the UR. The mean ratio for all UR miRNAs was 1.04 ± 0.27, 
the mean ratio for the subset of the spike-ins was 1.05 ± 0.10.  
Next, the spike ins alone (Cy3) versus the spike ins plus liver total RNA (Cy5) were 
hybridized, to compare the labeling of synthetic RNAs with the labeling of synthetic RNAs 
in the complex background of total RNA. The mean ratio of the 75 spike-ins was 1.06 ± 
0.50 (n=2), pointing to a higher degree of variation as observed in the self-self 
hybridizations of UR. Taken together, the results of these experiments led to the 
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conclusion that there is no single explanation for the 17 outliers and that, probably the 
complexity of a sample has the biggest impact on quantification accuracy. 
These experiments show that it is possible to measure the absolute amount of miRNAs in a 
complex sample using microarrays. 
3.2.4 Absolute quantification of miRNAs in primary cells 
The amount of miRNAs was calculated for miRNAs that were detected in 1 µg total liver 
RNA from four independent experiments. The amount of different miRNAs ranged 
between 0.005 and 8.8 fmol (28 – 52,567 miRNA copies per 10 pg total RNA) with the 
median amount being 0.11 fmol (633 copies per 10 pg total RNA), and the total amount 
being 19.2 fmol equivalent to 115,330 copies per 10 pg RNA (Figure 14A). As the miRNA 
proportion in total RNA has been estimated to 0.01 % in tissues (Peltier and Latham 2008), 
one would expect 0.1 ng (15 fmol) miRNAs in 1 µg total RNA, matching quite well with 
their calculated overall amount. 
Next, 0.5 µg total liver RNA were also labeled and hybridized in duplicate and the 
calculated miRNA copy numbers were compared to those obtained from 1 µg total RNA. 
The correlation coefficient between the experiments was 0.996±0.002 indicating almost no 
influence of the amount of starting material. The slope of the regression plot was 
0.50±0.07, showing that the calculated miRNA amount in 500 ng is half of the amount in 1 
µg, as expected (Figure 14B). 
The copy numbers of three selected miRNAs were validated via qRT-PCR. The amounts 
were calculated with respect to a standard curve based on a serial dilution of the UR. As 
control, synthetic miR-30b was used to generate a standard curve giving similar results. 
As shown in Figure 14D, the miRNA copy numbers determined by qRT-PCR for miR-30b, 
miR-122 and miR-16 agreed very well with the amounts that were measured by using 
microarrays. 
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Figure 14.  (A) Absolute expression level of the 25 highest expressed miRNAs detected in 1 µg liver (n=4). 1 
µg liver total RNA was labeled with Cy5 and hybridized together with 2.5 fmol/miRNA of UR. 
The median miRNA amount calculated from the signal intensities after comparison with the UR 
was 633 copies per 10 pg liver total RNA. (B) Dlog-plot showing the calculated amounts for the 
detected miRNAs in 500 ng and 1 µg liver RNA. The correlation coefficient is 0.997 and the slope 
0.51 (expected slope: 0.5). (C) Comparison of microarray and qRT-PCR data for miR-16, 
miR-30b and miR-122. 1-10 ng liver total RNA were used for the qRT-PCR. Copy numbers per 
10pg total RNA were calculated using standard curves based on the UR (n=3). Microarray data 
same as in A. 
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Next, the copy numbers of miRNAs in CD34+ human hematopoietic progenitor cells were 
determined. The RNA extracted from 7 x 105 to 1 x 106 CD34+CD133– cells of three 
different donors was analyzed. To reduce the biological noise introduced by individual 
differences between the three independent donors, we focused on strongly expressed 
miRNAs by applying a threshold filter of signal to background ratio of two. This resulted 
in 43 miRNAs detected in all three donors. The Spearman correlation coefficients of the 
miRNA expression profiles were 0.70 – 0.87 for the three biological replicates. The highest 
expressed miRNAs were miR-223 and miR-451 with copy numbers of up to 1,972 copies 
per cell. The copy numbers for the ten most abundant miRNAs are shown in Figure 15A 
and the numbers for all 43 detected miRNAs are listed in the appendix (see section 5.2, 
Table A3). The median copy number was 178 copies per cell and the overall copy number 
was 11,587 ± 945. The absolute measurement for the three samples had a mean variation 
coefficient of 39%. Figure 15B displays the net signal intensities on the left and the 
corresponding miRNA copy number per cell on the right for three different miRNAs. 
Interestingly, the UR net signal intensities for miR-30B, miR-126-3P, and miR-106A differ 
notably and do not correlate with the respective Gibbs free energies or melting 
temperatures (Table 3). This example demonstrates again (see also Figure 11), that the 
signal intensities of different miRNAs are not easily predictable and do not directly 
correspond with their absolute relation in terms of copy numbers per cell.  
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Figure 15.  MicroRNA copy numbers of CD34+CD133– cells prepared from three different donors. (A) The 
ten most abundant miRNAs in CD34+CD133– cells are shown. The copy numbers per cell for the 
highest expressed miRNAs miR-223 and miR-451 were determined to be between 828 and 1,972. 
(B) Net signal intensities (left) and miRNA copy numbers (right) for miR-30b, miR-126-3p and 
miR-106a are shown (donor 2).  
 
Table 3. Selected characteristics of miRNA examples shown in Figure 15B. 
 miR-30b miR-126-3p miR-106a 
length [nt] 22 22 23 
GC content [%] 40.9 45.5 47.8 
calculated Tm [°C] 49.8 46.8 50.2 
ΔG [kcal/mol] -36.22 -40.79 -40.23 
net signal intensity [LU] 2214 11466 24419 
 
Results 36
3.3 miRNA expression in human hematopoietic stem and progenitor cells 
In order to analyze the miRNA expression in human hematopoietic stem and progenitor 
cells, different subpopulations expressing CD133 and/or CD34 were isolated. After that 
semiquantitative and quantitative miRNA profiles were generated. The data was validated 
using Solexa sequencing and qRT-PCR. 
3.3.1 Separation of human hematopoietic stem and progenitor cells 
Different subpopulations of hematopoietic stem and progenitor cells expressing CD133 
and/or CD34 were isolated to characterize the role of miRNAs in the early steps of 
hematopoisis. CD133+ cells were isolated from bone marrow, followed by a second 
separation for CD34+CD133– cells using the negative fraction of the first separation 
(Figure 16). The negative fraction of the second separation, the CD133–CD34– cells were 
also applied to further analysis.  
 
Figure 16. Separation of CD133+ and CD34+ cells by using the CliniMACS Cell Separation System. CD133+ 
cells were isolated from bone marrow, followed by a second separation for CD34+CD133– cells 
using the negative fraction of the first separation. 
 
The separated cells were stained for standard flow cytometric analysis according to the 
ISHAG (Sutherland et al. 1996) guideline. An example of the gating procedure for the 
CD133+ cell separation is shown in Figure 17, for the CD34+ cell separation in Figure 18. 
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The mean donor age was 76 years. The mean purity (related to all cells) of the CD133+ 
cells was 69% (range 56% - 90%), of the CD34+CD133– cells 73% (range 55% - 83%). 
The mean purity related to all viable cells was 80% (range 68% - 91%) for the CD133+ 
cells and 84% (range 70% - 92%) for the CD34+CD133– cells. However, as the cells were 
applied to RNA isolation and microarray hybridization and not to cultivation, the mean 
purity related to all cells is the relevant one and listed in Table 4. The percentage of 
CD133+ cells within the starting material (oriori) lay between 0.19% and 0.72%. 
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Figure 17.  Four-color fluorescence analysis for CD133+ cells. The gating procedure for donor 10 is shown. 
The samples were stained with CD45-FITC, CD34-APC, CD133-PE and PI. Isotype control Ig2a 
was stained with Ig2a-APC, CD45-FITC and PI, control Ig2b with Ig2b-PE, CD45-FITC, 
CD34-APC and PI. Gate R1: Discrimination of all WBCs. Gate R2: Exclusion of dead cells. Gate 
R3: Gating of all CD34+ events. Gate R4: Gating of all CD133+ events. Gate R5: Cluster control 
of CD133+ events. Gate R6: Identification of CD133+ stem and progenitor cells. Oriori: sample 
before processing; Ori: sample after bead labeling and washing steps, before starting of 
CliniMACS device; Neg: negative fraction; Wash: washing fraction; Pos: positive fraction. 
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Figure 18. Fluorescence analysis for CD34+ cells. The gating procedure for donor 10 is shown. The samples 
were stained with CD45-FITC, CD34-PE and PI. Isotype control Ig2a-PE was stained with 
Ig2a-PE, CD45-FITC and PI. Gate R1: Discrimination of all WBCs. Gate R2: Exclusion of dead 
cells. Gate R3: Gating of all CD34+ events. Gate R4: Cluster control of CD34+ events. Gate R5: 
Identification of CD34+ progenitor cells. Ori: sample before starting of CliniMACS device; 
Neg: negative fraction; Pos: positive fraction. 
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  Table 4.   
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3.3.2 Microarray platform optimization for rare cell populations 
The miRNA expression in human hematopoietic stem and progenitor cells was analyzed in  
CD133+ and CD34+CD133– cells. After cell separation (see section 3.3.1), total RNA was 
isolated, labeled using Rnl1, and hybridized on miRNA microarrays. 
The first miRNA expression profiles of CD133+ and CD34+CD133– cells of donor one to 
six (Table 4) resulted in a lower number of detectable miRNAs than expected. Less than 
15 miRNAs were detectable in 6 out of 12 samples (Figure 19) using 1µg total RNA. The 
number of detectable miRNAs lay between one and 70, showing a high variability between 
the different samples. Such a variable sensitivity was never observed in the experiments 
before. Therefore, it was speculated, that the low cell number for the RNA isolation was 
the reason. Compared to the setup experiments (see section 3.1) where a total amount of up 
to 200 µg RNA was isolated out of one sample (50 mg mouse liver), the expected RNA 
yield for one sample of CD133+ or CD34+CD133– cells (~ 3 × 106 cells) was 3 µg total 
RNA.  
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Figure 19.  Number of detected miRNAs in 1µg RNA extracted from CD133+ and CD34+CD133– cells of 
donor 1-6. The RNA was isolated using a Trizol based method and labeled and hybridized on 
miRNA arrays. 
Therefore, it was tested whether the Trizol based RNA isolation method was suited for the 
processing of low cell numbers and compared with a column based method (miRNeasy). 
For the comparison of the methods, RNA from CD133+ cells separated from mobilized 
peripheral blood (mPB) was isolated and analyzed (see section 5.3, Table A4). The results 
clearly revealed a better performance of the silica based method as 33 miRNAs were 
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exclusively detected using miRNeasy (Figure 20). One possible explanation for the 
difficulties with the Trizol method was phenol remnants that are in particular enriched if 
low cells numbers are processed. The absorbance of phenol, at 230 nm and ~ 270 nm may 
overlap with the nucleic acid absorbance peak at 260 nm, which would result in an 
overestimation of the RNA amount. Therefore, it is possible that in the experiments 
described before a much lower RNA amount was hybridized as assumed, leading to a loss 
in sensitivity. Using a column based method may prevent remnants that disturb the RNA 
measurement. The RNA of the donors 7-13 was consequently isolated using the column 
based miRNeasy method.  
 
Figure 20.  Number of detected miRNAs in total RNA samples of two different isolation methods, namely 
miRNeasy and Trizol. RNA from CD133+ cells of donor L1 (see section 5.3, Table A4) was 
isolated with both methods and compared. The miRNAs expressed twice as high as the 
background intensity are shown. 
Next, it was also investigated if number and nature of the cell separations had an influence 
on the miRNA profiles. In our experimental setup (Figure 16) CD133+ cells – isolated in a 
one step cell separation – were compared with CD34+CD133– cells that had undergone a 
second cell separation. To test the possibility of differentially expressed miRNAs due to 
the second separation, a control experiment was performed as outlined in Figure 21A. The 
bone marrow sample of one donor was split, whereby one aliquot was used to directly 
isolate CD34+ cells in one step and the second aliquot was used to isolate CD34+ cells after 
an enrichment of CD133+ cells. Therefore, a comparison of CD34+ cells of a first and 
second separation was feasible. The correlation of the CD34+ cells (first separation) with 
the CD34+CD133– cells (second separation) was R2=0.9612 (Figure 21B-C). There were 
only two miRNAs significantly differentially expressed between both populations, namely 
miR-144 and miR-195, both higher expressed in the CD34+ cells of the first separation. 
Thus, a major influence of the second separation on the miRNA profiles could be 
excluded. 
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Figure 21.  Control experiment to exclude differentially expressed miRNAs due to the second separation. (A) 
Design of the control experiments. The bone marrow sample of donor 7 was split and the standard 
procedure was carried out with 70% of the sample (CD133+ cell separation followed by 
subsequent CD34+ cell separation). The other 30% of the sample were used to perform a CD34+ 
cell separation at first. (B) Dlog-plot showing the net signal intensities of miRNAs for the 
different CD34+ cell populations. The data for the CD34+ cells that were directly isolated are 
plotted on the x-axis, the data for the CD34+CD133– cells isolated from the negative fraction of 
the CD133+ cell separation on the y-axis. The correlation coefficient is 0.96. (C) Correlation 
matrix showing the relationship between the different subpopulations. 
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3.3.3 Description of the global miRNA expression 
For the final analysis of the global miRNA profile, the bone marrow subpopulations 
(Figure 16) – CD133+, CD34+CD133–, CD133–CD34– and CD133–CD34–L (with RBC 
lysis) – of five different donors (donor 7-11, Table 4) and additionally two samples of 
CD133+ cells from mobilized leukapheresis (see section 5.3, Table A4) were labeled with 
Cy5 and hybridized versus the Cy3 labeled universal reference. The usage of the universal 
reference, an equimolar pool of 954 synthetic miRNAs of known concentration, allows 
direct comparison of miRNA expression across multiple experiments and absolute 
quantification. 
First of all, Venn diagrams were constructed to get a general impression of the miRNA 
expression. The overall number of detected miRNAs in CD133+ cells was 109, compared 
to 126 miRNAs in CD34+CD133– cells (Figure 22), 151 miRNAs in CD133–CD34– cells 
without red blood cells (RBCs), and 216 miRNAs in CD133–CD34– cells with RBCs. 
59 miRNAs were exclusively expressed at detectable levels in CD133–CD34– cells with 
RBCs. Thus, the diversity of miRNAs was highest in the CD133–CD34– cell population 
including RBCs.  
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Figure 22.  Number of miRNAs expressed in the different hematopoietic subpopulations. Venn diagram 
displaying distinct and shared miRNA expression in CD133+, CD34+CD133– and CD133–CD34– 
cells. For the CD34–CD133– cells two sample types are shown, without (CD34–CD133–) or with 
(CD34–CD133–L) RBC lysis. The miRNAs that were expressed once as high as the background 
intensity in at least four out of five experiments are taken into account. 
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Previously five miRNAs, namely miR-142, miR-144 and miR-223, miR-150 and miR-155 
were identified as highly specific for hematopoietic cells (Landgraf et al. 2007). Three of 
them, namely miR-142, miR-144 and miR-223 were detected in all bone marrow samples; 
whereas miR-150 was only detected in the CD133–CD34– population and miR-155 was 
exclusively found in CD133+ and CD34+CD133– cells.  
Next, the miRNAs expressed in CD133+ and CD34+CD133– cells were analyzed in detail 
and a cluster analysis was performed. Clustering grouped all four subpopulations 
separately as visualized in Figure 23 and revealed distinct miRNA signatures for the 
different cell populations. As expected, the similarity between CD133+ and CD34+CD133– 
cells was higher than between CD133+ and CD34–CD133– cells. 
The miRNA profile of the CD133+ bone marrow samples and the CD133+ mobilized 
leukapheresis samples was very similar with exception of miR-451 and miR-144 
expression. Interestingly, both miRNAs were detected in all bone marrow samples but not 
in the leukapheresis samples. 
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 . 
Figure 23.  Average linkage cluster of miRNAs 
expressed in CD133+, CD34+CD133– and 
CD34–CD133– (Neg) cells. The cluster 
was obtained from array hybridizations 
of different bone marrow subpopulations 
(n=5) and leukapheresis samples (mPB, 
n=2) versus universal reference (UR). 
Those miRNAs are included where the 
net signal intensity of the sample miRNA 
was one fold over background in at least 
four of five donors in the CD133+ and/or 
CD34+CD133– cell population and where 
the miRNA was present in the UR. 
Neg: CD133–CD34–; Neg_L: CD133–
CD34– (RBC lysis). Log2-transformed 
expression ratios are indicated from -3.0 
(green) to 3.0 (red). 
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3.3.4 Differentially expressed miRNAs in hematopoietic subpopulations 
Significance analysis of microarrays (SAM) was performed to investigate the differences 
between CD133+ and CD34+CD133– cells (Figure 24). The analysis led to 18 significantly 
differentially expressed miRNAs [false discovery rate (median): 0.000000%] with three 
different expression signatures: 13 miRNAs (group 1 and 2) were significantly higher 
expressed in CD133+ compared to CD34+CD133– cells. These 13 miRNAs could be 
divided into one group of miRNAs that were not expressed in CD34–CD133– cells 
(group1) and another group where the expression in CD34–CD133– cells was even higher 
than in CD133+ cells (group 2). Five miRNAs (group 3) were significantly lower expressed 
in CD133+ cells. 
The ratios for the 18 miRNAs are shown in Table 5. miR-10a in donor 7 was, for example, 
3.2-fold higher expressed in CD133+ cells than in CD34+CD133– cells. 
 
group 1
highest expression in CD133+ cells
group 3
lowest expression in CD133+ cells
group 2
high expression in CD133+ and 
CD34-CD133- cells
 
Figure 24.  Cluster analysis of miRNAs identified by discriminatory gene analysis of CD133+ cells compared 
to CD34+CD133– cells. Discriminatory gene analysis (DGA) was done by the SAM (Significance 
Analysis of Microarrays) algorithm resulting in 18 miRNAs (false discovery rate (median): 
0.00000%) differentially expressed between CD133+ and CD34+CD133– cells. The resulting 
miRNAs were grouped by similarities in expression patterns using two-dimensional hierarchical 
average linkage clustering. 
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Table 5. miRNAs significantly differentially expressed in CD133+ cells compared to CD34+CD133–. The 
ratios were calculated by dividing the ratio of sample signal and UR signal of the CD133+ arrays 
and CD34+CD133– arrays and display the x-fold stronger or weaker expression of a miRNA in the 
CD133+ cells as compared to the CD34+CD133– cells. miRBase accession: MIMAT accession 
number. 
miRNA 
name 
miRBase 
accession  
Donor 7 Donor 8 Donor 9 Donor 10 Donor 11 mean 
miR-10a 0000253  3.2 5.1 8.8 3.2 8.0 6.3 
miR-125b 0000423 3.2 4.8 6.4 2.4 5.3 4.7 
miR-146a 0000449 2.6 3.2 3.5 2.1 6.7 3.9 
miR-125a-5p 0000443 4.9 6.0 3.6 0.6 2.8 3.2 
miR-551b 0003233  3.2 3.5 4.4 3.7 3.2 3.7 
miR-99a 0000097 2.9 5.0 4.2 2.1 2.6 3.5 
miR-29a 0000086 2.0 3.2 - 4.7 1.5 3.1 
miR-146b-5p 0002809 2.1 2.2 1.9 2.1 2.2 2.1 
miR-29b 0000100 1.5 3.4 2.0 2.4 0.7 2.1 
miR-29c 0000681 1.5 3.0 2.2 1.7 1.0 2.0 
miR-23a 0000078 1.3 1.9 1.9 1.8 0.9 1.6 
miR-24 0000080 1.4 1.5 1.6 1.8 1.1 1.5 
miR-23b 0000418 1.7 1.5 1.2 1.8 1.0 1.4 
miR-142-5p 0000433 0.9 0.7 0.9 0.5 0.5 0.7 
miR-191 0000440 0.8 0.8 0.7 0.5 0.6 0.6 
miR-142-3p 0000434 1.0 0.4 0.8 0.5 0.6 0.6 
miR-484 0002174 0.5 0.5 0.4 1.2 0.4 0.6 
miR-425 0003393 0.6 0.5 0.5 0.5 0.3 0.4 
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3.3.5 Absolute quantification of miRNAs expressed in CD133+ cells 
The microarray data was also used to calculate the miRNA copy numbers per cell for the 
hematopoietic cell populations of four different donors. This absolute quantification was 
possible as the samples were hybridized versus the UR (see section 3.3.3). The miRNA 
copy numbers were calculated for all detected miRNAs and Spearman correlation 
coefficients were determined to assess the overall performance and to show the 
relationship between the different samples. The Spearman correlation coefficients of the 
miRNA copy number expression profiles were 0.88 – 0.97 for the CD133+ cells and 0.90 – 
0.95 for the CD34+CD133– cells. A comparison of the CD133+ cells with the 
CD34+CD133– cells led to correlation coefficients between 0.81 – 0.94. 
 
Table 6. Spearman correlation coefficients for the miRNA copy number expression profiles. The miRNA 
copy numbers were calculated for all detected miRNAs (listed in Figure 23) and the coefficients 
were determined between the different samples.  
  CD133
+ cells CD34+CD133– cells 
  Donor 7 Donor 8 Donor 10 Donor 11 Donor 7 Donor 8 Donor 10 Donor 11 
Donor 7 - 0.93 0.97 0.94 0.94 0.92 0.91 0.84 
Donor 8 0.93 - 0.92 0.88 0.90 0.90 0.85 0.81 
Donor 10 0.97 0.92 - 0.96 0.92 0.93 0.94 0.89 C
D
13
3+
 
 c
el
ls 
Donor 11 0.94 0.88 0.96 - 0.90 0.90 0.93 0.93 
Donor 7 0.94 0.90 0.92 0.90 - 0.95 0.92 0.90 
Donor 8 0.92 0.90 0.93 0.90 0.95 - 0.95 0.92 
Donor 10 0.91 0.85 0.94 0.93 0.92 0.95 - 0.92 
C
D
34
+ C
D
13
3–
 
ce
lls
 
Donor 11 0.84 0.81 0.89 0.93 0.90 0.92 0.92 - 
 
Next, the miRNA copy numbers were analyzed in detail. The majority of all miRNAs, 
79% in CD133+ cells and 73% in CD34+CD133– cells, were present with less than 200 
copies per cell whereas the highest expressed miRNAs showed copy number of around 
2,000 per cell (Figure 25). The most abundant miRNAs in CD133+ cells were miR-26a 
(7.2% of overall copy numbers), miR-451 (7.0%), and miR-26b (6.5%). Furthermore, the 
25 highest expressed miRNAs in CD133+ (CD34+CD133–) cells accounted for 72.8% 
(74.2%) of the overall miRNA pool (Table 7).  
Assuming that similar miRNAs regulate similar targets, we also looked at the highest 
expressed sequence groups (seqgrp) that are groups of miRNAs with a high sequence 
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similarity (Landgraf et al. 2007). In CD133+ cells the highest expressed seqgrp was seqgrp-
miR-26 (miR-26a and miR-26b) amounting to 13.7% of the overall miRNA pool. 
Furthermore, seqgrp-miR-98 (let-7a, let-7b, let-7c, let-7-d, let-7f, let7-g and let-7i) 
amounted to 7.0% of the overall miRNA pool, seqgrp-miR-17 (miR-17, miR-18a, miR-
18b, miR-20a, miR-20b, miR-93, miR-106a and miR-106b) to 6.6% and seqgrp-miR-19a 
(miR-19a and miR-19b) to 6.2%. Lower expressed miRNAs such as the members of 
seqgrp-miR-17, e.g. miR-18a amounted to only 0.08% of the overall miRNA pool, maybe 
highly relevant in combination with other miRNAs of the same seqgrp.  
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Figure 25.  Histogram displaying the number of miRNAs in distinct copy number intervals, e.g. 87 of the 
miRNAs detected in CD133+ cells were present with less than 200 copy numbers per cell and 
10 miRNAs with copy numbers between 201 and 400.  
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Table 7. 25 most abundant miRNAs detected in CD133+ and/or CD34+CD133– cells. The percentages of 
the overall copy numbers for the most abundant miRNAs are shown, calculated as the median 
value of four independent measurements. 
CD133 
miRNAs [%] 
CD34 
miRNAs [%] 
miR-26a 7.2 miR-142-3p 8.5 
miR-451 7.0 miR-451 5.9 
miR-26b 6.5 miR-223 5.4 
miR-142-3p 5.7 miR-26b 5.1 
miR-16 4.7 miR-16 4.8 
miR-101 4.6 miR-101 4.6 
miR-19b 4.2 miR-26a 4.5 
miR-223 4.0 miR-19b 4.5 
let-7f 2.8 miR-20a 2.8 
miR-20a 2.4 miR-142-5p 2.8 
miR-222 2.1 let-7f 2.6 
miR-92a 2.0 miR-92a 2.1 
miR-19a 2.0 miR-19a 2.1 
miR-142-5p 2.0 miR-15a 2.0 
miR-15a 1.9 miR-30b 2.0 
miR-30b 1.9 miR-21 2.0 
miR-21 1.9 miR-144 1.9 
miR-126-3p 1.5 miR-126-3p 1.8 
miR-92b 1.4 miR-92b 1.5 
let-7a 1.3 miR-222 1.4 
miR-144 1.3 miR-17 1.4 
miR-17 1.2 miR-181a 1.1 
miR-29c 1.1 let-7a 1.0 
miR-221 1.1 miR-20b 1.0 
miR-20b 1.0 let-7g 1.0 
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The significantly differentially expressed miRNAs (Figure 27B) showed rather low 
expression levels with copy numbers below 200 copies per cell with exception of miR-142 
with up to 5,000 copies per cell for one donor. Figure 26 displays the copy numbers of 
three miRNAs representing the three different expression signatures of the differentially 
expressed miRNAs in CD133+ cells (Figure 24). miR-10a was expressed at highest level in 
CD133+ cells (group 1), miR-29a at high level in CD133+ and CD34–CD133– cells 
(group 2) and miR-425 at lowest level in CD133+ cells (group 3). 
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Figure 26.  MicroRNA copy numbers prepared from four different donors (donor no. 7, 8, 10 and 11). The 
three miRNAs represent the three different expression signatures of the differentially expressed 
miRNAs: miR-10a (group1), miR-29a (group 2) and miR-425 (group 3). Neg: CD133–CD34– cell 
subpopulation. 
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3.3.6 Validation of miRNA array results using qRT-PCR and Solexa sequencing 
Solexa sequencing and qRT-PCR was used to validate the microarray data. For Solexa 
sequencing 2 µg RNA of donor 7 and 10 were applied to small RNA isolation, followed by 
adapter ligation, reverse transcription, PCR amplification and sequencing-by-synthesis. 
Not relying on hybridization kinetics, sequencing is a completely independent method to 
validate the microarray results and allows furthermore the discovery of new miRNAs. 
95 miRNAs were sequenced with over 100 counts compared to 135 miRNAs (Figure 22) 
detected one fold over background on all arrays. The overlap between the two groups was 
81 miRNAs detected with both methods (Figure 27A). Most of the miRNAs that were only 
detected by one method showed low counts/net signal intensities. Exceptions were miR-
720, miR-1260, miR-1274a, miR-1274b, miR-1275, miR-1280 and miR-1826 with net 
signal intensities over 10,000 light units and no detectable counts.  
Comparison of sequencing and microarray hybridization for the miRNAs detected with 
both methods led to Spearman correlation coefficient of 0.74 (CD34+CD133– cells of 
donor 7), 0.73 (CD34+CD133– cells of donor 10), 0.82 (CD133+ cells of donor 7), 0.71 
(CD133+ cells of donor 10) and at least 0.94 within each method. A direct comparison of 
dlog-plots for both approaches is displayed in Figure 27B. 
The miRNA count ratios of the 18 significantly differentially expressed miRNAs (see 
section 3.3.4) are shown in Figure 28A. 12 out of 13 higher expressed and 4 out of 5 lower 
expressed miRNAs were validated for donor 7, for donor 10 all higher expressed miRNAs 
were validated and two of the lower expressed miRNAs.  
qRT-PCR was performed for six miRNAs (Figure 28B) and further confirmed higher 
expression of miR-10a, miR-125a, miR-125b, miR-551b and lower expression miR-425 
and miR-484 in CD133+ cells compared to CD34+CD133– cells. 
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Figure 27.  Comparison of Solexa sequencing and microarray data. (A) Venn diagram showing miRNAs 
detected with over 100 counts (sequencing) or one fold over background (array data) in CD133+ 
and/or CD34+CD133– cells. (B) Dlog-plots showing the miRNA copy numbers per cell based on 
the microarray data (left) and the counts based on the Solexa sequencing results (right) for 
donor 10. The higher expressed miRNA candidates are shown as red dot, the lower expressed ones 
as green dot. 
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Figure 28.  Validation of microarray data via Solexa sequencing and qRT-PCR. (A) The ratios of CD133+ 
counts vs CD34+CD133– counts for the 18 significantly differentially expressed miRNA are 
displayed for two donors. miRNAs that were present with less than 100 counts are marked with ‡. 
(B) The expression levels of six miRNAs were also determined by qRT-PCR using the miScript 
system for two (miR-125b, miR-551b) or three donors. RN5S1 was used for normalization.  
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3.4 mRNA expression in human hematopoietic stem and progenitor cells 
The molecular architecture of the CD133+ cells was further analyzed by generating mRNA 
expression profiles. In addition, the mRNA profiles were used to analyze the role of the 
differentially expressed miRNAs in CD133+ cells and to examine the coexpression of 
miRNAs and mRNAs. 
For mRNA expression profiling, the RNA of eight donors was amplified via SuperAmp 
technology and hybridized on Agilent Whole Genome Arrays.  
First of all, significantly differentially expressed transcripts between CD133+ and 
CD34+CD133– cells were analyzed by using SAM analysis and a less stringent t-test (see 
section 5.3, Table A5). 
SAM analysis (Figure 29) led to 80 mRNAs, 70 of them were lower expressed whereas 
only 10 were higher expressed in CD133+ cells. Among the transcripts higher expressed in 
CD133+ cells were Flt-3 and Baalc, two well known marker for HSC. 
A total of 972 significantly differentially expressed mRNAs were obtained via t-test 
(p<0.01) with 387 mRNAs being higher expressed in CD133+ cells. A correlation matrix 
of the 972 mRNAs is shown in Figure 30. 
Interestingly, 87.5% (60%) of the significantly differentially expressed mRNAs identified 
using SAM (t-test) were lower expressed in CD133+ cells, whereas 72% of the 
significantly differentially expressed miRNAs were higher expressed. In other words, most 
of the differentially expressed miRNAs were higher expressed in CD133+, whereas most of 
the mRNAs were lower expressed. 
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Figure 29. Average linkage cluster of 
mRNAs that are significantly 
differentially expressed between 
CD133+ and CD34+CD133- cells. 
Discriminatory gene analysis by 
the SAM algorithm resulted in 
80 mRNAs that are differentially 
expressed. 
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Figure 30. Correlation matrix for significantly differentially expressed mRNAs. Correlations between mRNA 
expression levels for the analyzed cell populations CD133+, CD34+CD133– and CD133–CD34–. 
The results are shown as correlation matrix based on Pearson coefficients for the 972 significantly 
differentially expressed mRNAs (t-test, p<0.01). 
 
As a first attempt to interpret the gene expression data, we compared them to published 
data on HSCs ( 22Table 8). PROM1 (the gene encoding for CD133/prominin-1) was 
overrepresented in eight out of eleven datasets. The RNA processing protein RBPM, the 
receptor tyrosine kinase c-kit, and CD34 were found in our own results plus six of the 
other datasets. The highest similarity was seen with CD133+ cells from cord blood (Toren 
et al. 2005), where 23 transcripts out of 46 compared transcripts showed the same 
overrepresentation. Altogether, 26 transcripts were found overexpressed in CD133+ bone 
marrow cells that have also been described as being overrepresented in CD133+ and 
CD34+CD38– cord blood cells before. However, in contrast to some of the other studies, 
the transcription factors GATA2 and CEBPB were lower expressed in CD133+ cells. The 
main reason for the variability among the studies is most probably the different stem cell 
source, e.g. BM, CB, and PB.  
 
Table 8  
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In order to broaden our understanding on the relevant molecular mechanisms in CD133+ 
cells, different functional analysis were performed.  
Functional grouping analysis was used to get a rough overview of the relevant biological 
processes. Frequent and significant biological processes which were more prominent in 
CD133+ cells as in CD34+CD133– cells were besides others, receptor signaling, cell 
differentiation, cell death, innate immunity and inflammation (Figure 31). 
number of genes
*
*
*
*
*
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Figure 31.  Biological process term distribution frequency for mRNAs up-regulated in CD133+ cells 
compared to CD34+CD133– cells (t-test results, see section 5.3, Table A5). The annotations used 
were derived from GO which provides information on the molecular function of grouped genes. 
Highly relevant categories with p-values < 10-6 are marked with an asterisk. 
A more detailed annotation enrichment analysis (AEA) was carried out by utilizing the 
proprietary TreeRanker software. As annotation sources, databases containing information 
on Gene Ontology (GO) categories, protein sequence motifs, interaction data, complex 
membership and involvement in biological pathways were used. The categories used for 
this analysis are much more specific than the general categories used for the functional 
grouping analysis. 
The more detailed AEA demonstrated that the higher expressed genes in CD133+ cells 
were enriched for cell marker of neutrophils and hematopoietic cells, the biological 
processes defense response and negative regulation of the immune system and for genes 
that are upregulated by IL4 Pathway (Table 9A). Genes lower expressed in CD133+ cells 
were enriched for the GO categories porphyrin and tetrapyrrole biosynthetic process and 
erythroid cell markers (Table 9B). 
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Table 9. Results of AEA. (A) List of transcripts related to significantly represented categories in CD133+ 
cells and (B) CD34+CD133– cells. Gene bank numbers are listed in the appendix (see section 5.2, 
Table A10). Count: number of genes in the respective category; Significance: calculated p-value; 
EF: Enrichment Factor.  
A 
Category and respective genes Count Significance EF 
cell marker neutrophils (Miltenyi Biotec) 10 6.00E-06 6.89 
FCGR3B; SH3BP5; MANSC1; TNFRSF10C; CASP5;  KRT23; IL6R; P2RY13; 
KIAA0329; CD44 
   
defense response (GO) 30 7.00E-06 3.29 
HCP5; CFH; LAG3; HMOX1; CD5L; BPI; C1QB; SERPING1; MX1; HP; 
NFKBIZ; VSIG4; CYSLTR1; IL27RA; IL18RAP; IL15; BCL2; GIMAP5; 
S100A8; CCL18; CCL2; LY96; HIST2H2BE; RSAD2; CALCOCO2; CYBB; 
IL6R; STAT3; CD44; C1QA 
   
negative regulation of immune system process (GO) 9 4.77E-04 6.94 
LAG3; HMOX1; BPI; SERPING1; VSIG4; IL27RA; GIMAP5; CDKN2A; FLT3    
cell marker hematopoietic cell (pathology outlines; ebiosience) 5 2.20E-05 25.6 
BAALC; CD34; PROM1; FLT3; ATXN1    
upregulated by IL4 Pathway (NetPath pathways) 14 3.00E-05 4.87 
RASGRP1; DUSP6; ARHGAP25; BCL2L11; CYSLTR1; CCPG1; BCL2; 
MS4A4A; CCL2; PRR16; ARID5B; HIST2H2BE; RSAD2; ATXN1 
   
B 
Category and respective genes Count Significance EF 
porphyrin and tetrapyrrole biosynthetic process (GO) 8 6.90E-07 10.58 
BLVRB; PPOX; ANK1; ALAD; FXN; UROD; SPTA1; HMBS    
Hemoglobin's Chaperone (Nature pathways) 5 2.70E-06 20.35 
ERAF; ALAD; UROD; HMBS; GATA1    
cell marker erythroid (pathologyoutlines; ebiosience) 4 8.30E-06 42.33 
CD36; ICAM4; RHAG; SPN    
biogenic amine synthesis (GenMAPP pathways, Wiki pathways) 4 1.50E-05 23.52 
PNMT; HDC; GAD1; ACHE    
actin filament bundle (GO) 7 2.30E-05 9.5 
MYH10; DLC1; SEPT5; TPM1; MYO1C; SORBS1; TPM1    
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3.5 Analysis of miRNA targets 
Identification of miRNA targets is crucial for understanding the biological function of 
miRNAs. Several computational methods such as TargetScan (Lewis et al. 2005), miRDB 
(Wang 2008; Wang and El Naqa 2008), PicTar (Krek et al. 2005), ElMMo (Gaidatzis et al. 
2007), miRanda (John et al. 2004) and PITA (Kertesz et al. 2007) have been developed to 
search for miRNA targets. Most computational prediction tools make use of a perfect seed 
match – a perfect match between the 6-8 nucleotides at the 5’end of the miRNA and its 
mRNA target – and evolutionary conservation. However, the currently available 
computational methods have several limitations and can lead to spurious targets. 
Furthermore, the predicted target sets are often large and contain hundreds to thousands of 
genes. Therefore, it is necessary to shorten the long lists of predicted targets by reasonable 
selection criteria, such as coexpression of bioinformatically predicted miRNA-mRNA 
pairs. 
3.5.1 Bioinformatic prediction of miRNA targets 
To further analyze the role of miRNAs in CD133+ stem cells, bioinformatic target 
prediction was performed using several computational methods. As an example the target 
prediction results for miR-29a are shown in Table 10A demonstrating that some algorithms 
predict over 1,000 potential targets. Furthermore as shown in Table 10B, some targets are 
predicted by all predictions tools whereas others are just predicted by one tool. The 
detailed target prediction results for the differentially expressed miRNAs are shown below 
(see section 3.5.2). 
Besides the possible targets of the differentially expressed miRNAs, we were interested in 
the question if the mRNAs of CD133, CD34 and HoxB4, a critical factor for stem cell 
expansion, can be targeted by miRNAs. We found a possible interaction between 
miR-125a-5p and CD34 (predicted by miRanda and PITA), miR-125a-3p and CD34 
(predicted by RNA22) as well as between miR-425 and HoxB4. The miRNAs 
miR-30a/30a-5p/30b/30b-5p/30cde/384-5p and miR-142-3p potentially interact with the 
3’UTR of the CD133 mRNA. The latter interaction is shown in Figure 32, highlighting the 
perfect seed match but also low complementarity of the remainder sequence. 
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Table 10. Overview of bioinformatics target prediction results for miR-29a. (A) Number of predicted targets 
for miR-29a obtained with the different prediction tools. (B) As an example 10 predicted targets 
are shown. 
A     B 
 
 
 
 
Target Gene 
Symbol miRDb PicTar Elmmo miRanda PITA TargetScan Counts 
COL2A1 X X X X X X 6 
AKT3   X X X X X 5 
FEM1B   X X   X X 4 
ABI1       X X   2 
ABCB6     X     X 2 
ARL4A       X   X 2 
SCML2 X         X 2 
SLC17A4       X     1 
PTPRU       X     1 
TSPAN3       X     1 
ARL4C       X     1 
target prediction  
tool 
number of  
predicted targets 
miRanda 1,045 
PicTar 144 
TargetScan 850 
miRDb 110 
Eimmo 728 
PITA 644 
by at least  
three tools predicted 594 
 
 
 
Figure 32.  TargetScan prediction for Prom1 (CD133). The seed sequence is highlighted in white. TargetScan 
predicts 8mer sites in addition to 7mer sites defined as an exact match to positions 2-8 of the 
mature miRNA followed by an 'A'. 
 
3.5.2 Combined miRNA and mRNA analysis 
The combined miRNA and mRNA analysis was performed to find miRNAs that are either 
coexpressed with their potential target mRNAs (strategy I) or inversely expressed 
(strategy II) (Figure 33). Strategy I is focused on miRNA actions where the repression of 
protein production is not a consequence of downregulation of mRNA levels (translation 
inhibition without mRNA degradation). In contrast, the assumption of strategy II is a 
downregulation of mRNA levels if the respective miRNAs are upregulated and vice versa.  
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Figure 33.  Workflow for the combined miRNA and mRNA analysis. 
 
In the framework of strategy Ia, the target mRNAs were predicted separately for miRNAs 
with a similar expression pattern (see section 3.3.4). For the first analysis target prediction 
was carried out for the seven miRNAs (miR-146b-5p, miR-125a-5p, miR-125b, miR-99a, 
miR-146a, miR-10a, miR-551b) higher expressed in CD133+ cells compared to 
CD34+CD133– cells and CD34–CD133– cells (Table 11).  
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Table 11. 
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Overall, 644 mRNA were predicted by at least three predictions tools for the seven 
miRNAs. Next, the mRNA expression profiles were used to select the expressed mRNAs 
among the 644 predicted mRNAs yielding to 281 mRNAs. After that, the 281 mRNAs 
were tested for a significant enrichment of annotations showing that annotation groups 
such as Insulin signaling, B-cell receptor signaling and positive regulation of cell 
differentiation were enriched (Table 12). Most interestingly, the predicted targets for the 
miRNAs higher expressed in CD133+ cells were also enriched for the GO category 
“hematopoietic or lymphoid organ development” which comprises transcription factors 
such as ETS1, KLF11 and HOXB3. 
 
Table 12. Significantly enriched categories among the predicted mRNA targets for the significantly 
differentially expressed miRNAs miR-146a, miR-146b-5p, miR-125a-5p, miR-125b, miR-99a, 
miR-10a, and miR-551b. Gene bank numbers are listed in the appendix (see section 5.2, Table 
A10).  
Category and the respective genes Count Significance EF 
Insulin Signaling (Wiki pathways, GenMAPP pathways) 11 2.90E-06 5.94 
GRB10; FRAP1; IGF1R; MAPK14; MAP3K7; FLOT2; MAP3K11;  
MAP3K10; MAP2K7; RPS6KA1; RHOQ    
BCR signaling (PathwayCommons, Nature pathways) 8 5.00E-06 8.42 
ETS1; MAPK14; CAMK2G; MAP3K7; CSNK2A1; TRAF6; 
PPP3CA; CSNK2A1    
hemopoietic or lymphoid organ development (GO) 17 1.80E-05 3.51 
HOXB3; HOXA3; PURB; BAK1; ESRRA; B3GAT2; BCL2; 
JARID2; HMGB3; NCOA6; BCL2L11; ETS1; ZFP36; MED1; 
MAPK14; KLF11; TRAF6 ; 
   
nuclear chromosome part (GO) 11 4.00E-05 5.22 
PURB; UBE2I; H3F3B; BAZ2A; PHC1; XRN1; ORC2L; SUV39H1; 
SUV420H2; CSNK2A1; CSNK2A1    
PHD (homology domain) 10 8.50E-05 7.4 
BAZ2B;A_23_P120644; DPF2; PHF20L1; PHF15; BAZ2A; BRPF1; 
ZMYND11; FBXL10; MLL2    
MAPKKK cascade (GO) 14 9.30E-05 4.22 
SEMA4C; FGFR3; CDC42SE1; IGF1R; MAPK14; MAP3K7; 
IRAK1; TRAF6; RB1CC1;  MAP3K11; SHANK3; MAPKBP1; 
MAP3K10; MAP2K7 ; 
   
positive regulation of cell differentiation (GO) 9 9.57E-03 3.41 
B3GAT2; TIAM1; BCL2; FGFR3; FNDC3B; ETS1; MAPK14; 
NUMB; SEMA4D    
 
The targets predicted for the second group of higher expressed miRNAs in CD133+ cells 
(miR-29a, miR-29b, miR-29c, miR-23a, miR-23b, miR-24) were, amongst others, enriched 
for annotations related to developmental processes, the plasma membrane-bound protein 
complex SNARE and negative regulation of cell migration (strategy Ia for group2 in 
Table 11 and Table A7 in section 5.4).  
The targets for the lower expressed miRNAs – miR-142-3p, miR-142-5p, miR-484, miR-
425 and miR-191 – in CD133+ cells (strategy Ib, Figure 33) showed a high enrichment for 
the ubiquitin proteasome system (Table 11 and Table A8 in section 5.4). This annotation 
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group comprised 39 mRNAs such as the ubiquitin-conjugating enzyme E2A and E2D1 
(UBE2), the ring finger proteins 138, 139 and 145 (RNF) and the ubiquitin specific 
peptidase 38 (USP38).  
In conclusion, the annotation analysis indicated that the significantly differentially 
expressed miRNAs in CD133+ cells play a role in maintaining the stem cell character: The 
higher expressed miRNAs target mRNAs involved in cell differentiation and may prevent 
differentiation, whereas the lower expressed miRNAs target relevant mRNAs for the 
ubiquitin proteasome system that is known to be involved in the fine-tuning of 
hematopoietic stem cell homeostasis. 
Besides the significantly differentially expressed miRNAs, the miRNAs present with high 
copy numbers may play an important role for hematopoisis. Therefore, the role of the most 
abundant miRNA in CD133+ cells miR-26 was analyzed (strategy Ic, Figure 33). The 
predicted and expressed targets for miR-26a and miR-26b were highly enriched for protein 
kinase activity (Table 11 and Table A9 in section 5.4). 
After that, we were interested in inversely expressed miRNAs and mRNAs and focused on 
higher expressed miRNAs and lower expressed mRNAs (strategy IIa, Figure 33). In detail, 
TargetScan algorithm was used to predict possible targets for the 13 miRNAs higher 
expressed in CD133+ cells. Among the 2,537 predicted targets were 46 targets that were 
significantly lower expressed in CD133+ cells (Table 13). Some of the predicted targets are 
targeted by more than one of the higher expressed miRNAs, e.g. FZD5 is targeted by miR-
99a, miR-24, miR-29a, miR-29b and miR-29c. A functional grouping analysis for the 
46 predicted and lower expressed mRNAs (Figure 34) revealed a significant enrichment of 
biological processes related to development, cellular import/export, cell differentiation, 
cytoskeleton and cell migration.  
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Table 13. Lower expressed mRNAs predicted (by TargetScan) as a target of the higher expressed miRNAs. 
The functional groups of the mRNAs are listed as well. Some of the miRNAs encompass a 
miRNA family as the predicted targets are often identical. miR-125: miR125a-5p and miR-125b; 
miR-29: miR-29a, miR-29b and miR-29c; miR-23: miR-23a and miR-23b.  
 
 
Results 70
number of genes
*
*
*
*
*
 
Figure 34.  Biological processes term distribution frequency for mRNAs lower expressed in CD133+ cells and 
predicted to be a target of higher expressed miRNAs (strategy IIa, Figure 33). The annotations 
used were derived from GO which provides information on molecular function. Highly relevant 
categories with p-values < 10-5 are marked with an asterisk. 
 
Just eight miRNA-mRNA interactions were found for the lower expressed miRNAs and 
higher expressed mRNAs in CD133+ cells (strategy IIb, Figure 33). Two of the higher 
expressed mRNAs were predicted as target of miR-425, six as target of miR-142-3p 
(Table 14). Interestingly, the miRNA-mRNA interaction miR-142-3p and CD133 was one 
of the predictions (see also Figure 32). None of the higher expressed mRNAs were 
predicted as targets for the lower expressed miRNAs miR-142-5p, miR-191 and miR-484. 
 
Table 14. Higher expressed mRNAs predicted (by TargetScan) to be target of the lower expressed  miRNAs.  
Target Gene 
Symbol 
Target Gene Description miR-142-3p miR-425 
INPP5F inositol polyphosphate-5-phosphatase F X  
COL24A1 collagen, type XXIV, alpha 1 X  
MYO5A myosin VA (heavy chain 12, myoxin) X  
NUDT11 nudix (nucleoside diphosphate linked 
moiety X)-type motif 11 
X  
ARID5B AT rich interactive domain 5B (MRF1-like) X  
PROM1 (CD133) prominin 1 X  
SH3RF1 SH3 domain containing ring finger 1  X 
LOC283824 hypothetical protein LOC283824  X 
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3.5.3 Validation of predicted miRNA targets using luciferase assays 
For target verification, luciferase reporter assays were used to analyze some of the 
miRNA-mRNA interactions. The principle of luciferase assays is based on the cloning of 
the respective miRNA binding site region of the 3’UTR behind a luciferase reporter gene 
in order to generate a Luciferase-target gene 3’UTR fusion. Direct interactions of miRNAs 
and putative target genes are then assessed based on selective degradation or translational 
repression of Luciferase-target gene 3’UTR fusion transcripts. 
To establish the luciferase assay in our lab and to validate the assay performance, two 
positive controls were used. The first control was the perfect miR-15a target sequence, the 
second one the recently validated miRNA-mRNA interaction of miR-15a and c-myb (Zhao 
et al. 2009). The prefect target sequence should lead to mRNA degradation, whereas the 
imperfect target sequence of the real target c-myb should lead to mRNA translation 
inhibition. 
Cotransfection of miR-15a and pMIR-Luc-15, the vector with the perfect miR-15a target 
sequence, in HEK-293 cells decreased the luciferase activity by up to 82% (Figure 35A). A 
transfection time of 18 hours was sufficient to decrease the luciferase activity and an 
extension of the transfection time did not lead to a further decrease in luciferase activity. 
On the contrary, the transfection time was critical when an imperfect target sequence was 
used (Figure 35B). A reduction of the luciferase activity by 44% comparable to the results 
of Zhao et al. (2009) was only observed after a 48 hours transfection. Furthermore, it was 
important to use chemically modified double-stranded RNA oligonucleotides, as native 
double-stranded RNA oligonucleotides were less effective. This difference was not 
observed for the perfect target sequence. A cotransfection of anti-miR-15a (sequence 
reverse complementary to miR-15a) and pMIR-Luc-15 led to an increase in luciferase 
activity by 15-30% as anti-miR15a functions as a sink that binds to endogenously 
expressed miR-15a. 
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Figure 35.  Control experiments for setup of luciferase reporter assays. Luciferase activities were measured 18 
and 48 hours after transfection. Relative luciferase activity represents firefly luciferase activity 
normalized versus renilla activity. (A) HEK-293 cells were cotransfected with 300 ng pMIR-Luc-
t15 (luciferase vector containing the target sequence of miR-15a and 1-20 nM concentration of 
miR-15a. (B) HEK-293 cells were cotransfected with 300 ng pMIR-Luc-Myb and 100 nM 
miR-15a. D: chemically modified oligonucleotide (Dharmacon); Q: native oligonucleotide 
(Qiagen). 
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To further elucidate the role of the miRNAs in CD133+ cells, the luciferase assays were 
next used for a panel of computational predicted miRNA-mRNA interactions (see section 
3.5.2). For experimental validation, some of the opposite expressed miRNAs and mRNAs 
were selected (Table 13), namely miR-29a/miR-99a/miR-24 and FZD5; miR-29a and 
TPM1; miR-142-3p and CD133; and miR-99a/miR-125b and Trib2. Furthermore, 
miR-125a-3p and CD34 as well as miR-425 and HoxB4 were analyzed (see section 3.5.1).  
It was not possible to confirm the computational data for Trib2, HoxB4 and CD34 (data 
not shown).  
The target verification for FZD5, TPM and CD133 is shown in Figure 36. The experiments 
were performed at least in quintuplicates. Reporter activity of pMIR-Luc-FZD5 and pMIR-
Luc-TPM were decreased by miR-29a, activity of pMIR-Luc-CD133 by miR-142-3p.  
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Figure 36.  Verification of miRNA-mRNA interactions via luciferase assay. Cotransfection of pMIR-Luc-
FZD5 and 100 nM miR-29a decreased 41% of the luciferase activity in comparison to the blank 
control. Cotransfection of pMIR-Luc-TPM and miR-29a decreased 33% of the luciferase activity, 
pMIR-Luc-CD133 and miR-142-3p 30%. For each cotransfection 300 ng vector and 50 nM 
(miR-142-3p) or 100 nM (miR-29a) oligonucleotide were used. Relative luciferase activity 
represents firefly luciferase activity normalized versus renilla activity. Data are representative of 
at least 5 independent experiments. miR-Neg: oligonucleotide designed to serve as negative 
control. 
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The results for the validated miRNA-mRNA interactions are shown in detail in Figure 37. 
Cotransfection of miR-29a and pMIR-Luc-FZD5 decreased the luciferase activity by 40% 
under standard conditions (300 ng vector, 100 nM mimic), an even higher decrease of 60% 
was achieved with lower vector amounts (Figure 37A). As besides miR-29a, binding sites 
for miR-24 and miR-99a are predicted within the FZD5 3’UTR, we also tried to validate 
these binding sites. However, a decrease in luciferase activity was achieved in one 
experiment but not reproducible in further experiments.  
The activity of pMIR-Luc-TPM was decreased by 35% and again an even higher decrease 
of 58% was observed using lower vector amounts (Figure 37B). Furthermore, there was no 
decrease in luciferase activity using pMIR-Luc without cloned target sequence and 
miR-29a.  
The influence of miR-142-3p on pMIR-Luc-CD133 was less strong, the luciferase activity 
was decreased by 20-30%. Interestingly, this effect was achieved reproducibly just with 
50 nM miR-142-3p mimic and not with 100 nM miR-142-3p (Figure 37C). 
In conclusion, the luciferase assays indicated that FZD5, a receptor of the Wnt-signaling 
pathway, and tropomyosin (TPM1), which are lower expressed in CD133+ cells, are 
controlled by miR-29a. The expression of CD133 is probably regulated by the 
hematopoietic specific miRNA miR-142-3p. 
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Figure 37.  Verification of miRNA-mRNA interactions using different mimic (oligonucleotides) and vector 
amounts. (A) Cotransfection of pMIR-Luc-FZD5 and miR-29a (B) Cotransfection of pMIR-Luc-
TPM and miR-29a (C) Cotransfection of pMIR-Luc-CD133 and miR-142-3p Relative luciferase 
activity represents firefly luciferase activity normalized versus renilla activity. Data are 
representative of at least 3 independent experiments. Data with an asterisk (*) were performed in 
duplicates.  
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3.6 miRNAs as a potential tool for in vitro expansion of CD133+ cells 
The current attempts to expand HSC in vitro can be divided into approaches using 
transcription factors, cell cycle regulators or signaling molecules. Most of the factors tested 
so far can induce proliferation but are unable to prevent differentiation of HSCs (see also 
section 1.2.2).  
A recent study indicated that expansion of primitive and self-renewing HSCs and HPCs 
might be facilitated by a novel growth factor combination consisting of SCF, TPO, FGF-1, 
Angptl5 and IGFBP2 (Zhang et al. 2008).  
The novel growth factor combination was used for the in vitro expansion of CD133+ cells 
from peripheral blood (PB) and mobilized leukapheresis (mPB). In the framework of this 
work, some of the miRNAs that are significantly differentially expressed in CD133+ cells 
(see section 3.3.4) were tested as a potential tool for in vitro expansion.  
3.6.1 In vitro expansion of CD133+ cells  
In order to find an appropriate medium for the cultivation of CD133+cells, two serum-free 
media – StemSpan (SS) and CellGro (CG) – were tested with different supplements. To 
this end, CD133+cells separated from peripheral blood of two different donors (PB1 and 
PB2) were cultivated for 7-14 days (Figure 38).  
At day 7 a maximum expansion of all nucleated cells (total cells) of 6.4-fold was observed 
for CD133+ cells cultivated in SS supplemented with SCF, TPO, FGF-1, Angptl5 and 
IGFBP2 (STF+A+I). However, there was no significant difference to SS supplemented 
only with SCF, TPO and FGF-1 (STF). On the contrary, the fold expansion was 
consistently lower with CG as basis medium (Figure 38A).  
At day 14, the expansion of total cells was highest for cells cultivated in SS supplemented 
with STF and showed a 24.7-fold increase. Furthermore, the total number of cells 
expanded less in SS supplemented with STF+I+A (20.2-fold) and in CG (17.1-fold). 
Based on these results, it was decided to focus on SS as basis medium. A more detailed 
analysis of the subpopulations for the cells cultivated in SS is shown in Figure 38B. The 
number of CD34+ cells was expanded 6.8-fold. On the contrary, almost no fold expansion 
was achieved for CD133+ cells, indicating that the CD133+ starting population 
differentiated and lost its CD133+ phenotype.  
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Figure 38.  Cultivation of CD133+ cells from PB. (A) Fold expansion at day 7 and day 14 (related to day 0) 
for different media. (B) Cell numbers for donor PB2 at day 0 and day 7 for all cells (overall) and 
the CD133+ and CD34+ cell population. As the purity of the starting population concerning CD133 
was 80%, the overall cell number is higher than the number of CD133+ cells. SS: StemSpan; 
CG: CellGro; STF: SCF, TPO and FGF-1; STF+I+A: SCF, TPO, FGF-1, Angplt5 and IGFBP2. 
 
As the starting cell populations were stained with CFSE, it was possible to further analyze 
the cell proliferations. The fluorescence dye CFSE is precisely halved at each cell 
generation. After 7 days, each CFSE fluorescence peak could be attributed to a certain 
number of cell divisions. 
The number of cell divisions was comparable for CD133+ cells cultivated in SS 
supplemented with STF to those cultivated in SS with STF+I+A (Figure 39A). 
Simultaneous analysis of surface marker expression and remaining CFSE dye, revealed a 
decrease in CD133 expression after a few cell divisions (2 to 3 doublings) whereas CD34 
expression remained high (Figure 39B). 
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Figure 39.  CD133 and CD34 expression in the context of cell number divisions. CD133+ cells were stained 
with CFSE and cultured for 7 days. (A) Comparison of SS medium supplemented with STF (left) 
and STF+I+A (right). The number of cell divisions is indicated for each peak. A sample aliquot 
was analyzed after 24 hours to determine the fluorescence intensity of non-dividing cells (grey 
peak). (B) CD133 expression decreased after several cell divisions (left) whereas CD34 
expression was maintained.  
 
To further elucidate the behavior of CD133+cells during a 14-days cultivation, cell 
numbers and immunophenotype were also analyzed at day1 and day 4 in the following 
experiment.  
During the first 24 hours of cultivation, the viability of the CD133+cells from mPB (donor 
L1, see section 5.3, Table A4) decreased from 90% after thawing to 64% during the first 
24 hours of cultivation. Therefore, the fold expansion was calculated related to the starting 
cell number (day 0) and the cell number at day 1 (Figure 40A). For the overall cell number 
a 15.5-fold expansion (11.3-fold) was observed for cells cultivated in SS supplemented 
with STF related to day 0 (day 1). In contrast, the fold expansion was 8.0 (3.1) for cells 
cultivated in SS supplemented with STF+I+A.  
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Figure 40.  Cultivation of CD133+ cells from mPB (donor L1). (A) Fold expansion at day 1, 4, 7 and 14 
related to day 0 [A] and day 1 [B] for the supplements STF and STF+I+A. (B) Cell numbers for 
cells cultivated in SS+STF. (C) CD133 and CD34 expression during cultivation of CD133+ cells 
in SS+STF. The percentage of CD133+ cells decreases from day1 to day 14, whereas the 
percentage of CD34+ cells increases up to day 7 and then sharply decreases. The quadrants were 
drawn based on isotype controls. SS: StemSpan; CG: CellGro; STF: SCF, TPO and FGF-1; 
STF+I+A: SCF, TPO, FGF-1, Angplt5 and IGFBP2. 
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For the cells cultivated in SS supplemented with STF, the increase in CD133+ cells was 
3.1-fold, in CD34+ cells containing all CD133+ cells 5.7-fold and in CD34+CD133– cells 
7.2-fold between day 1 and day 7. The cell number of CD133+ and CD34+ cells decreased 
between day 7 and day 14 (Figure 40B). 
The percentage of CD133+ cells decreased from day 1 to day 14 whereas the percentage of 
CD34+CD133- cells increased from day1 to day 7 and sharply decreased afterwards 
(Figure 40C).  
Furthermore, the developmental potential of CD133+ cells before and after in vitro 
expansion was compared. In both cases the CFU assay was started with 100 CD34+ cells. 
Thus, most of the seeded cells were CD133+CD34+ before in vitro expansion and CD133–
CD34+ after in vitro expansion (Figure 41A). The distribution of the different colony types 
was almost the same before and after expansion (Figure 41B). However, the percentage of 
BFU-E tended to be higher after expansion.  
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Figure 41.  Cultivation of CD133+ cells from mPB of three different donors in SS supplemented with STF. 
(A) Percentage of CD133+ and CD34+ cells before (day 0) and after cultivation (day 7). (B) 
HSC-CFU assays for the three different donor. 100 CD34+ cells were seeded before and after 
cultivation. After 14 days of cultivation CFU colonies were classified and counted.  
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3.6.2 Influence of miRNA transfection on CD133+ cells 
Next, it was analyzed whether transfection of miRNAs has an influence on in vitro 
expansion of CD133+ cells. Therefore different transfection reagents and conditions were 
tested by using a FITC labeled double stranded RNA.  
In the final protocol, CD133+ cells were thawed and cultivated in SS supplemented with 
STF. After one day of cultivation, the cells were transfected with 100 nM miRNA mimic 
for 24 hours using the lipofection reagent HiPerfect. Washing of the cells was carried out 
after transfection and the cultivation was continued for 5 days. 
First of all, it was analyzed if the transfection enabled miRNA uptake inside the cell. 
Therefore, the percentage of FITC positive cells was determined after separation of cells 
that could not be labeled by Anti-FITC microbeads. The separation step was carried out to 
distinguish cells with sticky miRNA mimics at the cell surface from cells with uptaken 
mimics (Figure 42A). Most of the cells were found in the unlabeled fraction with 37.7 % of 
FITC positive cells (Figure 42B). Thus, the transfected CD133+ cells contained FITC 
labeled miRNA mimics. However, the transfection efficiency was low and has to be 
further optimized. Nevertheless, some additional miRNA molecules within the cells may 
be sufficient to influence the cell behavior.  
The influence of some miRNAs – significantly differentially expressed in CD133+ cells 
compared to CD34+CD133– cells – on the cultivation of CD133+ cells was tested. The 
immunophenotype of the cultivated CD133+ cells was analyzed at day 7 of cultivation, five 
days after transfection. There was no significant difference between the controls (cell 
transfected with miR-Neg, non transfected and mock transfected cells) and the cells 
transfected with the miRNAs. The results are shown exemplarily for miR-Neg, miR-425 
and cotransfection of miR-24 and miR-27a in Figure 43A.  
Moreover, analysis of the colony-forming ability revealed no significant difference 
between the different transfections (Figure 43B). However, the number of colonies was 
slightly lower for the cells transfected with miR-142-3p and miR-425. This was in 
accordance with the assumption that overexpression of miRNAs – lower expressed in 
CD133+ cells – pushed the cells towards CD133– cells, leading to a lower colony-forming 
ability.  
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Figure 42.  Transfection of CD133+ cells with a FITC labeled miRNA mimic. (A) Experiment overview. One 
day after transfection cells were separated using Anti-FITC Microbeads. (B) Analysis of cells 
unlabeled and labeled with Anti-FITC. 37.7 % of the cells in the unlabeled fraction were FITC-
positive. Control: mock transfection.  
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Figure 43.  Transfection of CD133+ cells from mPB with different miRNA mimics. (A) CD133 and CD34 
expression five days after transfection (day 7 of cultivation). The starting population and 
untransfected cells at day 7 are shown in Figure 41A. (B) HSC-CFU assay for cells transfected 
with miRNAs. Cells were seeded five days after transfection. After 14 days of cultivation CFU 
colonies were classified and counted. Three different donors are shown. 
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4 Discussion 
4.1 Assessment of microarray performance and absolute quantification of 
miRNAs 
The fist part of this work aimed at the development of a microarray platform that allows 
besides relative quantification, absolute quantification of miRNAs. Absolute quantification 
of miRNAs has so far been difficult due to varying, hardly predictable labeling and 
hybridization efficiencies of miRNA probe/target pairs or primer/target pairs, respectively. 
The reasons for this are mainly the high sequence diversity and shortness of miRNAs but 
also some further properties like the secondary structure whose calculation goes beyond 
available algorithms for mere primary sequence based secondary structure prediction. 
Additionally, when dealing with complex array experiments, solid phase hybridization of 
DNA with RNA competes simultaneously with intramolecular hybridization of the 
respective DNA and RNA, with solid phase DNA/RNA hybridization of similar sequences 
and liquid phase RNA/RNA hybridization of miRNA/miRNA* pairs.  
The main approach to deal with some of these problems has been to adjust the melting 
temperatures of all miRNA probes used in an assay. This is either done by altering the 
probe length (Goff et al. 2005) or including nucleotide analogs (Castoldi et al. 2006). In 
addition, different DNA surface attachment strategies have been published to reduce the 
influence of surface physics and chemistry on the hybridization behavior of probe/target 
pairs.  
We have addressed some of these issues and found that using i) a simple and 
straightforward surface attachment procedure, ii) a probe sequence chemistry strictly 
reflecting the natural paradigm as close as possible and iii) an extrinsic referencing tool 
which allows a direct quantification of each single miRNA probe signal is best suited for 
the representation of the miRNA-content by microarrays. Especially, the universal 
reference (UR) consisting of synthetic oligos of a defined concentration can be used for 
absolute quantification of the respective target miRNA. Assuming that the different effects 
influencing microarray signal intensities are comparable for the UR and the sample of 
interest, miRNA amounts can be calculated by comparing UR vs. sample signal intensity. 
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Our data addressing different probe designs (Figure 6) confirm reported observations on 
important factors influencing binding interactions on microarrays (Shchepinov et al. 1997; 
Peterson et al. 2002; Luebke et al. 2003). According to Goff et al. (2005), dimer and trimer 
probes showed enhanced hybridization signal intensity as compared to the monomer. 
However, we observed a reduction of signal intensity when miRNA sequences are doubled 
or tripled. These discrepancies are likely explained by the multitude of factors which vary 
between the different array platforms, such as different attachment and surface chemistries, 
hybridization buffers, probe complexities and probe designs. It again underlines the 
complexity of nucleic acid hybridization reactions. Again in contrast to Goff et al. (2005), 
we did not find a uniform hybridization for oligo variants which had been adjusted with 
respect to their melting temperature but rather a severe loss in sensitivity, and most 
notably, a variable influence of individual miRNA sequences. Therefore, as also described 
by Pozhitkov et al. (2006) and Dimitrov and Zuker (2004), we doubt that there is, at least 
in complex assays, a simple consistency between Gibbs free energy and target sequence. 
A few alternative methods have been described for the absolute quantification of miRNAs 
not relying on altered probe/target design. These approaches, including TaqMan and 
primer extension assays (Chen et al. 2005; Raymond et al. 2005), an invader assay (Allawi 
et al. 2004) and a single-molecule analysis method (Neely et al. 2006) are based on the 
preparation of standard curves for the estimation of the miRNA copy number. However, 
this calibration curve has to be prepared individually for every miRNA due to the different 
secondary structure and primer efficiencies.  
We analyzed 11 randomly selected, synthetic miRNAs and observed CT-values differing 
by up to 4.8 despite of the same amount of input material (see section 5.2, Figure A2). This 
corresponds to a 27.9-fold difference of the miRNA amounts calculated without standard 
curves. Due to the arbitrary selection, we expect even bigger differences for other 
miRNAs. Therefore, a simple miRNA copy number quantification by comparing CT-values 
or by using one standard curve for all miRNAs is not feasible. However, the Universal 
Reference can be used to generate standard curves for nearly 1000 miRNAs allowing 
accurate quantification by qRT-PCR.  
The accuracy and reproducibility of our absolute microarray based microRNA 
quantification (see section 3.2.3) surpasses the one reported for mRNA quantification. Due 
to the mRNA length, it is currently hardly possible to work with a fully synthetic mRNA 
standard as presented here for miRNAs. Therefore, although the different available 
microarray platforms for mRNA expression profiling have been extensively evaluated 
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(Canales et al. 2006), there is still no gold standard for quantifying mRNA transcript 
concentrations by microarrays. The approaches developed so far encompass mathematical 
modelling (Hekstra et al. 2003; Frigessi et al. 2005), calibrated reference samples (Dudley 
et al. 2002), exogenous RNA controls (Carter et al. 2005) and combinations of 
mathematical modelling and spike measurements (Zhao et al. 2007). The TransCount 
method (Frigessi et al. 2005) is based on Bayesian statistical modelling and utilizes 
covariantes of the microarray experiment to calculate the concentration from the signal 
intensity of each probe. A second mathematical approach developed by Hekstra et al. 
(2003) is based on the Langmuir model. Dudley et al. (2002) used a calibrated reference 
sample. However, as they use the same reference for each spot, their approach does not 
control for some important aspects of the microarray system, including sequence-specific 
hybridization and labeling differences between transcripts. Such aspects are considered if a 
universal reference consisting of total RNA is used (Novoradovskaya et al. 2004). The 
disadvantage of current universal references consisting of total RNA is the unkown amount 
of each single mRNA or miRNA. Therefore, the existing universal reference total RNA is 
very well suited for the standardization and cross-referencing of microarray experiments 
but useless for the absolute quantification of mRNAs. In contrast to this, our universal 
reference consisting of synthetic oligos enables the cross-referencing of experiments and 
allows in addition for the absolute quantification of miRNAs.  
Our measurements of miRNA copy number in liver samples revealed that miR-122 was 
present with 52,567 copies per 10 pg and both miR-24 and miR-145 with about 600 copies 
per 10 pg (Figure 14). Thus, the copy numbers are in agreement with estimates of 
quantitative primer-extension PCR (Raymond et al. 2005), single molecule method (Neely 
et al. 2006), TaqMan (Chen et al. 2005), invader assay (Allawi et al. 2004) and RNase 
protection assay (Chang et al. 2004). The abundant liver-specific miR-122 has copy 
numbers 75 fold higher than median copy numbers of liver miRNAs, reflecting its 
important role in regulation of liver-specific processes, such as cholesterol biogenesis 
(Krutzfeldt et al). In addition to the copy number of miR-122, Chang et al. (2004) 
determined also the expression level of the target CAT-1, a high affinity cationic amino 
acid transporter. Interestingly, miR-122 is liver-specific, whereas CAT-1 is expressed 
universally in mammalian tissues with a very low expression in liver compared to other 
tissues.  
In comparison to the liver, the copy numbers of individual miRNAs in CD34+CD133– cells 
are low (Figure 15), when we assume a general amount of 10 pg total RNA per cell. As we 
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have only measured miRNAs which are known so far, we can not exclude that there are 
additional highly expressed unknown miRNAs which would raise the overall number of 
miRNAs per CD34+ cell. Interestingly, comparable miRNAs levels were reported by 
Neilson et al. (2007) for cells representing different stages of T-lymphocyte development. 
Furthermore, it was demonstrated that global miRNA abundance is higher at high cell 
densities in diverse animal cell lines (Hwang et al. 2009), so that the cell-cell contact in 
tissues could also lead to increased overall miRNA expression.  
The exact copy number measurement of miRNAs will be of increasing relevance for a 
detailed analysis of miRNAs and their interaction with other RNA species and proteins, 
since the expression levels of individual miRNAs influence the targeting properties (Bartel 
2009). Also, systems biology approaches and the study of the role of miRNAs in networks 
as described by Tsang et al. (2007) will gain explanatory power in the context of 
quantitative data. 
4.2 The miRNA signature of human hematopoietic stem and progenitor 
cells 
The miRNA signature of CD133+cells was analyzed in terms of relative and absolute 
expression levels by performing a detailed analysis that consists of microarray, qRT-PCR 
and Solexa sequencing data. To precisely analyze the miRNA profile of CD133+ cells, a 
comparison to CD34+CD133– cells was carried out. As nearly half of the CD34+ cells 
express CD133 and most of the CD133+ cells (>99%) express CD34 (Matsumoto et al. 
2000), it is meaningful to compare CD133+ cells with CD34+CD133– cells to elucidate the 
molecular architecture of CD133+ cells. Besides the CD34+CD133– cell population, CD34–
CD133– cell populations – with and without RBCs – were also analyzed and compared to 
CD133+ cells. The main cell type present in the CD34–CD133– cell without RBCs are 
neutrophilic granulocytes, as the bulk of bone marrow cells consists of neutrophilic 
granulocytes (Terstappen and Levin 1992; Brooimans et al. 2008). 
Currently, the available miRNA profiles for HSCs and HPCs are restricted to CD34+ cells 
from BM, PB, mPB and CB (Georgantas et al. 2007; Landgraf et al. 2007; Merkerova et al. 
2009), CD34+CD38– cells from CB (Liao et al. 2008; Han et al. 2010) and CD133+ cells 
from mPB (Jin et al. 2008).  
The initial study of Georgantas et al (2007) revealed 33 miRNAs expressed by CD34+ cells 
from both BM and PB. 29 of the 33 miRNAs were also found in our CD34+CD133– cells 
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(see section 5.3, Table A6). Landgraf et al (2007) prepared small RNA libraries from the 
human hematopoietic system as part of a mammalian miRNA expression atlas containing 
over 250 libraries from 26 different organ systems. In the framework of this atlas, miRNA 
precursors that either share a mature form or are clustered in the genome were grouped in 
so-called “precursor clusters’’. Cloning of CD34+ cells, lymphoid cells and myeloid cells 
revealed 21 precursor cluster, 20 of them were present in CD34+ cells. In our CD133+ and 
CD34+CD133– cells (see section 5.3, Figure A3), the mature miRNAs of 18 of the 
precursor cluster were expressed. Landgraf et al. cloned miR-150 from granulocytes but 
not from CD34+ cells. In contrast, miR-155 was cloned from CD34+ cells but not from 
granulocytes. This is in consistency with our data, where miR-155 was exclusively found 
in CD133+ and CD34+CD133– cells and miR-150 was only detected in CD133–CD34– 
cells. Besides miR-150, further granulocytic miRNAs like miR-338 and miR-199b 
(Bruchova et al. 2008) were present in our CD133–CD34– cells.  
The diversity of miRNAs was highest in the CD133–CD34– cell population containing 
RBCs with 59 miRNAs only expressed at detectable levels in this cell type (Figure 22). 
Among these miRNAs were for example miR-210 and miR-362 that are known to be 
highly expressed in erythrocytes (Kosaka et al. 2008).  
Another abundant  miRNA in erythrocytes is miR-451 (Rathjen et al. 2006) that is 
coexpressed with miR-144 in an erythroid-specific manner (Papapetrou et al. 2010). In our 
data miR-451 and miR-144 were expressed at high levels in all bone marrow cell 
subpopulations but not in the cells from mobilized peripheral blood (Figure 23). It remains 
elusive whether miR-451 is really expressed in CD133+ cells, CD34+ cells and neutrophilic 
granulocytes or whether the miR-451 expression may represent a contamination from 
erythrocytes or another artefact. However, Nelson et al. (2007) cloned miR-451 and miR-
144 most frequently from neutrophils. Furthermore, they described very unusual 
characteristics of miR-451 such as a high heterogeneity at the 3’-end and nucleotides on 
both sides of the pre-miRNA hairpin loop. Interestingly, two recent publications (Cheloufi 
et al. 2010; Cifuentes et al. 2010) suggested an alternative biogenesis for miR-451 in which 
the Dicer step is skipped and the pre-miRNA is directly loaded into Argonaute.  
As already mentioned, two miRNA profiles of primitive hematopoietic cell populations are 
available. Liao et al. (2008) compared CD34+CD38– cells to CD34+ cells from cord blood 
and Jin et al (2008) CD133+ cells mobilized by different agents such as G-CSF to mature 
peripheral blood cells. The detailed comparison to our data is shown in Table 15. 
miR-142-3p and miR-142-5p were lower expressed in the stem cell fraction in all three 
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data sets. miR-10 and miR-146a were higher expressed in CD133+ cells in the data of Jin 
et al and in our own results. Liao et al described twenty-two miRNAs as underexpressed in 
CD34+CD38– cells and nine as overexpressed. None of the higher expressed miRNAs was 
significantly differentially expressed in our data set. The reason for this difference is 
probable the varying stem cell source: A comparison between CD34+ cells from CB and 
BM carried out by Merkerova et al (2009) revealed 13 significantly altered miRNAs, e.g. 
miR-520h – one of the HSC enriched miRNAs found by Liao et al – was only detected in 
CD34+ cells from CB. miR-29a and miR-29b were lower expressed in the CD34+CD38– 
cells analyzed by Liao et al, but higher expressed in the CD34+CD38– analyzed by Han et 
al (2010) and in our CD133+ cells.  
 
Table 15. Common miRNAs between our study, the data of Liao et al (2008) and Jin et al. (2008). 
1: miRNAs higher expressed in the stem cell fraction; -1: miRNA lower expressed in the stem cell 
fraction; 0: no differentially expression. miRNAs differentially expressed by at least two datasets 
are listed. 
  Jin Liao our data 
source mPB CB BM BM 
stem cell fraction CD133+ CD34+CD38– CD133+ CD133+ 
control fraction PB CD34+ CD34+CD133– CD133–CD34–- 
miR-10a 1 n.a. 1 1 
miR-146a 1 n.a. 1 1 
miR-142-3p -1 -1 -1 -1 
miR-142-5p -1 -1 -1 -1 
miR-130a 1 -1 0 1 
miR-181a n.a. -1 0 1 
miR-30b -1 n.a. 0 1 
miR-19b 1 -1 0 1 
miR-20a n.a. -1 0 1 
miR-221 1 n.a. 0 1 
miR-126-3p 1 n.a. 0 1 
miR-26a 1 n.a. 0 1 
miR-144 n.a. -1 0 -1 
miR-15a n.a. -1 0 -1 
LET-7i -1 n.a. 0 -1 
miR-18a n.a. -1 0 -1 
miR-191 -1 n.a. 0 -1 
miR-16 -1 -1 0 0 
miR-17 1 -1 0 0 
miR-21 -1 -1 0 0 
miR-93 1 -1 0 0 
miR-19a 1 -1 0 0 
miR-20b 1 -1 0 0 
miR-29b -1 n.a. 1 0 
miR-29a -1 n.a. 1 0 
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Besides relative expression level, absolute miRNA expression levels were analyzed. Most 
of the miRNAs (79%) in CD133+ cells were present with less than 200 copies per cell and 
the 25 highest expressed miRNAs accounted for 72.8% of miRNA pool. Thus, the majority 
of miRNAs was expressed at low levels whereas only a few miRNAs were expressed at 
high level with around 2,000 copies per cell (Figure 25), e.g. miR-26a amounted to 7.2 % 
of the overall miRNA pool. Although miR-26a was expressed at high levels, it is possible 
that the majority of low expressed miRNAs are of biological significance when acting in 
combination with other low expressed miRNAs (Peter 2010). 
For validation of the miRNA expression profiles of the CD133+ and CD34+CD133– cells, 
two hybridization independent methods were used, a sequencing based approach (Solexa) 
and an amplification based approach (qRT-PCR). The significantly differentially expressed 
miRNAs obtained by miRNA microarray analysis were clearly confirmed by Solexa 
sequencing and qRT-PCR (Figure 28).  
Interestingly, some miRNAs detected with high signal intensities on the microarray, were 
not sequenced. In contrast to microarrays, digital gene expression profiling by next-
generation sequencing such as the Solexa platform allows the evaluation of already 
annotated miRNAs. The miRNAs only detected on the microarray seemed to be wrongly 
annotated miRNAs – currently present in the miRNA sequence database miRBase – as 
their sequence had no miRNA-like features. For example miR-1280 and miR-1274b 
showed no uniform 5’ terminus (M. Hafner personal communication), that is one of the 
criteria for the annotation of miRNAs. This observation is in accordance to a recently 
published published study (Chiang et al. 2010) that revealed more than 150 previously 
annotated miRNAs failing to yield sequenced RNAs with miRNA-like features. The 
difficulties arise from the fact that the previously annotated miRNAs are often 
nonconserved and poorly expressed.  
In conclusion, a distinct and characteristic miRNA expression pattern for CD133+ was 
described. The 18 significantly differentially expressed miRNAs in CD133+ cells can yield 
valuable information about the mechanisms by which CD133+ cells maintain their function 
and identity in comparison to CD34+ cells.  
4.3 The biological role of miRNAs in CD133+ cells 
The biological role of miRNAs in hematopoiesis has been studied by genetic inactivation 
of individual (Rodriguez et al. 2007; Thai et al. 2007; Zhou et al. 2007) and of all miRNAs 
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using conditional Dicer and Ago2 knockouts (Bernstein et al. 2003; O'Carroll et al. 2007). 
Both approaches showed the tremendous importance of miRNAs for hematopoiesis (see 
also section 1.3). However, the exact role of miRNAs in the early steps of hematopoiesis 
remains elusive as only few data are available concerning miRNA expression in 
hematopoietic stem and progenitor cells. 
In order to study the role of the 18 differentially expressed miRNAs in CD133+ stem cells, 
the targets of the miRNAs had to be identified. The most widely used tool for target 
identification are miRNA target prediction algorithms (Bartel 2009). As these algorithms 
provide a list of hundreds of predictions for each miRNA with high false-positive rates, 
they can only be a guide. To reduce the number of predictions, we only considered targets 
predicted by at least three out of six algorithms. However, hundreds of targets were 
observed for the groups of significantly differentially expressed miRNAs (Table 11). 
Therefore, the data set was further filtered by examining the coexpression of the 
bioinformatically predicted miRNA-mRNA pairs. The mRNA data used for filtering was 
generated from the same cells as the miRNA profiles, allowing a meaningful analysis of 
target gene modulation by miRNAs.  
A comparison of our mRNA data to other published data on HSCs (Table 8) revealed a 
number of transcripts higher expressed in HSCs in our own results and the other datasets, 
e.g. PROM1 (CD133), CD34, c-kit and RBPMS.  
Genes higher expressed in CD133+ cells compared to CD34+CD133– cells were classified 
as marker for hematopoietic and neutrophils cells (Table 9A). One could speculate that the 
enrichment of neutrophilic marker was a hint of contaminating cells. However, among the 
neutrophilic markers is for example CD44, a transmembran protein, that is involved in the 
polarization of HPCs together with CD133 (Giebel et al. 2004) and essential for homing 
and proliferation (Holloway et al. 1999). Genes higher expressed in CD34+CD133– cells 
were classified as related to porphyrin and tetrapyrrole biosynthetic process and erythroid 
markers (Table 9B). The erythroid potential of CD34+ is known as Matsumoto et al. (2000) 
showed that CD34+CD133– cells consist mainly of erythroid-commited progenitors. 
The analysis of our mRNA data – encompassing a comparison to other published data and 
annotation enrichment analysis – revealed that it is well suitable for the analysis of 
coexpressed bioinformatically predicted miRNA-mRNA pairs. In the framework of the 
combined miRNA and mRNA analysis (Figure 33), two approaches were used. Strategy I 
focused on coexpression without considering if the miRNA-mRNA pairs were inversely 
expressed. Thus, miRNA targets that are principally downregulated at the protein level and 
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not at the mRNA level were also part of the analysis. Furthermore, the exception that 
miRNAs can switch from repression to activation of target translation, depending on the 
cell cycle state of the cell (Vasudevan et al. 2007) was also considered with strategy I.  
Strategy II focused on inversely correlated miRNA and mRNAs, e.g. higher expressed 
miRNAs and lower expressed mRNAs. A number of studies (Lim et al. 2005; Nielsen et al. 
2009) showed a measurable effect on mRNA levels in microarray studies. However, the 
effect was typically mild (Baek et al. 2008; Selbach et al. 2008), especially if cells not 
transfected with miRNAs were analyzed. However, the high advantage of analysing 
mRNA profiles of non miRNA transfected cells, is that no artifacts are measured (Khan et 
al. 2009). The disadvantage, that microarrays might not resolve slight changes in mRNA 
expression induced by miRNAs and might therefore miss some inversely correlated 
miRNA targets. 
Because miRNAs can repress many genes (Lim et al. 2005; Peter 2010), it was of interest 
to identify groups of genes targeted by the same miRNAs that share a biological function 
or localization. This functional profiling of expressed mRNAs that were classified as 
predicted targets of the differentially expressed miRNAs was performed through 
annotation enrichment analysis. 
Notably, mRNAs expressed in CD133+ cells and predicted to be targeted by miRNAs 
higher expressed in CD133+ cells as compared to CD34+CD133– and CD34–CD133– cells 
(Figure 24, group 1: miR-146a, miR-146b-5p, miR-99a, miR-10a, miR-125b, miR-551b, 
miR-125a-5p) were enriched for different signaling pathways such as insulin signaling, 
BCR signaling and MAPK signaling. All miRNAs of group 1 except for miR-551b were 
predicted to target members of the MAPK signaling pathway. Two members of the GO 
category “MAPKKK cascade” namely IL-1 receptor associated kinase (IRAK1) and TNF 
receptor-associated factor 6 (TRAF6)  are already experimentally validated targets of 
miR-146a/b, miRNA members of group 1 (Taganov et al. 2006). In the context of stem cell 
biology MAPK signaling pathways play an important role in HSC maintenance (Geest and 
Coffer 2009). For example, activation of Januskinases (JNKs), one major groups of 
MAPKs, is important for erythrocyte development. 
Furthermore, the predicted targets for the miRNAs higher expressed in CD133+ cells were 
enriched for the GO category “hematopoietic or lymphoid organ development”. The 
known function of the miRNAs leading to this GO category further supported the 
important role of these miRNAs for hematopoiesis. The miR-10 family attracted attention 
because of its position within the Hox clusters and seems to be an important developmental 
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regulator (Lund 2010). One miRNA-mRNA pair that was part of our analysis was miR-10a 
and HOXA3, an interaction recently validated by Han et al. (2007). Moreover, in vitro 
differentiation of CD34+ cells into megakaryocytes was accompanied by a marked 
decrease in miR-10a expression (Garzon et al. 2006).  
Overexpression of miR-146a in CD34+ cells suppresses megakaryopoiesis (Labbaye et al. 
2008) and overexpression of miR-125b inhibited differentiation of primary B cells 
(Gururajan et al. 2010). Furthermore, p53 and the pro-apoptotic Bcl-2 antagonist killer 1 
(BAK1) are targeted by miR-125b, suppressing apoptosis in human cancer cells (Le et al. 
2009; Zhou et al. 2010). Suppression of ERBB2 and ERBB3 by enforced expression of 
miR-125a or miR-125b led to impaired anchorage-dependent growth in breast cancer cells 
(Scott et al. 2007). As activation of ERBB2 can induce loss of cell polarity (Kufe 2009), 
suppression of ERBB2 by miR-125 in CD133+ cells might lead to a more polarized 
morphology.  
Taken together, the known function of miR-146, miR-10a and miR-125b fits perfectly to 
the GO category “hematopoietic or lymphoid organ development” as these miRNAs 
prevent differentiation. Moreover, miR-125b seems to play an anti-apoptotic role in 
CD133+ cells as well as a function in remodelling of the cytoskeleton. A model for the 
miRNA-mRNA interactions related to differentiation, apoptosis and cytoskeletal 
remodelling is shown in Figure 44. No data are currently available for the role of miR-99a, 
miR-125a-5p and miR-551b in hematopoietic cells.  
The second group of higher expressed miRNAs in CD133+ cells compared to 
CD34+CD133– cells were also highly expressed in neutrophilic granulocytes (Figure 24, 
group 2: miR-23a, miR-23b, miR-24, miR-29a, miR-29b and miR-29c) and were amongst 
others enriched for annotations related to developmental processes, negative regulation of 
cell migration and collagens (Table 11).  
Roles for the respective miRNAs in developmental processes were already shown for 
miR-23a, miR-23b, miR-29a and miR-24. The miR-23a cluster consisting of miR-23a, 
miR-27a, and miR-24-2 (one of the two precursors of miR-24) inhibits B-cell development 
(Kong et al. 2010) and the miR-23b cluster consisting of miR-23b, miR-27b and miR-24-1 
regulates liver stem cell differentiation by targeting Smads (Rogler et al. 2009). Han et al 
(2010) showed that miR-29a induces aberrant self-renewal capacity in hematopoietic 
progenitors.  
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The role of miR-29b on the regulation of the extracellular matrix was demonstrated by 
Luna et al. (2009). COL4A1 and COL5A1 were both validated as targets of miR-29b and 
also predicted in our combined miRNA and mRNA analysis. 
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Figure 44.  Model for the biological role of significantly differentially expressed miRNAs in CD133+ cells. 
The targets of the miRNAs are highly relevant in the context of differentiation (green), apoptosis 
(blue) and cytoskeletal remodelling (red). Predicted miRNA-mRNA interactions are shown as 
dashed line. Targets that were validated in our lab are encircled (see section 3.5.3). The references 
for the other validated miRNA-mRNA interactions are mentioned in the text.  
Overexpression of miR-24 in CD34+ cells inhibits erythropoiesis (Wang et al. 2008a). 
Furthermore, miR-24a negatively regulates the proapoptotic factor caspase 9 in the 
developing neural retina (Walker and Harland 2009).  
The predicted targets of the lower expressed miRNAs (Figure 24, group 3: miR-142-3p, 
miR-142-5p, miR-425, miR-191 and miR-484) were highly enriched for the ubiquitin-
proteasome system (UPS) and the regulation of cytoskeleton organisation. Interestingly, a 
function of miR-142-5p in ubiquitin mediated proteolysis and of miR-142-3p in regulation 
of cytoskeleton was predicted by Tsang et al. (2010) using mirBridge. The computational 
method miRBridge starts with a gene set of known function and then assesses whether 
functional sites for a given miRNA are enriched in the gene set compared to random gene 
sets with similar properties. A comparison of the putative targets named for both functions 
with our data revealed RAC1 and ROCK2 as highly putative target for miR-142-3p in the 
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context of cytoskeleton regulation as well as UBE2D1 and UBE2 as targets for 
miR-142-5p within UPS (see section 5.4, Table A8). Besides miR-142-5p, a function for 
all five miRNAs lower expressed in CD133+ cells in the ubiquitin proteasome system was 
predicted in our data. 
The UPS is highly relevant in the context of stem cell biology (Naujokat and Saric 2007), 
as fundamental processes in mammalian stem and progenitor cells are directly controlled 
by this cellular proteolytic machinery. The UPS works either via proteolytic degradation of 
key regulatory proteins of signalig pathways or via nonproteolytic mechanisms involving 
the proteasome itself or posttranslational modification of target proteins by ubiquitin. It 
was shown that extracellular ubiquitin inhibits hematopoietic lineage commitment (Daino 
et al. 1996) and that the 26S proteasome – the central proteolytic machinery of the UPS – 
is important for maintenance of viability and promotes differentiation as well as lineage 
commitment in CD34+ cells (Zavrski et al. 2003).  
After analysing the coexpression of bioinformatically predicted miRNA-mRNA pairs 
(strategy I), it was focused on inversely correlated miRNA-mRNAs (strategy II). 
46 predicted targets were significantly lower expressed and their corresponding miRNAs 
higher expressed in CD133+ cells. Compared to the overall number of several hundred 
predicted and coexpressed targets this was a quite low number, indicating that the changes 
in mRNA expression are often modestly, the targets may be masked by additional 
regulatory machineries such as transcription factors or that translation repression is the 
major mechanism for target gene suppression. Functional profiling for the 46 predicted 
targets revealed an enrichment for mRNAs associated with development and cell 
differentiation (Figure 34) suggesting that the miRNAs higher expressed in CD133+ cells 
may be important for their stem cell character.  
Some of the inversely correlated miRNA-mRNA pairs were further analyzed via luciferase 
assays (see section 3.5.3). One of those pairs was miR-29a and TPM1, an important 
component of the cytoskeleton playing a fundamental role in many aspects of eukaryotic 
cell behavior such as cell morphology, divisions and motility. In animals, TPM1 is one of 
four tropomyosin genes coding – due to alternative splicing – for more than 40 isoforms 
that are expressed in a tissue specific manner (Schevzov et al. 2005). TPMs are known to 
regulate lamellipodial actin-based motility (Walker and Harland 2009) and focal adhesion. 
Our results revealed that TPM1 can be regulated by miR-29a and that this interaction 
might lead to a lower expression of TPM1 in CD133+ cells. As tropomyosin inhibits 
lamellipodium formation (Gupton et al. 2005), a lower expression of TPM1 in CD133+ 
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cells might lead to enhancend podia formation as compared to CD34+CD133– cells. 
Interestingly, it was described that more primitive HPCs possess more lamellipodia with 
strong expression of CD133 (Wagner et al. 2004). 
Another inversely correlated miRNA-mRNA interaction was miR-29a and FZD5, one of 
the seven-pass transmembrane Frizzled receptors, which bind Wnt proteins. Through 
several cytoplasmatic components, the signal is then transduced to β-catenin which 
localizes to the nucleus and forms a complex with TCF to activate transcription of Wnt 
target genes (Nusse 2008). Wnt signaling controls diverse processes such as cell 
proliferation and stem cell maintenance. A role for Wnt signaling in self-renewal of HSCs 
was demonstrated by Reya et al (2003). Furthermore, Wnt proteins were used by Willert et 
al (2003) as stem cell growth factor for in vitro cultivation of HSCs. Regulation of cell 
polarity and migration by ß-Catenin-independent Wnt pathways was also described (Lai et 
al. 2009).  
The predicted miRNA-mRNA interaction of miR-29a and FZD5 was validated by using 
luciferase assays that contained the predicted binding site of miR-29a. The result 
(Figure 36) suggested that FZD5 might be controlled by miR-29a.  
Interestingly, an influence of Tenascin-C on TPM1 and Wnt signaling was described by 
Ruiz et al. (2004). Tenascin-C – an adhesion-modulating extracellular matrix molecule –
downregulated TPM1 and enhanced Wnt signaling in T98G glioblastoma cells. As 
miR-29a potentially targets TPM1 and FZD5 in CD133+ cells, a similar simultaneous 
regulation of TPM1 and Wnt signaling might be achieved.  
Just eight miRNA-mRNA interactions were found for lower expressed miRNAs and higher 
expressed mRNAs in CD133+ cells (Table 14). Among these interactions was a very 
interesting one, namely the interaction of miR-142-3p – lower expressed in CD133+ cells 
than in CD34+CD133– cells – with the CD133 mRNA. Again it was possible to validate the 
interaction via luciferase assay. A regulation of CD133 expression via miRNAs might be 
highly relevant for the in vitro expansion of CD133+ cells (see below section 4.4). 
However, future analysis will be necessary to show if the surface expression of CD133 is 
controlled by miRNAs. 
On miRNA level, 18 significantly differentially expressed miRNAs (Figure 24) accounted 
for the differences between CD133+ and CD34+CD133– bone marrow cells and the targets 
of the miRNAs higher expressed in CD133+ cells were predicted to be involved in 
hematopoietic development. As the influence of most of the significantly differentially 
expressed miRNAs on their targets seemed to be modestly, they appear to function as a 
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modulator rather than a developmental switch. In this sense the miRNAs act like a rheostat, 
in that they modulate their targets rather than simply turning them on or off. In the rheostat 
analogy proposed by Bartel and Chen (2004), the resistance that is imparted by miRNAs is 
adjusted as the miRNA expression profile changes during cellular development. In our 
case the rheostats – that are the target sites within the 3’UTR of mRNAs relevant for 
hematopoietic cell differentiation – are adjusted to high resistance by the corresponding 
miRNAs higher expressed in CD133+ cells (Figure 45). Thus the productive translation of 
mRNAs is dampened to achieve the optimal protein level for CD133+ cells. Subsequently, 
the CD133+ cells are maintained in a more primitive state. By contrast, the rheostat is 
adjusted to low resistance by the lower expression of the respective miRNAs in 
CD34+CD133– cells leading to a less primitive cell state.   
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Figure 45.  Model for the modulation of the hematopoietic development by miRNAs higher expressed in 
CD133+ cells as compared to CD34+CD133– cells. The higher expressed miRNAs in CD133+ cells 
(left) tune the signaling rheostat to high resistance by binding to their mRNA targets. Thus, the 
protein output of the targets is dampend leading to less proteins responsible for differentiation of 
CD133+ cells in less primitive cells such as CD34+CD133– cells. In CD34+CD133– cells (right) the 
miRNAs are lower expressed tuning the signaling rheostat to low resistance by binding less 
mRNA targets. Thus the protein level increases and the cell differentiation is activated. miR-A 
represents miRNA members of group 1, miR-B miRNAs of group 2 (Figure 24).  
According to the biological effects of the miRNAs described above (Figure 44), the 
miRNAs higher expressed in CD133+ cells prevent differentiation, are anti-apoptotic and 
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regulate the cytoskeleton leading to enhanced podia formation and cell polarity 
(Figure 46). The miRNAs higher expressed in CD34+CD133– cells repress the ubiquitin-
proteasome-sytem and down-regulate CD133 expression. Taken together, it is proposed 
that the miRNAs significantly differentially expressed in CD133+ cells function by fine-
tuning the expression of their targets to a precise level at which the gene will execute its 
specific function in processes such as differentatiation, apoptosis and remodelling of the 
cytoskeleton. 
CD133+ CD34+CD133-
in CD133+ cells
- prevent differentiation
- are anti-apoptotic
- regulate the cytoskeleton
enhanced podia formation
in CD34+CD133- cells
- repress the ubiquitin-proteasome
system
- down-regulate CD133 expression
miRNAs higher expressed
 
Figure 46.  Hypothesis for the biological role of miRNAs in CD133+ cells.  
 
In contrast to the modulator function of the significantly differentially expressed miRNAs, 
the highest expressed miRNAs, e.g. miR-26, that were not differentially expressed between 
CD133+ and CD34+CD133– cells may confer signaling robustness. A role for miR-26a in 
different signaling networks was demonstrated recently (Inui et al. 2010). One validated 
target of miR-26a is PTEN, a factor that acts downstream of receptor tyrosin kinases (Huse 
et al. 2009), another one SMAD1, a factor of the TGF-ß signaling (Luzi et al. 2008). Both 
genes were coexpressed with miR-26a in our data sets and part of the GO category post-
translational protein modification (Table 11 and Table A9 in section 5.4). Thus, miR-26 
might impart robustness to the signaling network in CD133+ and CD34+CD133– cells. 
As miRNAs usually operate in concert with other regulatory machineries of the cells such 
as transcription factors, the functional importance of miRNAs is – beside fine-tuning of 
gene expression and conferring robustness – determined by the underlying network 
structures (Tsang et al. 2007). Future studies focusing on the underlying complex networks 
will gain further insights into the role of miRNAs in CD133+ cells. 
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4.4 miRNAs as a tool for in vitro expansion of HSCs 
Growing HSCs in vitro has turned out to be surprisingly difficult (see also section 1.2.2), 
as most of the tested growth factors can induce extensive proliferation but are unable to 
prevent differentiation of HSCs (Reya 2003). Current ex vivo systems (Table 16) achieved 
fold expansion in CD133+ cells between 3-fold and 28-fold using different supplements. 
The expansion in total nucleated cells was up to 1000-fold, indicating that most of these 
protocols generate large numbers mature cells, but little if any true expansion of 
repopulating stem cells. The identification of expansion in primitive cells is difficult as the 
evaluation depends on in vivo assays such as NOD/SCID transplantation (Coulombel 
2004). However, in vitro assays can yield valuable information about the developmental 
potential of expanded cells and are the method of choice for screening experiments. 
Crucial for further development of ex vivo expansion systems is the understanding of the 
molecular pathways involved in HSC proliferation and maintenance. A new possibility for 
the optimization of culture conditions could be miRNAs, as they fine-tune cell 
differentiation (see section 4.3) and it was already shown that they influence stem cell 
behavior (Han et al. 2010). If miRNAs can stimulate ex vivo expansion of HSCs as culture 
supplement, is currently unknown.  
In order to test miRNAs as a potential tool for in vitro expansion, we sought to analyze (1) 
the behavior of CD133+ cells during cultivation in a medium, that is currently the gold 
standard for expansion of HSCs (2) transfection of miRNAs by using a FITC-labeled 
double-stranded RNA and (3) the influence of different miRNAs on CD133+ cells.  
The medium of Zhang et al (2008) consisting of StemSpan with the growth factor 
combination SCF (S), TPO (T), FGF-1 (F), Angptl-5 (A) and IGFBP2 (I) was used as gold 
standard, as their publication reports a 20-fold net expansion of repopulating human HSCs.  
The analysis of cultivated CD133+ cells revealed a 3.1-fold expansion in the number of 
CD133+ cells at day 7 (Figure 40) which is quite low in comparison to other published data 
(Table 16). However, the data are difficult to compare as the published data worked with 
CD133+ cells from cord blood, whereas we used frozen CD133+ cells from mobilized 
peripheral blood. Moreover, the cell densities in the starting populations were different and 
seemed to have a great influence on the viability and proliferation of the cells. 
Immunophenotyping showed a decrease in CD133 expression from day 1 to day 14, 
whereas the CD34 expression increased up to day 7 and then sharply decreased. CFSE 
staining – an assay to analyze cell proliferation – revealed a decrease in CD133 expression 
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after several cell divisions whereas CD34 expression was maintained (Figure 39). In other 
words the CD133+ cells divided about 3 times before the CD133 expression was lost. 
Maintenance of CD133 expression over a higher number of cell divisions would be one of 
the goals for an optimized medium. 
Table 16. Described media for in vitro expansion of CD133+ cells. The fold expansion in CD133+ cells 
based on in vitro assays is listed except for Zhang et al. (2008) who analyzed the expansion in 
repopulating cells in vivo. MGDF: megakaryocyte growth and development factor, 
AP: autologous cord blood plasma 
                 Ex-vivo expansion of  
Reference Basal medium Supplements 
CD133+ cells 
[x-fold] 
total cells 
[x-fold] day 
Kobari et al. 
(2001) 
LTCM Flt3, SCF, 
MGDF,G-CSF 
28 
 
1000 14 
Bonanno et al. 
(2004) 
IMDM + 
25% serum 
substitute 
SCF, Flt3, IL-6 2.9 n.a. 10 
Robinson et al. 
(2006) 
αMEM + 
10% FBS 
G-CSF, SCF, TPO 6 
31 (co-culture with MSCs) 
46 
n.a. 
14 
Nikolova et al. 
(2007) 
IMDM + 
10% FBS 
WNT-conditioned  8.5 
25 
n.a. 7 
14 
Bordeaux-Rego 
et al. (2009) 
IMDM + 
10% FBS 
IL-3, I-L6 18 n.a. 8 
Schlechta et al. 
(2010) 
IMDM + AP SCF, TPO, Flt3, 
IL-6 
7.9 
22.1 
25 
95 
7 
14 
Zhang et al. 
(2008) 
StemSpan STF, I, A 20 (expansion of 
repopulating HSCs) 
220 10 
 
The miRNA transfection experiments showed an uptake of miRNA mimics inside the cells 
(Figure 42). Thus, lipofection is suited to transfect miRNA mimics in CD133+ cells and a 
panel of miRNA mimics – significantly differentially expressed in CD133+ cells compared 
to CD34+CD133– cells – was transfected in CD133+ cells (Figure 43). The hypothesis was 
that transfection of miRNAs higher expressed in CD133+ cells prevents differentiation of 
CD133+ cells in CD34+CD133– cells and leads to higher developmental potential as 
measured by CFU assays. Contrarily, transfection of miRNAs lower expressed in CD133+ 
cells would restrict the developmental potential as differentiation is supported. 
Transfection of these miRNAs in CD34+ cells could be an interesting approach to see if a 
conversion in CD133+ cells takes place. The initial experiments led to no different 
immunophentypes of the transfected cells and no significant difference in the colonoy-
forming ability. However, the number of colonies was slightly lower for CD133+ cells 
transfected with miR-142-3p or miR-425 mimics indicating that these miRNAs lower 
expressed in CD133+ cells might negatively influence the developmental potential of 
CD133+ cells. Further experiments are required to confirm these preliminary findings and a 
further optimization of the system has to be carried out.  
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Important aspects to consider are among others the cell source, the optimal miRNA 
concentration for transfection, the combinatorial effect of miRNAs and the optimal design 
and delivery form of miRNA mimics and inhibitors for application in culture media.  
The concentration of the miRNA mimics has to be carefully chosen as miRNA transfection 
affects the expression of genes predicted to be under endogenous miRNA regulation (Khan 
et al. 2009). This effect is generated by the competition of transfected miRNAs with 
endogenous miRNAs for the RISC complex and other machinery of the miRNA pathway 
leading to a higher expression of endogenous miRNA targets.  
For in vitro expansion of CD133+ cells by using miRNAs it is furthermore unclear, if it is 
an advantage to apply all miRNAs higher or lower expressed in CD133+ cells 
simultaneously. Due to combinatorial regulation miRNAs used in combination can induce 
additional changes not seen by individual miRNAs (Forrest et al. 2010). However, as 
shown in the field of reprogramming less factors can sometimes be better than a huge pool 
(Takahashi and Yamanaka 2006). 
Mimics and inhibitors can be designed with chemically modifications such as 
phosphorothioate backbone, cholesterol moieties and locked nucleic acids (LNAs). 
Cholesterol modifications and LNAs are commonly introduced in miRNA inhibitors to 
block miRNA function (Horwich and Zamore 2008). In our experiments, we used 
doublestranded miRNA mimics chemically modified at the 5' end of the sense strand 
(Applied Biosystems) to hold the higher expressed miRNAs in CD133+ cells at a high 
level. Delivery of inhibitors for the lower expressed miRNAs in CD133+ could be a 
possibility to hold the respective miRNAs at a low level and to prevent differentiation.  
The broad biodistribution of antagomirs – chemically modified, cholesterol-conjugated 
single-stranded RNA analogues complementary to miRNAs – after tail-vein injections in 
all tissues except brain in mice (Krutzfeldt et al. 2005) indicates a high capability of cells 
to take up antagomirs. The mechanisms for antagomir uptake in cells might depend on 
interactions with lipoprotein particles, lipoprotein receptors and transmembrane proteins as 
described for uptake of cholesterol-conjugated siRNAs (Wolfrum et al. 2007). The 
transmembrane protein and RNA transporter SID-1 was originally described for spreading 
of RNAi between cells in Caenorhabditis elegans where SID-1 expression is detected in 
all nonneuronal cells (Feinberg and Hunter 2003). As Wolfrum et al. demonstrated that the 
mammalian homolog of SID-1 is required for cellular siRNA uptake in mice, one could 
speculate that a cellular uptake of miRNA mimics and inhibitors in CD133+ cells is 
possible unassisted by transfection reagents.  
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The delivery of miRNA mimics and/or inhibitors to CD133+ cells by just adding them to 
the medium would be an elegant way to improve the expansion of HSCs. Considering the 
stability and bioavailability of miRNA mimics and/or inhibitors in media solutions, it has 
to be tested if cholesterol-conjugated oligonucleotides, LNAs or potentially also 
unmodified oligonucleotides are best suited as culture supplement.  
4.5 Conclusion and Outlook 
The described microarray-based approach for global and absolute quantification of 
miRNAs relies on the parallel hybridization of the sample of interest labeled with Cy5 and 
a universal reference of 954 synthetic miRNAs in equimolar concentrations that are labeled 
with Cy3. Each single miRNA is quantified with respect to the universal reference 
canceling biases related to sequence, labeling, or hybridization. The accuracy of the 
method was demonstrated by various spike-in experiments. 
The second part of this doctoral thesis presents the first relative and absolute miRNA 
profile of CD133+ bone marrow cells and the first comparison of CD133+ and 
CD34+CD133– cells from the same donor on miRNA level. The results were clearly 
confirmed by qRT-PCR and Solexa sequencing. The biological role of the 18 miRNAs 
differentially expressed between CD133+ and CD34+CD133– cells was further analyzed by 
examining the coexpression of bioinformatically predicted miRNA-mRNA pairs. The 
analysis revealed that the differentially expressed miRNAs in CD133+ cells are involved in 
inhibition of differentiation, prevention of apoptosis and cytoskeletal remodelling. Thus, it 
is proposed that the miRNA repertoire of CD133+ cells helps to maintain the stem cell 
character of the cells. 
Detailed functional analysis of miRNA effects in CD133+ cells will gain further insights 
into the role of miRNAs in stem cells. It will be important in future studies to identify 
which specific miRNAs positively influence in vitro expansion of CD133+ cells.  
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5 Appendix 
5.1 Microarray data – GEO accessions 
Table A1. Accession numbers for each microarray deposited at the National Center for Biotechnology 
Information Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). GSE: series number; 
GPL: platform number; GSM: sample number; Array ID: internal Miltenyi ID; Donor ID: ID as 
listed in Table 4; *: Agilent ID 2514850374. 
Experiment Section Figure/Table  GPL# GSM# Array ID Sample/Donor ID 
Microarray probe design (GSE#15832)     
 3.1.1 Figure 6  8437 397600 469052 UR 
    8437 397601 469053 UR 
Sensitivity and linear dynamic range (GSE#15834)     
 3.1.3 Figure 8  8440 397615 685001 UR 
    8440 397616 685002 UR 
    8440 397617 685003 UR 
    8440 397618 685004 UR 
    8440 397619 685005 UR 
    8440 397620 685006 UR 
    8440 397621 685007 UR 
    8440 397622 685008 UR 
    8440 397623 685009 UR 
Specificity and comparison to sequencing data (GSE#7233)    
 3.1.2 Figure 7  4867 173154 517063 Hepatoma-PLC 
 3.1.4 Figure 10  4867 173155 517064 Hepatocell-carcinoma-
Huh7-mock 
    4867 173156 517065 Gliobl-SNB19 
    4867 173157 517066 Hippocamp-adult 
    4867 173158 517067 T-cell-CD4-A301 
    4867 173158 517068 T-cell-CD4-A301 
Relative quantification of miRNAs (GSE#15833)     
 3.2.2 Table 2  8438 397602 589031 liver 
    8438 397603 589032 brain 
    8438 397604 589033 liver vs brain 
    8438 397605 589037 brain 
    8438 397606 589038 liver vs brain 
    8438 397607 589042 brain 
    8438 397608 589093 liver vs brain 
Absolute quantification of miRNAs (GSE#15835)     
 3.2.3 Figure 13  8440 397610 685012 liver and spike-in 
 3.2.4   8440 397611 685013 liver and spike-in 
    8440 397612 685014 liver and spike-in 
    8440 397613 685015 liver and spike-in 
    8440 397614 685077 liver and spike-in 
    8441 397625 700071 liver and spike-in 
Absolute quantification of CD34+CD133– cells (GSE#15831)    
 3.2.4 Figure 15  8436 397586 692033 CD34+CD133–, #8 
    8436 397587 692037 CD34+CD133–, #6 
    8439 397609 661018 CD34+CD133–, #5 
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Experiment Section Figure/Table  GPL# GSM# ArrayID Sample 
Combined miRNA and mRNA analysis (GSE#22460)     
 3.3. Figure 21-25  8436 558005 692032 CD133+, #8 
 3.5.2 Table 5-6  8436 558006 692033 CD34+CD133–, #8 
    8436 558007 692034 Neg, #8 
    8436 558008 692035 Neg_L, #8 
    8436 558009 692042 Neg_L, #9 
    8436 558010 692043 Neg, #9 
    8436 558011 692045 CD133+, #9 
    8436 558012 692046 CD34+CD133–, #9 
    8436 558013 692049 CD133+, #10 
    8436 558014 692050 CD34+CD133–, #10 
    8436 558015 692051 Neg, #10 
    8436 558016 692052 Neg_L, #10 
    8436 558017 692054 CD133+, #11 
    8436 558018 692055 CD34+CD133–, #11 
    8436 558019 692057 Neg_L, #11 
    8436 558020 692058 Neg, #11 
    8436 558021 692066 CD133+, #7 
    8436 558022 692068 CD34+CD133–, #7 
    8436 558023 692069 Neg, #7 
    8436 558024 692070 Neg_L, #7 
    8439 558025 661025 CD133+, mPB, #L2 
    8439 558026 661026 CD133+, mPB, #L1 
 3.4 Figure 29-30  6480 557921 *59_1_1 CD133+, #9 
 3.5.2   6480 557922 *58_1_3 CD133+, #12 
    6480 557923 *58_1_1 CD133+, #11 
    6480 557924 *61_1_2 CD133+, #7 
    6480 557925 *57_1_1 CD133+, #1 
    6480 557926 *59_1_4 CD133+, #2 
    6480 557927 *60_1_2 CD133+, #6 
    6480 557928 *60_1_4 CD133+, #8 
    6480 557929 *59_1_2 CD34+CD133–, #9 
    6480 557930 *58_1_2 CD34+CD133–, #11 
    6480 557931 *61_1_3 CD34+CD133–, #7 
    6480 557932 *57_1_2 CD34+CD133–, #1 
    6480 557933 *60_1_1 CD34+CD133–, #2 
    6480 557934 *60_1_3 CD34+CD133–, #6 
    6480 557935 *57_1_3 CD34+CD133–, #8 
    6480 557936 *59_1_3 Neg_L, #9 
    6480 557937 *61_1_1 Neg_L, #11 
    6480 557938 *61_1_4 Neg_L, #7 
    6480 557939 *57_1_4 Neg_L, #8 
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5.2 Supplemental data – Absolute quantification of miRNAs  
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Figure A1. Liver total RNA was supplemented with 0.3125 to 20 fmol of all together 75 spike ins (synthetic 
miRNAs that are not detectable in liver) and hybridized vs. the universal reference. The measured 
and expected amounts for the 75 spike ins are shown (empty black diamonds). The measured 
mean value is shown as black square together with its standard deviation. Each diagram (A-C) 
displays one array experiment (see also Table A2 for the measured amount of the spiked in 
miRNAs). 
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Figure A2. qRT-PCR of synthetic miRNAs. qRT-PCR assays were carried out for 11 randomly selected, 
synthetic miRNAs. In each assay 10 amol synthetic RNA oligo was used. The CT values ranged 
from 22.6 to 27.4. 
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5.3 Supplemental Data – miRNA and mRNA expression in HSCs and 
HPCs 
Table A4. CD133+ cells from mobilized leukapheresis. 
ID/No Age Sex Purity [%] 
before freezing 
Purity [%] 
after thawing 
L1 21 m 81.9 74.3 
L2 31 f 79.6 - 
L3 32 m 98.6 91.6 
L4 24 m 90.3 90.1 
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Table A5. Significantly differentially expressed transcripts between CD133+ and CD34+CD133– cells (see 
section 3.4). The transcripts were identified by using SAM analysis (false discovery rate: 
0.000000%) and t-test (p-value < 0.01). 
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Table A6. Comparison of 33 miRNAs detected in CD34+ cells published by Georgantas et al. (2007) with 
our data.  
miRNA name Georgantas et al. our data 
LET-7B x x 
MIR-16A x x 
MIR-16B x x 
MIR-17 x x 
MIR-20 x x 
MIR-23A x x 
MIR-23B x x 
MIR-24 x x 
MIR-25 x x 
MIR-26A x x 
MIR-26B x x 
MIR-30B x x 
MIR-30d x x 
MIR-92-1 x x 
MIR-92-2 x x 
MIR-93 x x 
MIR-103-2 x x 
MIR-103 x x 
MIR-106 x x 
MIR-107 x x 
MIR-123 x - 
MIR-130A x x 
MIR-146 x x 
MIR-155 x x 
MIR-181A x x 
MIR-191 x x 
MIR-193 x - 
MIR-197 x - 
MIR-213 x - 
MIR-221 x x 
MIR-222 x x 
MIR-222 x x 
MIR-223 x x 
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5.4  Supplemental Data – Combined miRNA and mRNA analysis 
Table A7. Significantly enriched categories among the predicted mRNA targets for the significantly 
differentially expressed miRNAs miR-29, miR-23 and miR-24 (strategy Ia, group 2 in Table 11). 
Gene bank numbers are listed below (Table A10). 
Category and respective genes Count Significance EF 
Reproductive developmental process (GO) 23 5E-09 4.49 
STAT5B; CCND2; FEM1B; HMGB2; CDKN1B; CSDA; HMGCR; BCL2L11; 
FOXO3; PLAG1;BCL2L2; NCOA4; PTEN; ROBO2; VEGFA; NKX2-1; 
CCND1; HNF1B; CHD7; CSDA; LGR4; MMP2; IDH1 
   
Sensory organ development (GO) 26 6.89E-08 3.83 
SPRY2; NUDT6; COL5A1; MAFB; ZEB1; ZFP91; CDKN1B; INSIG1; 
TSHZ1; BCL2L11; MAF; BHLHE22; MITF; PVRL1; SPARC; PRKRA; 
MUTED; MAB21L2; VEGFA; YY1; MEIS1; ZFP91; CHD7; KCNMA1; 
KLF4; TSPAN12 
   
SNARE complex, SNAP receptor activity, SNARE interactions in vesicular 
transport (GO) 
11 4.10E-06 10.38 
VTI1A; VTI1B; SCAMP5; STX1A; STX17; SNAP25; STX5; STX12; BET1; 
BET1; STX16;  
   
Negative regulation of cell migration (GO) 12 5.00E-06 4.52 
PNRC2; TRIB1; NUDT6; CDKN1B; TPM1; DLC1; PTEN; PDGFB; VCL; 
LOC728003; TPM1; ABHD2 
   
ECM and collagens (cancermodules) 20 7.50E-06 3.06 
PMP22; COL6A3; ZEB1; COL4A2; TPM1; MARCKS; MLLT11; PLAU;  
ADNP; BMP1; MAF; MRC2; COL4A1; FBN1; SPARC; PLAGL1; WDTC1; 
CXCL12; TPM1; MMP2 
   
Serine/Threonine protein kinases, catalytic domain (homology domains, 
SMART) 
27 1.00E-05 3.11 
MAP4K4; GRK5; MAP3K5; MARK3; NLK; AKT3; CDK6; SGK1; DYRK2; 
MAP3K3; MAP2K6; DYRK1A; NEK6; ICK; PIM1; CAMK2G; CLK3; PAK6; 
STK4; ADRBK1; CSNK2A2; PRPF4B; PAK2; LOC646214; CAMK1D; 
PRKG1; MAP2K4 
   
Protein kinase inhibitor activity (GO) 10 1.10E-05 5.48 
YWHAG; TRIB1; CDKN1B; GMFB; WNK1; PKIA; YWHAE; TRIB2; 
HEXIM1; LOC440917 
   
Figure A3. miRNA precursor cluster cloned from hematopoietic 
cells (Landgraf et al. 2007). 21 precursor cluster were 
present in HSCs (CD34+ cells). In our data mature 
miRNAs of all precursor cluster except for miR-143 
and miR-145 (cluster-miR-143) were detected in 
CD34+CD133– and CD133+cells. 
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Table A8. Significantly enriched categories among the predicted mRNA targets for the significantly 
differentially expressed miRNAs miR-484, miR-425, miR-191 and miR-142 (strategy Ib, group 3 
in Table 11). Gene bank numbers are listed below (Table A10). 
 Category and respective genes Count Significance EF 
Ubiquitin proteasome system (Miltenyi) 39 5.13E-09 3.13 
ZBTB11; MARCH6; ASB7; PAFAH1B1; ZFAND3; SACS; MARK3; 
KIAA0368; RNF139; UBE2A; MYCBP2; CUL4A; RNF145; MAP3K7IP2; 
SENP1; BACH1; OTUD4; PCGF3; UBQLN1; TFG; ATXN7L2; CBL; 
FAM63B; ZBTB47; USP38; HECTD1; HGS; GNB2; WDR26; EPN2; RNF138; 
SH3RF1; UBE2D1; TRIM2; BTBD7; HLTF; SPOPL; SOCS6; RC3H1 
      
Regulation of cytoskeleton organization (GO) 10 4.30E-04 4.86 
MYCBP2; ROCK2; RAC1; TNKS; XPO1; CIT; ARHGEF2; MLL; RICTOR; 
RHOQ 
     
Chromatin modification (GO) 14 2.69E-04 3.72 
MORF4L2; UBE2A; CHD9; MYST2; UTX; SATB1; PHF21A; SETD2; MLL; 
BAZ1A; HLTF; RCOR1; RERE; CBX6 
     
Protein serine/threonine kinase activity (GO) 15 6.20E-05 3.87 
HIPK1; MARK3; MYLK; CDK6; ROCK2; DYRK1A; PKN2; ZAK; OXSR1; 
CIT; STK38L; DYRK4; MAP3K11; SMG1; PRPF4B 
     
Reelin signaling pathway (PathwayCommons, Nature pathways) 4 8.60E-05 17.35 
PAFAH1B1; CBL; ARHGEF2; MAP3K11      
Table A9. Significantly enriched categories among the predicted mRNA targets for the high expressed 
miRNAs miR-26a and miR-26b (strategy Ic in Table 11). Gene bank numbers are listed below 
(Table A10). 
 Category and respective genes Count Significance EF 
Post-translational protein modification (GO) 67 1.8E-17 3.11 
HIPK1; VGLL4; AADACL1; ABL2; CDK2AP1; CCND2; GALNT7; 
HECTD3; EPHA2; UBE2K; NLK; MEX3B; CREBBP; CDK6; B3GNT5; 
UBE4B; GMFB; PPM1B; DYRK1A; SMAD1; NIPBL; JARID2; CDC2L5; 
NEK6; USP9X; WNK1; FBXW2; USP25; EZH2; UBE2G1; MGAT4A; 
MAP3K2; MAPK6; HDAC9; CHFR; PIM1; ERO1LB; MAN2A1; B3GNT9; 
ACVR1C; EP400; TWF1; ULK2; MTM1; YWHAE; ULK1; RTF1; FBXO11; 
PTP4A1; STRADB; TRIB2; STK39; SERP1; HGF; PTEN; METAP2; 
UBE2D1; GALNT10; MLL3; UBE3A; PDIK1L; PAN3; PPP3CB; PAK2; 
STYX; LOC440917; PAK2 
      
Protein serine/threonine kinase activity (GO)  17 2.40E-05 3.78 
HIPK1; NLK; CDK6; DYRK1A; CDC2L5; NEK6; WNK1; MAP3K2; 
MAPK6; PIM1; ACVR1C; ULK2; ULK1; STK39; PDIK1L; PAK2; PAK2 
      
Protein serine/threonine kinase domain (homology domains, SMART) 16 2.90E-06 4.58 
HIPK1; NLK; CDK6; DYRK1A; CDC2L5; NEK6; MAP3K2; MAPK6; PIM1; 
ULK2; ULK1; STK39; PDIK1L; PAK2; PAK2; EPHA2 
      
Chromatin modification (GO) 16 2.00E-05 3.81 
RCBTB1; CREBBP; RB1; NIPBL; JARID2; UTX; EZH2; HDAC9; PHF21A; 
EPC2; EP400; HMGA1; RTF1; MLL3; RCOR1; SRCAP 
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Table A10. Gene bank numbers (Entrez IDs) are listed in alphabetical order for the genes analyzed in 
 the framework of the combined miRNAs and mRNA analysis (see section 3.5.2). 
Gene name Entrez ID Gene name Entrez ID Gene name Entrez ID 
AADACL1 57552 COL24A1 255631 HCN3 57657 
ABHD2 100129616;11057;728003 COL4A1 1282 HDAC7 51564 
ABL2 27 COL4A2 1284 HDAC9 9734 
ACHE 43 COL5A1 1289 HECTD1 25831 
ACVR1C 130399 COL6A3 1293 HECTD3 79654 
ADAMTS14 140766 CREBBP 1387 HEXIM1 10614 
ADNP 23394 CSDA 440359;8531 HGF 3082 
ADRBK1 156 CSNK2A1 1457;283106 HGS 9146 
AKT3 10000 CSNK2A2 1459 HIPK1 204851 
AMMECR1 9949 CUL4A 8451 HLTF 6596 
ANK1 286 CXCL12 6387 HMGA1 3159 
ARHGAP19 84986 DHRS11 79154 HMGB2 3148 
ARHGEF2 100289466;9181 DLC1 10395 HMGB3 3149 
ARID5B 84159 DOT1L 84444 HMGCR 3156 
ARL8A 127829 DPF2 5977 HNF1B 6928 
ASB7 140460 DYRK1A 1859 HOXA3 3200 
ATXN7L2 127002 DYRK2 8445 HOXB3 3213 
B3GAT2 135152;60682 DYRK4 8798 ICK 22858 
B3GNT5 84002 EP400 57634 IDH1 3417 
B3GNT9 80262;84752 EPC2 26122 IGF1R 3480 
BACH1 571 EPHA2 1969 INPP5F 22876 
BAK1 578 EPN2 22905 INSIG1 3638 
BAZ1A 11177 ERO1LB 56605 IRAK1 3654 
BAZ2A 11176 ESRRA 2101 JARID2 3720 
BAZ2B 29994 ETS1 2113 KCNK5 8645 
BCL2 596 EXOC5 10640 KCNMA1 3778 
BCL2L11 10018 EZH2 2146 KIAA0368 23392 
BCL2L2 599 FAM129B 64855 KLF11 8462 
BET1 100128542;10282 FAM63B 54629 KLF4 9314 
BHLHE22 27319 FBN1 2200 LGR4 55366 
BMP1 649 FBXL10 84678 LOC440917 440917;7531 
BRPF1 7862 FBXO11 80204 LOC646214 5062;646214 
BSDC1 55108 FBXW2 26190 LOC728003 11057;728003 
BTBD7 55727 FEM1B 10116 MAB21L2 10586 
CAMK1D 57118 FGFR3 2261 MAF 4094 
CAMK2G 818 FLOT2 2319 MAFB 9935 
CBL 867 FNDC3B 64778 MAGOHB 55110 
CBX6 23466 FOXO3 2309;2310 MAN2A1 4124 
CCND1 595 FRAP1 2475 MAP2K4 6416 
CCND2 894 FUT1 2523 MAP2K6 5608 
CDC2L5 8621 FZD5 7855 MAP2K7 5609 
CDC42SE1 54964;56882 GAD1 2571 MAP3K10 4294 
CDK2AP1 8099 GALNT10 55568 MAP3K11 4296 
CDK6 1021 GALNT7 51809 MAP3K2 10746 
CDKN1B 1027 GMFB 2764 MAP3K3 4215 
CHD7 55636 GNB2 2783 MAP3K5 4217 
CHD9 80205 GRB10 2887 MAP3K7 6885 
CHFR 55743 GRK5 2869 MAP3K7IP2 23118 
CIT 11113 GTPBP1 9567 MAP4K4 9448 
CLK3 1198 H3F3B 3021;440093 MAPK14 1432 
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Gene name Entrez ID Gene 
name 
Entrez ID Gene 
name 
Entrez ID 
MAPK6 5597 PHC1 1911;4074 SERP1 27230 
MAPKBP1 23005 PHF15 23338 SETD2 29072 
MARCH6 10299 PHF20 51230 SGK1 6446 
MARCKS 4082 PHF20L1 51105 SH3RF1 57630 
MARCKSL1 65108 PHF21A 51317 SHANK3 85358 
MARK3 4140 PIM1 5292 SLC25A15 10166 
MED1 5469 PITPNA 5306 SMAD1 4086 
MEIS1 4211 PKIA 5569 SMG1 100271836;23049; 
440354;595101;641298 
METAP2 10988 PKN2 5586 SNAP25 6616 
MEX3B 84206 PLAG1 5324 SNX22 79856 
MGAT4A 11320 PLAGL1 5325 SOCS6 9306 
MITF 4286 PLAU 5328 SPARC 6678 
MLL 4297 PMP22 5376 SPNS1 83985 
MLL2 8085 PNRC2 100131261;55629 SPOPL 339745 
MLL3 58508 PPM1B 5495 SPRY2 10253 
MLLT11 10962 PPP3CA 5530 SRCAP 10847 
MMP2 4313 PPP3CB 5532 STAT5B 6777 
MORF4L2 9643 PRKG1 5592 STK38L 23012 
MRC2 9902 PRKRA 8575 STK39 27347 
MTM1 4534 PROM1 8842 STK4 6789 
MUTED 63915 PRPF4B 8899 STRADB 55437 
MYBL2 4605 PSTPIP2 9050 STX12 23673 
MYCBP2 23077 PTEN 11191;5728 STX16 8675 
MYLK 4638 PTP4A1 7803 STX17 55014 
MYO5A 4644 PURB 5814 STX1A 6804 
MYST2 11143 PVRL1 5818 STX5 6811 
NCOA4 8031 RAC1 5879 STYX 6815 
NCOA6 23054 RARG 5916 SUV39H1 6839 
NEK6 10783 RB1 5925 SUV420H2 84787 
NIPBL 25836 RB1CC1 9821 TFG 10342 
NKX2-1 7080 RBPMS2 348093 TIAM1 7074 
NLK 51701 RC3H1 149041 TNKS 8658 
NUDT11 55190 RCBTB1 55213 TPM1 100128979;7168 
NUDT21 11051 RCOR1 23186 TRAF6 7189 
NUDT6 11162;2247 RERE 473 TRIB1 10221 
NUMB 8650 RHOQ 23433;284988;730041 TRIB2 28951 
ORC2L 4999 RICTOR 253260 TRIM2 23321 
OTUD4 54726 RNF138 379013;51444 TSHZ1 10194 
OXSR1 9943 RNF139 11236 TSPAN12 23554 
PAFAH1B1 5048 RNF145 153830 TSPAN14 81619 
PAK2 5062;646214 ROBO2 6092 TUBB2A 7280 
PAK6 56924 ROCK2 9475 TUSC2 11334 
PAN3 255967 RPS6KA1 6195 TWF1 5756 
PCGF3 10336 RTF1 23168 UBE2A 7319 
PCSK7 9159 SACS 26278 UBE2D1 7321 
PCYT1B 9468 SATB1 6304 UBE2G1 7326 
PDCD4 27250 SCAMP5 192683 UBE2I 7329 
PDGFB 5155 SEMA4C 54910 UBE2K 3093 
PDIK1L 149420 SEMA4D 10507 UBE3A 7337 
PGP 283871 SENP1 29843 UBE4B 10277 
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Gene name Entrez ID Gene name Entrez ID Gene name Entrez ID 
UBQLN1 29979 VTI1A 143187 ZAK 51776 
ULK1 8408 VTI1B 10490;384 ZBTB11 27107 
ULK2 9706 WDR26 80232 ZBTB47 92999 
USP25 29761 WDTC1 23038 ZEB1 6935 
USP31 57478 WNK1 65125 ZFAND3 60685 
USP38 84640 XPO1 7514 ZFP36 7538 
USP9X 8239 XRN1 54464 ZFP36L1 677 
UTX 7403 XYLT1 64131 ZFP91 386607;80829 
VCL 7414 YBX2 51087 ZMYND11 10771 
VEGFA 7422 YWHAE 649395;7531 ZMYND11 10771 
VGLL4 10533;9686 YWHAG 100289506;7532  
VPS37B 79720 YY1 7528   
 
(Ivanova et al. 2002; Georgantas et al. 2004; He et al. 2005; Huang et al. 2008)  
 125
6 References 
Allawi HT, Dahlberg JE, Olson S, Lund E, Olson M, Ma WP, Takova T, Neri BP, 
Lyamichev VI. 2004. Quantitation of microRNAs using a modified Invader assay. 
RNA 10:1153-1161. 
Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, 
Griffiths-Jones S, Marshall M et al. 2003. A uniform system for microRNA 
annotation. RNA 9:277-279. 
Aravin A, Tuschl T. 2005. Identification and characterization of small RNAs involved in 
RNA silencing. FEBS Lett 579:5830-5840. 
Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of 
microRNAs on protein output. Nature 455:64-71. 
Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, Einav U, Gilad S, 
Hurban P, Karov Y et al. 2004. MicroRNA expression detected by oligonucleotide 
microarrays: system establishment and expression profiling in human tissues. 
Genome Res 14:2486-2494. 
Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-
233. 
Bartel DP, Chen CZ. 2004. Micromanagers of gene expression: the potentially widespread 
influence of metazoan microRNAs. Nat Rev Genet 5:396-400. 
Baskerville S, Bartel DP. 2005. Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes. RNA 11:241-247. 
Bender JG, Unverzagt KL, Walker DE, Lee W, Van Epps DE, Smith DH, Stewart CC, To 
LB. 1991. Identification and comparison of CD34-positive cells and their 
subpopulations from normal peripheral blood and bone marrow using multicolor 
flow cytometry. Blood 77:2591-2596. 
Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, Still 
BJ, Spitzer G, Buckner CD, Bernstein ID et al. 1991. Engraftment after infusion of 
CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 
77:1717-1722. 
Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge 
SJ, Anderson KV, Hannon GJ. 2003. Dicer is essential for mouse development. Nat 
Genet 35:215-217. 
Bissels U, Wild S, Tomiuk S, Holste A, Hafner M, Tuschl T, Bosio A. 2009. Absolute 
quantification of microRNAs by using a universal reference. RNA 15:2375-2384. 
Blank U, Karlsson G, Karlsson S. 2008. Signaling pathways governing stem-cell fate. 
Blood 111:492-503. 
Bonanno G, Perillo A, Rutella S, De Ritis DG, Mariotti A, Marone M, Meoni F, Scambia 
G, Leone G, Mancuso S et al. 2004. Clinical isolation and functional 
characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion 
44:1087-1097. 
Bordeaux-Rego P, Luzo AC, Costa FF, Saad ST, Crosara Alberto DP. 2009. Both IL-3 and 
IL-6 are necessary for better ex vivo expansion of CD133+ cells from Umbilical 
Cord Blood. Stem Cells Dev. 
Bosio A, Huppert V, Donath S, Hennemann P, Malchow M, Heinlein UA. 2009. Isolation 
and enrichment of stem cells. Adv Biochem Eng Biotechnol 114:23-72. 
References 126
Boxall SA, Cook GP, Pearce D, Bonnet D, El-Sherbiny YM, Blundell MP, Howe SJ, Leek 
JP, Markham AF, de Wynter EA. 2009. Haematopoietic repopulating activity in 
human cord blood CD133+ quiescent cells. Bone Marrow Transplant 43:627-635. 
Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Lowenberg B, Gratama JW. 2008. 
Flow cytometric differential of leukocyte populations in normal bone marrow: 
Influence of peripheral blood contamination1. Cytometry B Clin Cytom 76B:18-26. 
Bruchova H, Merkerova M, Prchal JT. 2008. Aberrant expression of microRNA in 
polycythemia vera. Haematologica 93:1009-1016. 
Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. 2007. Regulated expression of 
microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 
35:1657-1667. 
Bryder D, Rossi DJ, Weissman IL. 2006. Hematopoietic stem cells: the paradigmatic 
tissue-specific stem cell. Am J Pathol 169:338-346. 
Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, Hunkapiller K, 
Jensen RV, Knight CR, Lee KY et al. 2006. Evaluation of DNA microarray results 
with quantitative gene expression platforms. Nat Biotechnol 24:1115-1122. 
Carter MG, Sharov AA, VanBuren V, Dudekula DB, Carmack CE, Nelson C, Ko MS. 
2005. Transcript copy number estimation using a mouse whole-genome 
oligonucleotide microarray. Genome Biol 6:R61. 
Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, Muckenthaler 
MU. 2006. A sensitive array for microRNA expression profiling (miChip) based on 
locked nucleic acids (LNA). RNA 12:913-920. 
Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, 
Moloshok T, Bort R et al. 2004. miR-122, a mammalian liver-specific microRNA, 
is processed from hcr mRNA and may downregulate the high affinity cationic 
amino acid transporter CAT-1. RNA Biol 1:106-113. 
Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. 2010. A dicer-independent miRNA 
biogenesis pathway that requires Ago catalysis. Nature 465:584-589. 
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, 
Mahuvakar VR, Andersen MR et al. 2005. Real-time quantification of microRNAs 
by stem-loop RT-PCR. Nucleic Acids Res 33:e179. 
Chen CZ, Li L, Lodish HF, Bartel DP. 2004. MicroRNAs modulate hematopoietic lineage 
differentiation. Science 303:83-86. 
Chen J, Lozach J, Garcia EW, Barnes B, Luo S, Mikoulitch I, Zhou L, Schroth G, Fan JB. 
2008. Highly sensitive and specific microRNA expression profiling using 
BeadArray technology. Nucleic Acids Res 36:e87. 
Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, Johnston WK, 
Russ C, Luo S, Babiarz JE et al. 2010. Mammalian microRNAs: experimental 
evaluation of novel and previously annotated genes. Genes Dev 24:992-1009. 
Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, 
Hannon GJ, Lawson N et al. 2010. A Novel miRNA Processing Pathway 
Independent of Dicer Requires Argonaute2 Catalytic Activity. Science. 
Coulombel L. 2004. Identification of hematopoietic stem/progenitor cells: strength and 
drawbacks of functional assays. Oncogene 23:7210-7222. 
Daino H, Shibayama H, Machii T, Kitani T. 1996. Extracellular ubiquitin regulates the 
growth of human hematopoietic cells. Biochem Biophys Res Commun 223:226-228. 
de Wynter EA, Buck D, Hart C, Heywood R, Coutinho LH, Clayton A, Rafferty JA, Burt 
D, Guenechea G, Bueren JA et al. 1998. CD34+AC133+ cells isolated from cord 
blood are highly enriched in long-term culture-initiating cells, NOD/SCID-
repopulating cells and dendritic cell progenitors. Stem Cells 16:387-396. 
References 127
Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. 2010. 
Notch-mediated expansion of human cord blood progenitor cells capable of rapid 
myeloid reconstitution. Nat Med 16:232-236. 
Dimitrov RA, Zuker M. 2004. Prediction of hybridization and melting for double-stranded 
nucleic acids. Biophys J 87:215-226. 
Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW, Yu D, Klein AM, 
Dorman C, Wu W et al. 2008. A GATA-1-regulated microRNA locus essential for 
erythropoiesis. Proceedings of the National Academy of Sciences of the United 
States of America 105:3333-3338. 
Dudley AM, Aach J, Steffen MA, Church GM. 2002. Measuring absolute expression with 
microarrays with a calibrated reference sample and an extended signal intensity 
range. Proc Natl Acad Sci U S A 99:7554-7559. 
Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of 
genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868. 
Feinberg EH, Hunter CP. 2003. Transport of dsRNA into cells by the transmembrane 
protein SID-1. Science 301:1545-1547. 
Feller N, van der Pol MA, Waaijman T, Weijers GW, Westra G, Ossenkoppele GJ, 
Schuurhuis GJ. 2005. Immunologic purging of autologous peripheral blood stem 
cell products based on CD34 and CD133 expression can be effectively and safely 
applied in half of the acute myeloid leukemia patients. Clin Cancer Res 11:4793-
4801. 
Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, 
Santoro S et al. 2005. MicroRNAs 221 and 222 inhibit normal erythropoiesis and 
erythroleukemic cell growth via kit receptor down-modulation. Proceedings of the 
National Academy of Sciences of the United States of America 102:18081-18086. 
Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F, Croce CM, Brunetti E, 
Grignani F, Peschle C. 2007. MicroRNAs 17-5p-20a-106a control monocytopoiesis 
through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 9:775-
787. 
Ford CE, Hamerton JL, Barnes DW, Loutit JF. 1956. Cytological identification of 
radiation-chimaeras. Nature 177:452-454. 
Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, 
de Hoon MJ, Kubosaki A, Kaiho A, Suzuki M et al. 2010. Induction of 
microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic 
differentiation through combinatorial regulation. Leukemia 24:460-466. 
Frigessi A, van de Wiel MA, Holden M, Svendsrud DH, Glad IK, Lyng H. 2005. Genome-
wide estimation of transcript concentrations from spotted cDNA microarray data. 
Nucleic Acids Res 33:e143. 
Furst G, Schulte am Esch J, Poll LW, Hosch SB, Fritz LB, Klein M, Godehardt E, Krieg 
A, Wecker B, Stoldt V et al. 2007. Portal vein embolization and autologous 
CD133+ bone marrow stem cells for liver regeneration: initial experience. 
Radiology 243:171-179. 
Gaidatzis D, van Nimwegen E, Hausser J, Zavolan M. 2007. Inference of miRNA targets 
using evolutionary conservation and pathway analysis. BMC Bioinformatics 8:69. 
Gallacher L, Murdoch B, Wu DM, Karanu FN, Keeney M, Bhatia M. 2000. Isolation and 
characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem 
cells using cell surface markers AC133 and CD7. Blood 95:2813-2820. 
Gangaraju VK, Lin H. 2009. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell 
Biol 10:116-125. 
References 128
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, 
Alder H, Marcucci G et al. 2006. MicroRNA fingerprints during human 
megakaryocytopoiesis. Proc Natl Acad Sci U S A 103:5078-5083. 
Geest CR, Coffer PJ. 2009. MAPK signaling pathways in the regulation of hematopoiesis. 
J Leukoc Biol 86:237-250. 
Georgantas RW, 3rd, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, Calin GA, 
Croce CM, Civin CI. 2007. CD34+ hematopoietic stem-progenitor cell microRNA 
expression and function: a circuit diagram of differentiation control. Proceedings of 
the National Academy of Sciences of the United States of America 104:2750-2755. 
Georgantas RW, 3rd, Tanadve V, Malehorn M, Heimfeld S, Chen C, Carr L, Martinez-
Murillo F, Riggins G, Kowalski J, Civin CI. 2004. Microarray and serial analysis of 
gene expression analyses identify known and novel transcripts overexpressed in 
hematopoietic stem cells. Cancer Res 64:4434-4441. 
Giebel B, Corbeil D, Beckmann J, Hohn J, Freund D, Giesen K, Fischer J, Kogler G, 
Wernet P. 2004. Segregation of lipid raft markers including CD133 in polarized 
human hematopoietic stem and progenitor cells. Blood 104:2332-2338. 
Goff LA, Yang M, Bowers J, Getts RC, Padgett RW, Hart RP. 2005. Rational probe 
optimization and enhanced detection strategy for microRNAs using microarrays. 
RNA Biol 2:93-100. 
Griffiths-Jones S. 2006. miRBase: the microRNA sequence database. Methods Mol Biol 
342:129-138. 
Guo Y, Lubbert M, Engelhardt M. 2003. CD34- hematopoietic stem cells: current concepts 
and controversies. Stem Cells 21:15-20. 
Gupton SL, Anderson KL, Kole TP, Fischer RS, Ponti A, Hitchcock-DeGregori SE, 
Danuser G, Fowler VM, Wirtz D, Hanein D et al. 2005. Cell migration without a 
lamellipodium: translation of actin dynamics into cell movement mediated by 
tropomyosin. J Cell Biol 168:619-631. 
Gururajan M, Haga CL, Das S, Leu CM, Hodson D, Josson S, Turner M, Cooper MD. 
2010. MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int 
Immunol. 
Hafner M, Landgraf P, Ludwig J, Rice A, Ojo T, Lin C, Holoch D, Lim C, Tuschl T. 2008. 
Identification of microRNAs and other small regulatory RNAs using cDNA library 
sequencing. Methods 44:3-12. 
Han L, Witmer PD, Casey E, Valle D, Sukumar S. 2007. DNA methylation regulates 
MicroRNA expression. Cancer Biol Ther 6:1284-1288. 
Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, Liu M, Zou Y, Weissman IL, Gu 
H. 2010. microRNA-29a induces aberrant self-renewal capacity in hematopoietic 
progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 
207:475-489. 
He X, Gonzalez V, Tsang A, Thompson J, Tsang TC, Harris DT. 2005. Differential gene 
expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem 
progenitor cells. Stem Cells Dev 14:188-198. 
Hekstra D, Taussig AR, Magnasco M, Naef F. 2003. Absolute mRNA concentrations from 
sequence-specific calibration of oligonucleotide arrays. Nucleic Acids Res 31:1962-
1968. 
Hemmoranta H, Hautaniemi S, Niemi J, Nicorici D, Laine J, Yli-Harja O, Partanen J, 
Jaatinen T. 2006. Transcriptional profiling reflects shared and unique characters for 
CD34+ and CD133+ cells. Stem Cells Dev 15:839-851. 
Ho CK, Wang LK, Lima CD, Shuman S. 2004. Structure and mechanism of RNA ligase. 
Structure 12:327-339. 
References 129
Holloway W, Martinez AR, Oh DJ, Francis K, Ramakrishna R, Palsson BO. 1999. Key 
adhesion molecules are present on long podia extended by hematopoietic cells. 
Cytometry 37:171-177. 
Horwich MD, Zamore PD. 2008. Design and delivery of antisense oligonucleotides to 
block microRNA function in cultured Drosophila and human cells. Nat Protoc 
3:1537-1549. 
Huang TS, Hsieh JY, Wu YH, Jen CH, Tsuang YH, Chiou SH, Partanen J, Anderson H, 
Jaatinen T, Yu YH et al. 2008. Functional network reconstruction reveals somatic 
stemness genetic maps and dedifferentiation-like transcriptome reprogramming 
induced by GATA2. Stem Cells 26:1186-1201. 
Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le 
Sage C, Agami R, Tuschl T et al. 2009. The PTEN-regulating microRNA miR-26a 
is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 
23:1327-1337. 
Hwang HW, Wentzel EA, Mendell JT. 2009. Cell-cell contact globally activates 
microRNA biogenesis. Proc Natl Acad Sci U S A 106:7016-7021. 
Inui M, Martello G, Piccolo S. 2010. MicroRNA control of signal transduction. Nat Rev 
Mol Cell Biol 11:252-263. 
Isidori A, Motta MR, Tani M, Terragna C, Zinzani P, Curti A, Rizzi S, Taioli S, Giudice 
V, D'Addio A et al. 2007. Positive selection and transplantation of autologous 
highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic 
leukemia patients results in rapid hematopoietic reconstitution without an adequate 
leukemic cell purging. Biol Blood Marrow Transplant 13:1224-1232. 
Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. 2002. A stem 
cell molecular signature. Science 298:601-604. 
Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H, Marincola FM, Stroncek DF. 2008. 
Differentiation of two types of mobilized peripheral blood stem cells by microRNA 
and cDNA expression analysis. J Transl Med 6:39. 
John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. 2004. Human MicroRNA 
targets. PLoS Biol 2:e363. 
Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. 2007. The role of site accessibility in 
microRNA target recognition. Nat Genet 39:1278-1284. 
Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. 2009. Transfection of 
small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat 
Biotechnol 27:549-555. 
Kobari L, Giarratana MC, Pflumio F, Izac B, Coulombel L, Douay L. 2001. CD133+ cell 
selection is an alternative to CD34+ cell selection for ex vivo expansion of 
hematopoietic stem cells. J Hematother Stem Cell Res 10:273-281. 
Kong KY, Owens KS, Rogers JH, Mullenix J, Velu CS, Grimes HL, Dahl R. 2010. MIR-
23A microRNA cluster inhibits B-cell development. Exp Hematol. 
Kosaka N, Sugiura K, Yamamoto Y, Yoshioka Y, Miyazaki H, Komatsu N, Ochiya T, 
Kato T. 2008. Identification of erythropoietin-induced microRNAs in 
haematopoietic cells during erythroid differentiation. Br J Haematol 142:293-300. 
Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade 
I, Gunsalus KC, Stoffel M et al. 2005. Combinatorial microRNA target predictions. 
Nat Genet 37:495-500. 
Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. 2003. A microRNA array 
reveals extensive regulation of microRNAs during brain development. RNA 
9:1274-1281. 
References 130
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. 2005. 
Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689. 
Kufe DW. 2009. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 
9:874-885. 
Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E, Biffoni M, Nuzzolo 
ER, Billi M, Foa R et al. 2008. A three-step pathway comprising PLZF/miR-
146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 10:788-801. 
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. 2001. Identification of novel genes 
coding for small expressed RNAs. Science 294:853-858. 
Lai SL, Chien AJ, Moon RT. 2009. Wnt/Fz signaling and the cytoskeleton: potential roles 
in tumorigenesis. Cell Res 19:532-545. 
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, 
Kamphorst AO, Landthaler M et al. 2007. A mammalian microRNA expression 
atlas based on small RNA library sequencing. Cell 129:1401-1414. 
Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B. 2009. 
MicroRNA-125b is a novel negative regulator of p53. Genes Dev 23:862-876. 
Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell 
120:15-20. 
Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D, Chen Z, Zhang S. 2008. MicroRNAs 
play a role in the development of human hematopoietic stem cells. J Cell Biochem 
104:805-817. 
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley 
PS, Johnson JM. 2005. Microarray analysis shows that some microRNAs 
downregulate large numbers of target mRNAs. Nature 433:769-773. 
Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel 
DP. 2003. The microRNAs of Caenorhabditis elegans. Genes Dev 17:991-1008. 
Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu 
M, Zupo S, Dono M et al. 2004. An oligonucleotide microchip for genome-wide 
microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A 
101:9740-9744. 
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert 
BL, Mak RH, Ferrando AA et al. 2005. MicroRNA expression profiles classify 
human cancers. Nature 435:834-838. 
Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, Pretz J, Schlanger R, Wang JY, Mak 
RH et al. 2008. MicroRNA-mediated control of cell fate in megakaryocyte-
erythrocyte progenitors. Dev Cell 14:843-853. 
Luebke KJ, Balog RP, Garner HR. 2003. Prioritized selection of oligodeoxyribonucleotide 
probes for efficient hybridization to RNA transcripts. Nucleic Acids Res 31:750-
758. 
Luna C, Li G, Qiu J, Epstein DL, Gonzalez P. 2009. Role of miR-29b on the regulation of 
the extracellular matrix in human trabecular meshwork cells under chronic 
oxidative stress. Mol Vis 15:2488-2497. 
Lund AH. 2010. miR-10 in development and cancer. Cell Death Differ 17:209-214. 
Luzi E, Marini F, Sala SC, Tognarini I, Galli G, Brandi ML. 2008. Osteogenic 
differentiation of human adipose tissue-derived stem cells is modulated by the miR-
26a targeting of the SMAD1 transcription factor. J Bone Miner Res 23:287-295. 
Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, 
Segura JJ. 2009. Stem-cell transplantation into the frontal motor cortex in 
amyotrophic lateral sclerosis patients. Cytotherapy 11:26-34. 
References 131
Martinez J, Busslinger M. 2007. Life beyond cleavage: the case of Ago2 and 
hematopoiesis. Genes Dev 21:1983-1988. 
Matsumoto K, Yasui K, Yamashita N, Horie Y, Yamada T, Tani Y, Shibata H, Nakano T. 
2000. In vitro proliferation potential of AC133 positive cells in peripheral blood. 
Stem Cells 18:196-203. 
Merkerova M, Vasikova A, Belickova M, Bruchova H. 2009. MicroRNA expression 
profiles in umbilical cord blood cell lineages. Stem Cells Dev. 
Naujokat C, Saric T. 2007. Concise review: role and function of the ubiquitin-proteasome 
system in mammalian stem and progenitor cells. Stem Cells 25:2408-2418. 
Neely LA, Patel S, Garver J, Gallo M, Hackett M, McLaughlin S, Nadel M, Harris J, 
Gullans S, Rooke J. 2006. A single-molecule method for the quantitation of 
microRNA gene expression. Nat Methods 3:41-46. 
Neilson JR, Zheng GX, Burge CB, Sharp PA. 2007. Dynamic regulation of miRNA 
expression in ordered stages of cellular development. Genes Dev 21:578-589. 
Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. 2004. 
Microarray-based, high-throughput gene expression profiling of microRNAs. Nat 
Methods 1:155-161. 
Nelson PT, De Planell-Saguer M, Lamprinaki S, Kiriakidou M, Zhang P, O'Doherty U, 
Mourelatos Z. 2007. A novel monoclonal antibody against human Argonaute 
proteins reveals unexpected characteristics of miRNAs in human blood cells. RNA 
13:1787-1792. 
Nielsen JA, Lau P, Maric D, Barker JL, Hudson LD. 2009. Integrating microRNA and 
mRNA expression profiles of neuronal progenitors to identify regulatory networks 
underlying the onset of cortical neurogenesis. BMC Neurosci 10:98. 
Nikolova T, Wu M, Brumbarov K, Alt R, Opitz H, Boheler KR, Cross M, Wobus AM. 
2007. WNT-conditioned media differentially affect the proliferation and 
differentiation of cord blood-derived CD133+ cells in vitro. Differentiation 75:100-
111. 
Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, Usary J, 
Karaca M, Wong WK, Aprelikova O, Fero M et al. 2004. Universal Reference 
RNA as a standard for microarray experiments. BMC Genomics 5:20. 
Nusse R. 2008. Wnt signaling and stem cell control. Cell Res 18:523-527. 
O'Carroll D, Mecklenbrauker I, Das PP, Santana A, Koenig U, Enright AJ, Miska EA, 
Tarakhovsky A. 2007. A Slicer-independent role for Argonaute 2 in hematopoiesis 
and the microRNA pathway. Genes Dev 21:1999-2004. 
Orkin SH, Zon LI. 2008. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 
132:631-644. 
Pan W. 2002. A comparative review of statistical methods for discovering differentially 
expressed genes in replicated microarray experiments. Bioinformatics 18:546-554. 
Papapetrou EP, Korkola JE, Sadelain M. 2010. A genetic strategy for single and 
combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. 
Stem Cells 28:287-296. 
Peltier HJ, Latham GJ. 2008. Normalization of microRNA expression levels in quantitative 
RT-PCR assays: identification of suitable reference RNA targets in normal and 
cancerous human solid tissues. RNA 14:844-852. 
Pena JT, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, Mihailovic A, Lim C, Holoch 
D, Berninger P, Zavolan M et al. 2009. miRNA in situ hybridization in 
formaldehyde and EDC-fixed tissues. Nat Methods 6:139-141. 
Peter ME. 2010. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 
29:2161-2164. 
References 132
Peterson AW, Wolf LK, Georgiadis RM. 2002. Hybridization of mismatched or partially 
matched DNA at surfaces. J Am Chem Soc 124:14601-14607. 
Pfeffer S, Lagos-Quintana M, Tuschl T. 2005. Cloning of small RNA molecules. Curr 
Protoc Mol Biol Chapter 26:Unit 26 24. 
Pozhitkov A, Noble PA, Domazet-Loso T, Nolte AW, Sonnenberg R, Staehler P, Beier M, 
Tautz D. 2006. Tests of rRNA hybridization to microarrays suggest that 
hybridization characteristics of oligonucleotide probes for species discrimination 
cannot be predicted. Nucleic Acids Res 34:e66. 
Rajewsky N. 2006. microRNA target predictions in animals. Nat Genet 38 Suppl:S8-13. 
Rathjen T, Nicol C, McConkey G, Dalmay T. 2006. Analysis of short RNAs in the malaria 
parasite and its red blood cell host. FEBS Lett 580:5185-5188. 
Raymond CK, Roberts BS, Garrett-Engele P, Lim LP, Johnson JM. 2005. Simple, 
quantitative primer-extension PCR assay for direct monitoring of microRNAs and 
short-interfering RNAs. RNA 11:1737-1744. 
Reya T. 2003. Regulation of hematopoietic stem cell self-renewal. Recent Prog Horm Res 
58:283-295. 
Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, 
Weissman IL. 2003. A role for Wnt signalling in self-renewal of haematopoietic 
stem cells. Nature 423:409-414. 
Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel 
M, Messinger R et al. 2006. Superior ex vivo cord blood expansion following co-
culture with bone marrow-derived mesenchymal stem cells. Bone Marrow 
Transplant 37:359-366. 
Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, 
Grocock RJ, Das PP, Miska EA et al. 2007. Requirement of bic/microRNA-155 for 
normal immune function. Science 316:608-611. 
Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T, Norel R, Rogler LE. 2009. 
MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone 
morphogenetic protein signaling and liver stem cell differentiation by targeting 
Smads. Hepatology 50:575-584. 
Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-
Ehrismann R, Orend G. 2004. Growth promoting signaling by tenascin-C 
[corrected]. Cancer Res 64:7377-7385. 
Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, 
Thiagarajan M et al. 2003. TM4: a free, open-source system for microarray data 
management and analysis. Biotechniques 34:374-378. 
Saeland S, Duvert V, Caux C, Pandrau D, Favre C, Valle A, Durand I, Charbord P, de 
Vries J, Banchereau J. 1992. Distribution of surface-membrane molecules on bone 
marrow and cord blood CD34+ hematopoietic cells. Exp Hematol 20:24-33. 
Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'Neill G M, Yang N, Verrills 
NM, Kavallaris M, Gunning PW. 2005. Tissue-specific tropomyosin isoform 
composition. J Histochem Cytochem 53:557-570. 
Schlechta B, Wiedemann D, Kittinger C, Jandrositz A, Bonaros NE, Huber JC, Preisegger 
KH, Kocher AA. 2010. Ex-vivo expanded umbilical cord blood stem cells retain 
capacity for myocardial regeneration. Circ J 74:188-194. 
Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. 2007. Coordinate 
suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-
125a or miR-125b. J Biol Chem 282:1479-1486. 
References 133
Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. 
Widespread changes in protein synthesis induced by microRNAs. Nature 455:58-
63. 
Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. 2004. 
Expression profiling of mammalian microRNAs uncovers a subset of brain-
expressed microRNAs with possible roles in murine and human neuronal 
differentiation. Genome Biol 5:R13. 
Shchepinov MS, Case-Green SC, Southern EM. 1997. Steric factors influencing 
hybridisation of nucleic acids to oligonucleotide arrays. Nucleic Acids Res 25:1155-
1161. 
Shingara J, Keiger K, Shelton J, Laosinchai-Wolf W, Powers P, Conrad R, Brown D, 
Labourier E. 2005. An optimized isolation and labeling platform for accurate 
microRNA expression profiling. RNA 11:1461-1470. 
Snove O, Jr., Rossi JJ. 2006. Toxicity in mice expressing short hairpin RNAs gives new 
insight into RNAi. Genome Biol 7:231. 
Sorrentino BP. 2004. Clinical strategies for expansion of haematopoietic stem cells. Nat 
Rev Immunol 4:878-888. 
Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold 
A, Nienaber C, Zurakowski D et al. 2007. Intramyocardial delivery of CD133+ 
bone marrow cells and coronary artery bypass grafting for chronic ischemic heart 
disease: safety and efficacy studies. J Thorac Cardiovasc Surg 133:717-725. 
Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schumichen C, 
Nienaber CA, Freund M, Steinhoff G. 2003. Autologous bone-marrow stem-cell 
transplantation for myocardial regeneration. Lancet 361:45-46. 
Summers YJ, Heyworth CM, de Wynter EA, Hart CA, Chang J, Testa NG. 2004. AC133+ 
G0 cells from cord blood show a high incidence of long-term culture-initiating cells 
and a capacity for more than 100 million-fold amplification of colony-forming cells 
in vitro. Stem Cells 22:704-715. 
Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. 1996. The ISHAGE 
guidelines for CD34+ cell determination by flow cytometry. International Society 
of Hematotherapy and Graft Engineering. J Hematother 5:213-226. 
Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006. NF-kappaB-dependent induction 
of microRNA miR-146, an inhibitor targeted to signaling proteins of innate 
immune responses. Proc Natl Acad Sci U S A 103:12481-12486. 
Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676. 
Terstappen LW, Levin J. 1992. Bone marrow cell differential counts obtained by 
multidimensional flow cytometry. Blood Cells 18:311-330; discussion 331-312. 
Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, 
Valenzuela D, Kutok JL et al. 2007. Regulation of the germinal center response by 
microRNA-155. Science 316:604-608. 
Toren A, Bielorai B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, 
Yitzhaky A, Itskovitz-Eldor J et al. 2005. CD133-positive hematopoietic stem cell 
"stemness" genes contain many genes mutated or abnormally expressed in 
leukemia. Stem Cells 23:1142-1153. 
Tsang J, Zhu J, van Oudenaarden A. 2007. MicroRNA-mediated feedback and feedforward 
loops are recurrent network motifs in mammals. Mol Cell 26:753-767. 
Tsang JS, Ebert MS, van Oudenaarden A. 2010. Genome-wide dissection of microRNA 
functions and cotargeting networks using gene set signatures. Mol Cell 38:140-153. 
References 134
Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the 
ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121. 
Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: 
microRNAs can up-regulate translation. Science 318:1931-1934. 
Wagner W, Ansorge A, Wirkner U, Eckstein V, Schwager C, Blake J, Miesala K, Selig J, 
Saffrich R, Ansorge W et al. 2004. Molecular evidence for stem cell function of the 
slow-dividing fraction among human hematopoietic progenitor cells by genome-
wide analysis. Blood 104:675-686. 
Walker JC, Harland RM. 2009. microRNA-24a is required to repress apoptosis in the 
developing neural retina. Genes Dev 23:1046-1051. 
Wang H, Ach RA, Curry B. 2007a. Direct and sensitive miRNA profiling from low-input 
total RNA. RNA 13:151-159. 
Wang Q, Huang Z, Xue H, Jin C, Ju XL, Han JD, Chen YG. 2008a. MicroRNA miR-24 
inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood 111:588-
595. 
Wang X. 2008. miRDB: a microRNA target prediction and functional annotation database 
with a wiki interface. Rna 14:1012-1017. 
Wang X, El Naqa IM. 2008. Prediction of both conserved and nonconserved microRNA 
targets in animals. Bioinformatics 24:325-332. 
Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. 2008b. Embryonic 
stem cell-specific microRNAs regulate the G1-S transition and promote rapid 
proliferation. Nat Genet 40:1478-1483. 
Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R. 2007b. DGCR8 is essential for 
microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat 
Genet 39:380-385. 
Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, 3rd, 
Nusse R. 2003. Wnt proteins are lipid-modified and can act as stem cell growth 
factors. Nature 423:448-452. 
Winter J, Jung S, Keller S, Gregory RI, Diederichs S. 2009. Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nat Cell Biol 11:228-234. 
Wognum AW, van Gils FC, Wagemaker G. 1993. Flow cytometric detection of receptors 
for interleukin-6 on bone marrow and peripheral blood cells of humans and rhesus 
monkeys. Blood 81:2036-2043. 
Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, 
Nakayama T, Charrise K, Ndungo EM et al. 2007. Mechanisms and optimization of 
in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149-1157. 
Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, 
Rajewsky K. 2007. MiR-150 controls B cell differentiation by targeting the 
transcription factor c-Myb. Cell 131:146-159. 
Xiao C, Rajewsky K. 2009. MicroRNA control in the immune system: basic principles. 
Cell 136:26-36. 
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, 
Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem 
and progenitor cells. Blood 90:5002-5012. 
Zanjani ED, Almeida-Porada G, Livingston AG, Porada CD, Ogawa M. 1999. Engraftment 
and multilineage expression of human bone marrow CD34- cells in vivo. Ann N Y 
Acad Sci 872:220-231; discussion 231-222. 
Zavrski I, Naujokat C, Niemoller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker 
J, Possinger K, Sezer O. 2003. Proteasome inhibitors induce growth inhibition and 
References 135
apoptosis in myeloma cell lines and in human bone marrow myeloma cells 
irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 129:383-391. 
Zhan M, Miller CP, Papayannopoulou T, Stamatoyannopoulos G, Song CZ. 2007. 
MicroRNA expression dynamics during murine and human erythroid 
differentiation. Exp Hematol 35:1015-1025. 
Zhang CC, Kaba M, Iizuka S, Huynh H, Lodish HF. 2008. Angiopoietin-like 5 and 
IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells 
as assayed by NOD/SCID transplantation. Blood 111:3415-3423. 
Zhao H, Engelen K, De Moor B, Marchal K. 2007. CALIB: a Bioconductor package for 
estimating absolute expression levels from two-color microarray data. 
Bioinformatics 23:1700-1701. 
Zhao H, Kalota A, Jin S, Gewirtz AM. 2009. The c-myb proto-oncogene and microRNA-
15a comprise an active autoregulatory feedback loop in human hematopoietic cells. 
Blood 113:505-516. 
Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. 2007. miR-150, a microRNA expressed 
in mature B and T cells, blocks early B cell development when expressed 
prematurely. Proc Natl Acad Sci U S A 104:7080-7085. 
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O et al. 2010. 
MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel 
through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression. 
J Biol Chem 285:21496-21507. 
 
 136
Acknowledgements 
First of all, I wish to thank Dr. Andreas Bosio for excellent supervision of my PhD project, 
for continuous support, valuable advice and many stimulating scientific discussions. I am 
particulary grateful to him for introducing me to the exciting research field of miRNAs and 
stem cells. 
I am also very grateful to Prof. Dr. Ralf Weiskirchen for supervising this thesis, for great 
support and helpful advice. I thank Prof. Dipl. Ing. Dr. Werner Baumgartner for being the 
second referee. 
A very special thanks goes to Dr. Stefan Wild for lots of helpful advice, constructive 
comments and extensive scientific discussions around my work. I would also like to thank 
our bioinformatics department, especially Dr. Stefan Tomiuk and Dr. Hartmut Scheel for 
bioinformatical support and for answering a lot of questions. I am grateful to Dr. Frank 
Hübel for support during microarray data analysis, to Juliane Stuth for sharing her 
expertise with me in carrying out CliniMACS separations, to Jan Drewes for great help 
with the GENios Reader and to Sascha Nicodem for technical assistance with the 
luciferase assays. Moreover, I would like to thank our cooperation partners for very good 
collaboration and numerous interesting scientific discussions, especially Prof. Dr. Dr. 
Wolfgang Wagner and Thomas Walenda in Aachen as well as Prof. Dr. Thomas Tuschl 
and Dr. Markus Hafner in New York. 
I thank all Miltenyi colleagues for their helpfulness and the friendly working atmosphere 
with special thanks to the former and present people in office 2101, namely Stephan & 
Stefan, Anja, Björn, Lena and Marina.  
The financial support of the Miltenyi Biotec GmbH is gratefully acknowledged as well as 
the partial funding by the German Federal Ministry of Education and Research (project No. 
0312138B). 
Mein persönlicher Dank gilt meinem Freundeskreis für motivierende Worte und dauerhafte 
Unterstützung, allen voran wird dieser besondere Dank Katja, Kathrin und Matze sowie 
meinem Bruder Peter zuteil. Von ganzem Herzen danke ich meinen Eltern, die mir stets 
zur Seite stehen und es mir ermöglicht haben, meine Ziele verfolgen und erreichen zu 
können. 
 137
Publications 
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, 
Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foà R, 
Schliwka J, Fuchs U, Novosel A, Müller RU, Schermer B, Bissels U, Inman J, Phan Q, 
Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, 
Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, 
Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, 
Russo JJ, Sander C, Zavolan M, Tuschl T. 
A mammalian microRNA expression atlas based on small RNA library sequencing 
Cell 2007, 129(7):1401-14. 
 
Ute Bissels, Stefan Wild, Stefan Tomiuk, Markus Hafner, Thomas Tuschl, Andreas Bosio 
Absolute quantification of microRNAs by using a universal reference 
RNA 2009, 15:2375-2384. 
 
Anna-Barbara Stittrich, Claudia Haftmann, Evridiki Sgouroudis, Ahmed Nabil Hegazy, 
Isabel Panse, Rene Riedel, Michael Flossdorf, Jun Dong, Franziska Fuhrmann, Gitta Anne 
Heinz, Zhuo Fang, Na Li, Ute Bissels, Farahnaz Hatam, Angelina Jahn, Ben Hammoud, 
Mareen Matz, Felix-Michael Schulze, Ria Baumgrass, Andreas Bosio, Hans-Joachim 
Mollenkopf, Joachim Grün, Andreas Thiel, Wei Chen, Thomas Höfer, Christoph 
Loddenkemper, Max Löhning, Hyun-Dong Chang, Nikolaus Rajewsky, Andreas Radbruch 
and Mir-Farzin Mashreghi 
The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated 
helper T lymphocytes 
Nature Immunology 2010, 11:1057-1062. 
 
In submission: 
Ute Bissels, Stefan Wild, Stefan Tomiuk, Markus Hafner, Hartmut Scheel, Aleksandra 
Mihailovic, Yeong-Hoon Choi, Thomas Tuschl, Andreas Bosio 
Combined characterization of microRNA and mRNA profiles delineates early 
differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells 
 
Johannes Besser, Robert Heinen, Marc Rehmsmeier, Ute Bissels, Andreas Bosio, Carsten 
Drepper 
Dysregulated miRNAs in Motoneuron Diseases 
 
 138
 
In print: 
Ute Bissels, Stefan Miltenyi, Andreas Bosio 
Characterization and classification of stem cells 
in Steinhoff G (Ed.), Regenerative Medicine, Springer  
 
Stefan Wild, Ute Bissels, Barbara Schaffrath, Andreas Bosio 
Microarrays 
in Nijkamp and Parnham (Eds.), Principles of Immunopharmacology, Springer Basel AG 
 
